Venetoclax Clinical Trials (2026): 686 Studies for Acute Myeloid Leukemia & Chronic Lymphocytic Leukemia
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
686 Venetoclax clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 232 indications (including Acute Myeloid Leukemia & Chronic Lymphocytic Leukemia) and 79,548 total planned enrollment. 59 Phase 3 Venetoclax trials and 269 Phase 2, 5 Phase 4 are listed. 303 Venetoclax clinical trials are actively recruiting at 2,387 U.S. sites across 50 states. Most recent activity: NCT05725200 (Dec 2040).
Where to Participate: All Venetoclax Trial Sites in the U.S. (2,387 sites across 50 states)
Every actively recruiting Venetoclaxtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Children's Hospital of Alabama | Birmingham35233 | NCT06317662 | Map |
| AL | O'Neal Comprehensive Cancer Center, University of Alabama | Birmingham35233 | NCT04588922 | Map |
| AL | The Kirklin Clinic of UAB Hospital | Birmingham35233 | NCT03850574 | Map |
| AL | University of Alabama at Birmingham | Birmingham35294 | NCT03331198 | Map |
| AL | University of Alabama at Birmingham | Birmingham35294 | NCT06852222 | Map |
| AL | University of Alabama at Birmingham | Birmingham35294 | NCT07044544 | Map |
| AL | University of Alabama at Birmingham Cancer Center | Birmingham35233 | NCT05554393 | Map |
| AL | University of Alabama at Birmingham Cancer Center | Birmingham35233 | NCT05554406 | Map |
| AL | University of Alabama at Birmingham Cancer Center | Birmingham35233 | NCT05564390 | Map |
| AL | University of Alabama at Birmingham Cancer Center | Birmingham35233 | NCT06317649 | Map |
| AL | University of Alabama Birmingham | Birmingham35294 | NCT03331198 | Map |
| AK | Providence Alaska Medical Center | Anchorage99508 | NCT06317662 | Map |
| AZ | Banner MD Anderson Cancer Center | Gilbert85234 | NCT03331198 | Map |
| AZ | Banner MD Anderson Cancer Center | Gilbert85234 | NCT03331198 | Map |
| AZ | Banner MD Anderson Cancer Center | Gilbert85234 | NCT07007312 | Map |
| AZ | Cancer Treatment Center of America Phoenix | Goodyear85338 | NCT06852222 | Map |
| AZ | City of Hope - Phoenix | Goodyear85338 | NCT04588922 | Map |
| AZ | Banner Children's at Desert | Mesa85202 | NCT06317662 | Map |
| AZ | Mayo Clinic - Phoenix | Phoenix85054 | NCT05735184 | Map |
| AZ | Mayo Clinic Hospital in Arizona | Phoenix85054 | NCT05554406 | Map |
| AZ | Mayo Clinic Hospital in Arizona | Phoenix85054 | NCT05564390 | Map |
| AZ | Phoenix Children's Hospital | Phoenix85016 | NCT05183035 | Map |
| AZ | Arizona Oncology - Tucson - Rudasill /ID# 267552 | Tucson85704 | NCT06428019 | Map |
| AZ | Banner University Medical Center - Tucson | Tucson85719 | NCT05554393 | Map |
| AZ | Banner University Medical Center - Tucson | Tucson85719 | NCT05554406 | Map |
| AZ | Banner University Medical Center - Tucson | Tucson85719 | NCT05564390 | Map |
| AZ | Banner University Medical Center - Tucson | Tucson85719 | NCT04840602 | Map |
| AZ | Banner University Medical Center - Tucson | Tucson85719 | NCT04269902 | Map |
| AZ | Banner University Medical Center - Tucson | Tucson85719 | NCT06317649 | Map |
| AZ | Banner University Medical Center - Tucson | Tucson85719 | NCT06672146 | Map |
| AZ | Southern VA Health Care System /ID# 266254 | Tucson85723 | NCT06428019 | Map |
| AZ | The University of Arizona Cancer Center | Tucson85724 | NCT06852222 | Map |
| AZ | University of Arizona Cancer Center-North Campus | Tucson85719 | NCT05554393 | Map |
| AZ | University of Arizona Cancer Center-North Campus | Tucson85719 | NCT05554406 | Map |
| AZ | University of Arizona Cancer Center-North Campus | Tucson85719 | NCT05564390 | Map |
| AZ | University of Arizona Cancer Center-North Campus | Tucson85719 | NCT04840602 | Map |
| AZ | University of Arizona Cancer Center-North Campus | Tucson85719 | NCT04269902 | Map |
| AZ | University of Arizona Cancer Center-North Campus | Tucson85719 | NCT06317649 | Map |
| AZ | University of Arizona Cancer Center-North Campus | Tucson85719 | NCT06672146 | Map |
| AR | NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro | Jonesboro72401 | NCT04269902 | Map |
| AR | St Bernards Medical Center | Jonesboro72401 | NCT06846671 | Map |
| AR | Arkansas Children's Hospital | Little Rock72202 | NCT05183035 | Map |
| AR | Arkansas Children's Hospital | Little Rock72202-3591 | NCT06317662 | Map |
| AR | University of Arkansas at Little Rock | Little Rock72204 | NCT06852222 | Map |
| AR | University of Arkansas for Medical Sciences | Little Rock72205 | NCT05554393 | Map |
| AR | University of Arkansas for Medical Sciences | Little Rock72205 | NCT05554406 | Map |
| AR | University of Arkansas for Medical Sciences | Little Rock72205 | NCT05564390 | Map |
| AR | University of Arkansas for Medical Sciences | Little Rock72205 | NCT06317649 | Map |
| AR | University of Arkansas for Medical Sciences | Little Rock72205 | NCT06672146 | Map |
| AR | Highlands Oncology Group ( Site 5405) | Springdale72762 | NCT05947851 | Map |
| CA | Kaiser Permanente-Anaheim | Anaheim92806 | NCT04269902 | Map |
| CA | Kaiser Permanente-Baldwin Park | Baldwin Park91706 | NCT04269902 | Map |
| CA | Kaiser Permanente-Bellflower | Bellflower90706 | NCT04269902 | Map |
| CA | Alta Bates Summit Medical Center-Herrick Campus | Berkeley94704 | NCT05554406 | Map |
| CA | Alta Bates Summit Medical Center-Herrick Campus | Berkeley94704 | NCT06317649 | Map |
| CA | Alta Bates Summit Medical Center-Herrick Campus | Berkeley94704 | NCT06672146 | Map |
| CA | Marshall Cancer Center | Cameron Park95682 | NCT04269902 | Map |
| CA | The Oncology Institute Clinical Research | Cerritos90703 | NCT05963074 | Map |
| CA | UCSF FRESNO/Community Cancer Institute /ID# 270874 | Clovis93611 | NCT06428019 | Map |
| CA | UCSF-Fresno | Clovis93611 | NCT04905810 | Map |
| CA | University of California, Fresno | Clovis93611 | NCT07007312 | Map |
| CA | UC Irvine Health Cancer Center-Newport | Costa Mesa92627 | NCT04269902 | Map |
| CA | City of Hope | Duarte91010 | NCT03331198 | Map |
| CA | City of Hope | Duarte91010 | NCT03113643 | Map |
| CA | City of Hope | Duarte91010 | NCT06852222 | Map |
| CA | City Of Hope | Duarte91010 | NCT03331198 | Map |
| CA | City of Hope (City of Hope National Medical Center, City of Hope Medical Center) | Duarte91010 | NCT04227847 | Map |
| CA | City of Hope Comprehensive Cancer Center | Duarte91010 | NCT04269902 | Map |
| CA | City of Hope Comprehensive Cancer Center | Duarte91010 | NCT06311227 | Map |
| CA | City of Hope Medical center | Duarte91010 | NCT03523975 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT05861050 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT03969446 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT06501196 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT06763341 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT07133997 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT07218510 | Map |
| CA | City of Hope National Medical Center | Duarte91010 | NCT04588922 | Map |
| CA | IP Address: City of Hope Investigational Drug Services(IDS) | Duarte91010 | NCT04227847 | Map |
| CA | Kaiser Permanente Dublin | Dublin94568 | NCT05564390 | Map |
| CA | Kaiser Permanente Dublin | Dublin94568 | NCT06317649 | Map |
| CA | Kaiser Permanente-Fontana | Fontana92335 | NCT04269902 | Map |
| CA | Kaiser Permanente-Fremont | Fremont94538 | NCT05564390 | Map |
| CA | Kaiser Permanente-Fremont | Fremont94538 | NCT06317649 | Map |
| CA | Kaiser Permanente Fresno Orchard Plaza | Fresno93720 | NCT05564390 | Map |
| CA | Kaiser Permanente Fresno Orchard Plaza | Fresno93720 | NCT06317649 | Map |
| CA | Kaiser Permanente-Fresno | Fresno93720 | NCT05564390 | Map |
| CA | Kaiser Permanente-Fresno | Fresno93720 | NCT06317649 | Map |
| CA | Kaiser Permanente South Bay | Harbor City90710 | NCT04269902 | Map |
| CA | City of Hope Seacliff | Huntington Beach92648 | NCT04269902 | Map |
| CA | City of Hope at Irvine Lennar | Irvine92618 | NCT04269902 | Map |
| CA | City of Hope at Irvine Lennar | Irvine92618 | NCT06311227 | Map |
| CA | City of Hope at Irvine Lennar | Irvine92618 | NCT07218510 | Map |
| CA | Kaiser Permanente-Irvine | Irvine92618 | NCT04269902 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT05564390 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT04269902 | Map |
| CA | University of California Irvine | Irvine92697 | NCT03850574 | Map |
| CA | Moores Cancer Center at UC San Diego /ID# 230157 | La Jolla92093 | NCT04895436 | Map |
| CA | Moores UC San Diego Cancer Center | La Jolla92093 | NCT05735184 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT03331198 | Map |
| CA | University Of California San Diego Moores Cancer Center | La Jolla92093 | NCT03331198 | Map |
| CA | University of California, San Diego | La Jolla92093 | NCT07007312 | Map |
| CA | Uci Health Laguna Hills | Laguna Hills92653 | NCT06943872 | Map |
| CA | UCI Health Laguna Hills | Laguna Hills92653 | NCT04269902 | Map |
| CA | City of Hope Antelope Valley | Lancaster93534 | NCT04269902 | Map |
| CA | Loma Linda University Medical Center | Loma Linda92354 | NCT06317662 | Map |
| CA | City of Hope at Long Beach Elm | Long Beach90813 | NCT04269902 | Map |
| CA | City of Hope at Long Beach Elm | Long Beach90813 | NCT07218510 | Map |
| CA | MemorialCare Health System - Long Beach Medical Center ( Site 5421) | Long Beach90806 | NCT05947851 | Map |
| CA | MemorialCare Miller Children's and Women's Hospital Long Beach | Long Beach90806 | NCT05183035 | Map |
| CA | Miller Children's and Women's Hospital Long Beach | Long Beach90806 | NCT06317662 | Map |
| CA | Cancer and Blood Specialty Clinic | Los Alamitos90720 | NCT05963074 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT05554393 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT05554406 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT05564390 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT06317649 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT06649812 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT07007312 | Map |
| CA | David Geffen School of Medicine at the University of California at Los Angeles | Los Angeles90095-1406 | NCT06810778 | Map |
| CA | Kaiser Permanente Los Angeles Medical Center | Los Angeles90027 | NCT04269902 | Map |
| CA | Kaiser Permanente West Los Angeles | Los Angeles90034 | NCT04269902 | Map |
| CA | Keck School of Medicine of USC | Los Angeles90089 | NCT04256317 | Map |
| CA | Ronald Reagan UCLA Medical Center | Los Angeles90095 | NCT04227847 | Map |
| CA | UCLA - Bowyer Oncology Center | Los Angeles90095 | NCT05735184 | Map |
| CA | UCLA Department of Medicine Hematologyoncology | Los Angeles90095-3075 | NCT06846671 | Map |
| CA | UCLA Hematology-Oncology Clinic | Los Angeles90095 | NCT04227847 | Map |
| CA | UCLA Ronald Reagan Medical Center | Los Angeles90095 | NCT03013998 | Map |
| CA | University of California Los Angeles | Los Angeles90095 | NCT06501196 | Map |
| CA | University of California, Los Angeles | Los Angeles90095 | NCT03331198 | Map |
| CA | University of California, Los Angeles | Los Angeles90095 | NCT06456463 | Map |
| CA | University of California, Los Angeles | Los Angeles90095 | NCT07007312 | Map |
| CA | USC / Norris Comprehensive Cancer Center | Los Angeles90033 | NCT05735184 | Map |
| CA | USC/Norris Comprehensive Cancer Center | Los Angeles90033 | NCT03850574 | Map |
| CA | Valkyrie Clinical Trials /ID# 268151 | Los Angeles90067 | NCT06428019 | Map |
| CA | Fremont - Rideout Cancer Center | Marysville95901 | NCT04269902 | Map |
| CA | Kaiser Permanente- Modesto MOB II | Modesto95356 | NCT05564390 | Map |
| CA | Kaiser Permanente- Modesto MOB II | Modesto95356 | NCT06317649 | Map |
| CA | Kaiser Permanente-Modesto | Modesto95356 | NCT05564390 | Map |
| CA | Kaiser Permanente-Modesto | Modesto95356 | NCT06317649 | Map |
| CA | City of Hope Newport Beach | Newport Beach92660 | NCT04269902 | Map |
| CA | Hoag Family Cancer Center | Newport Beach92663 | NCT04988555 | Map |
| CA | Kaiser Permanente-Oakland | Oakland94611 | NCT05564390 | Map |
| CA | Kaiser Permanente-Oakland | Oakland94611 | NCT06317649 | Map |
| CA | Kaiser Permanente-Oakland | Oakland94611 | NCT06317662 | Map |
| CA | UCSF Benioff Children's Hospital Oakland | Oakland94609 | NCT06317662 | Map |
| CA | Kaiser Permanente-Ontario | Ontario91761 | NCT04269902 | Map |
| CA | Chao Family Comprehensive Cancer Center | Orange92868-3201 | NCT06943872 | Map |
| CA | Children's Hospital of Orange County | Orange92868 | NCT06317662 | Map |
| CA | Children's Hospital of Orange County Main Campus - Orange | Orange92868 | NCT05183035 | Map |
| CA | UC Irvine Health - Chao Family Comprehensive Cancer Center | Orange92868 | NCT04256317 | Map |
| CA | UC Irvine Health Chao Family Comprehensive Cancer Center | Orange92868 | NCT05735184 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT05564390 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT04269902 | Map |
| CA | UCI Chao Family Comprehensive Cancer Center | Orange92868 | NCT06382168 | Map |
| CA | University of California, Irvine | Orange92868 | NCT07007312 | Map |
| CA | Stanford Cancer Center | Palo Alto94304 | NCT03850574 | Map |
| CA | Stanford Cancer Center | Palo Alto94304 | NCT06501196 | Map |
| CA | Stanford Cancer Institute | Palo Alto94304-2205 | NCT06943872 | Map |
| CA | Kaiser Permanente - Panorama City | Panorama City91402 | NCT04269902 | Map |
| CA | Kaiser Permanente-Riverside | Riverside92505 | NCT04269902 | Map |
| CA | Kaiser Permanente-Roseville | Roseville95661 | NCT05564390 | Map |
| CA | Kaiser Permanente-Roseville | Roseville95661 | NCT06317649 | Map |
| CA | Kaiser Permanente Downtown Commons | Sacramento95814 | NCT05564390 | Map |
| CA | Kaiser Permanente Downtown Commons | Sacramento95814 | NCT06317649 | Map |
| CA | Kaiser Permanente-South Sacramento | Sacramento95823 | NCT05564390 | Map |
| CA | Kaiser Permanente-South Sacramento | Sacramento95823 | NCT06317649 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT05554406 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT05564390 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT04905810 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT04269902 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT06317649 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT06317662 | Map |
| CA | University of California Davis Health (UC Davis Health) | Sacramento95817 | NCT05184842 | Map |
| CA | University of California, Davis | Sacramento95817 | NCT03850574 | Map |
| CA | Kaiser Permanente-San Diego Zion | San Diego92120 | NCT04269902 | Map |
| CA | Rady Children's Hospital | San Diego92132 | NCT06177067 | Map |
| CA | Rady Children's Hospital | San Diego92123 | NCT06390319 | Map |
| CA | Scripps Prebys Cancer Center | San Diego92103-2106 | NCT06943872 | Map |
| CA | Benioff Children's Hospital - Mission Bay | San Francisco94158 | NCT05183035 | Map |
| CA | Kaiser Permanente-San Francisco | San Francisco94115 | NCT05564390 | Map |
| CA | Kaiser Permanente-San Francisco | San Francisco94115 | NCT06317649 | Map |
| CA | San Francisco VA Medical Center, San Francisco, CA | San Francisco94121-1563 | NCT06520098 | Map |
| CA | UCSF Medical Center-Mission Bay | San Francisco94158 | NCT06317662 | Map |
| CA | UCSF Medical Center-Parnassus | San Francisco94143 | NCT05554393 | Map |
| CA | UCSF Medical Center-Parnassus | San Francisco94143 | NCT05554406 | Map |
| CA | UCSF Medical Center-Parnassus | San Francisco94143 | NCT05564390 | Map |
| CA | UCSF Medical Center-Parnassus | San Francisco94143 | NCT06317649 | Map |
| CA | UCSF Medical Center-Parnassus | San Francisco94143 | NCT06672146 | Map |
| CA | University of California San Francisco-Benioff Children's Hospital | San Francisco94158 | NCT05292664 | Map |
| CA | University of California, San Francisco | San Francisco94143 | NCT03331198 | Map |
| CA | University of California, San Francisco | San Francisco94143 | NCT03013998 | Map |
| CA | Kaiser Permanente-Santa Teresa-San Jose | San Jose95119 | NCT05564390 | Map |
| CA | Kaiser Permanente-Santa Teresa-San Jose | San Jose95119 | NCT06317649 | Map |
| CA | Kaiser Permanente San Leandro | San Leandro94577 | NCT05564390 | Map |
| CA | Kaiser Permanente San Leandro | San Leandro94577 | NCT06317649 | Map |
| CA | SLO Oncology and Hematology Health Center | San Luis Obispo93401 | NCT05963074 | Map |
| CA | Kaiser Permanente-San Marcos | San Marcos92078 | NCT04269902 | Map |
| CA | Mills Health Center | San Mateo94401 | NCT05554406 | Map |
| CA | Mills Health Center | San Mateo94401 | NCT06317649 | Map |
| CA | Mills Health Center | San Mateo94401 | NCT06672146 | Map |
| CA | Kaiser San Rafael-Gallinas | San Rafael94903 | NCT05564390 | Map |
| CA | Kaiser San Rafael-Gallinas | San Rafael94903 | NCT06317649 | Map |
| CA | Kaiser Permanente Medical Center - Santa Clara | Santa Clara95051 | NCT05564390 | Map |
| CA | Kaiser Permanente Medical Center - Santa Clara | Santa Clara95051 | NCT06317649 | Map |
| CA | Kaiser Permanente-Santa Rosa | Santa Rosa95403 | NCT05564390 | Map |
| CA | Kaiser Permanente-Santa Rosa | Santa Rosa95403 | NCT06317649 | Map |
| CA | Providence Medical Foundation | Santa Rosa95403 | NCT05963074 | Map |
| CA | City of Hope South Pasadena | South Pasadena91030 | NCT04269902 | Map |
| CA | Kaiser Permanente-South San Francisco | South San Francisco94080 | NCT05564390 | Map |
| CA | Kaiser Permanente-South San Francisco | South San Francisco94080 | NCT06317649 | Map |
| CA | Stanford Health Care | Stanford94305 | NCT06456463 | Map |
| CA | City of Hope South Bay | Torrance90503 | NCT04269902 | Map |
| CA | City of Hope Upland | Upland91786 | NCT04269902 | Map |
| CA | Kaiser Permanente-Vallejo | Vallejo94589 | NCT05564390 | Map |
| CA | Kaiser Permanente-Vallejo | Vallejo94589 | NCT06317649 | Map |
| CA | Kaiser Permanente-Walnut Creek | Walnut Creek94596 | NCT05564390 | Map |
| CA | Kaiser Permanente-Walnut Creek | Walnut Creek94596 | NCT06317649 | Map |
| CA | Berenson Cancer Center | West Hollywood90069 | NCT06115135 | Map |
| CA | PIH Health Hospital | Whittier90602 | NCT05963074 | Map |
| CA | Pih Health Whittier Hospital | Whittier90602 | NCT06846671 | Map |
| CA | Kaiser Permanente-Woodland Hills | Woodland Hills91367 | NCT04269902 | Map |
| CO | Children's Hospital Colorado | Aurora80045 | NCT05292664 | Map |
| CO | Children's Hospital Colorado | Aurora80045 | NCT05183035 | Map |
| CO | Children's Hospital Colorado | Aurora80045 | NCT06177067 | Map |
| CO | Children's Hospital Colorado | Aurora80045 | NCT06317662 | Map |
| CO | CU Anschutz Medical Campus | Aurora80045 | NCT05287568 | Map |
| CO | Rocky Mountain Cancer Centers | Aurora80012 | NCT06852222 | Map |
| CO | Rocky Mountain Cancer Centers - Aurora /ID# 267549 | Aurora80012 | NCT06428019 | Map |
| CO | Rocky Mountain Cancer Centers (Williams) Usor | Aurora80012-5405 | NCT06846671 | Map |
| CO | Rocky Mountain Cancer Centers (Williams) Usor | Aurora80012-5405 | NCT06943872 | Map |
| CO | University of Colorado | Aurora80045 | NCT05735184 | Map |
| CO | University of Colorado | Aurora80045 | NCT07007312 | Map |
| CO | University of Colorado Hospital | Aurora80045 | NCT05287568 | Map |
| CO | University of Colorado Hospital | Aurora80045 | NCT06429449 | Map |
| CO | Universtiy of Colorado Hospital | Aurora80045 | NCT06232655 | Map |
| CO | Colorado Blood Cancer Institute | Denver80218 | NCT04988555 | Map |
| CO | Colorado Blood Cancer Institute | Denver80218 | NCT05735184 | Map |
| CO | Colorado Blood Cancer Institute | Denver80218 | NCT03331198 | Map |
| CO | Colorado Blood Cancer Institute | Denver80218 | NCT06634394 | Map |
| CO | Colorado Blood Cancer Institute | Denver80218 | NCT07007312 | Map |
| CO | Grand Valley Oncology | Grand Junction81505 | NCT04269902 | Map |
| CO | Grand Valley Oncology | Grand Junction81505 | NCT05963074 | Map |
| CT | Smilow Cancer Hospital-Derby Care Center | Derby06418 | NCT06649812 | Map |
| CT | Smilow Cancer Hospital Care Center - Guilford | Guilford06437 | NCT06649812 | Map |
| CT | Connecticut Children's Medical Center | Hartford06106 | NCT06317662 | Map |
| CT | Hartford HealthCare Cancer Institute | Hartford06106 | NCT07007312 | Map |
| CT | Yale Cancer Center and Smilow Cancer Hospital | New Haven06510 | NCT05735184 | Map |
| CT | Yale University | New Haven06520 | NCT05554406 | Map |
| CT | Yale University | New Haven06520 | NCT05564390 | Map |
| CT | Yale University | New Haven06510 | NCT04256317 | Map |
| CT | Yale University | New Haven06520 | NCT03850574 | Map |
| CT | Yale University | New Haven06511 | NCT05183035 | Map |
| CT | Yale University | New Haven06520 | NCT06317649 | Map |
| CT | Yale University | New Haven06520 | NCT06317662 | Map |
| CT | Yale University | New Haven06520 | NCT06649812 | Map |
| CT | Yale University School of Medicine | New Haven06510 | NCT07007312 | Map |
| CT | Yale University School of Medicine /ID# 266224 | New Haven06510 | NCT06428019 | Map |
| CT | Yale University Yale Cancer Center | New Haven06520-8028 | NCT06943872 | Map |
| CT | Yale-New Haven Hospital | New Haven06510 | NCT06419634 | Map |
| CT | Eastern Connecticut Hematology and Oncology | Norwich06360-2700 | NCT06943872 | Map |
| CT | Veterans Affairs Connecticut Healthcare System-West Haven Campus | West Haven06516 | NCT05564390 | Map |
| CT | Veterans Affairs Connecticut Healthcare System-West Haven Campus | West Haven06516 | NCT06317649 | Map |
| DE | Beebe South Coastal Health Campus | Millville19967 | NCT04269902 | Map |
| DE | Helen F Graham Cancer Center | Newark19713 | NCT04269902 | Map |
| DE | Medical Oncology Hematology Consultants PA | Newark19713 | NCT04269902 | Map |
| DE | Medical Oncology Hematology Consultants, PA | Newark19713 | NCT06852222 | Map |
| DE | Beebe Health Campus | Rehoboth Beach19971 | NCT04269902 | Map |
| DE | Alfred I duPont Hospital for Children | Wilmington19803 | NCT06317662 | Map |
| DE | Nemours Alfred I. Dupont Hospital for Children | Wilmington19803 | NCT05183035 | Map |
| DC | Children's National - Main Hospital | Washington D.C.20010 | NCT05183035 | Map |
| DC | Children's National Medical Center | Washington D.C.20010 | NCT06317662 | Map |
| DC | Georgetown University Medical Center | Washington D.C.20007 | NCT03331198 | Map |
| DC | Sibley Memorial Hospital | Washington D.C.20016 | NCT04269902 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Aventura | Aventura33180 | NCT06311227 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables33146 | NCT04840602 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables33146 | NCT06311227 | Map |
| FL | University of Miami, Lennar Foundation Medical Center | Coral Gables33146 | NCT05530421 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Springs | Coral Springs33065 | NCT04840602 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Springs | Coral Springs33065 | NCT06311227 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach33442 | NCT04840602 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach33442 | NCT06311227 | Map |
| FL | University of Miami, Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach33442 | NCT05530421 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Doral | Doral33166 | NCT04840602 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Doral | Doral33166 | NCT06311227 | Map |
| FL | Holy Cross Hospital | Fort Lauderdale33308 | NCT04269902 | Map |
| FL | Florida Cancer Specialists & Research Institute | Fort Myers33901 | NCT06852222 | Map |
| FL | Florida Oncology and Hematology | Fort Myers33912 | NCT06846671 | Map |
| FL | Golisano Children's Hospital of Southwest Florida | Fort Myers33908 | NCT05183035 | Map |
| FL | Malcolm Randall V.A. Medical Center /ID# 267825 | Gainesville32608 | NCT06428019 | Map |
| FL | UF Health Cancer Institute - Gainesville | Gainesville32610 | NCT05564390 | Map |
| FL | UF Health Cancer Institute - Gainesville | Gainesville32610 | NCT06317649 | Map |
| FL | UF Health Cancer Institute - Gainesville | Gainesville32610 | NCT06317662 | Map |
| FL | University of Florida Health Shands Children's Hospital | Gainesville32610 | NCT05183035 | Map |
| FL | Memorial Regional Hospital/Joe DiMaggio Children's Hospital | Hollywood33021 | NCT06317662 | Map |
| FL | Memorial Regional Hospital/Joe DiMaggio Children's Hospital | Hollywood33021 | NCT06672146 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Hollywood | Hollywood33021 | NCT04840602 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Hollywood | Hollywood33021 | NCT06311227 | Map |
| FL | Baptist Md Anderson Cancer Center | Jacksonville32207-8432 | NCT06846671 | Map |
| FL | Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 266713 | Jacksonville32256 | NCT06428019 | Map |
| FL | Mayo Clinic | Jacksonville32224 | NCT03331198 | Map |
| FL | Mayo Clinic - Jacksonville | Jacksonville32224 | NCT03331198 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT05554406 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT05564390 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT04840602 | Map |
| FL | Mayo Clinic Jacksonville | Jacksonville32224 | NCT05735184 | Map |
| FL | Nemours Children's Clinic-Jacksonville | Jacksonville32207 | NCT06317662 | Map |
| FL | Nemours Children's Specialty Care Jacksonville | Jacksonville32207 | NCT05183035 | Map |
| FL | Jupiter Research | Jupiter33458 | NCT06852222 | Map |
| FL | Miami Cancer Institute | Miami33176 | NCT05554393 | Map |
| FL | Miami Cancer Institute | Miami33176 | NCT05554406 | Map |
| FL | Miami Cancer Institute | Miami33176 | NCT05564390 | Map |
| FL | Miami Cancer Institute | Miami33176 | NCT06317649 | Map |
| FL | Miami Cancer Institute | Miami33176 | NCT06672146 | Map |
| FL | Sylvester Comprehensive Cancer Center | Miami33136 | NCT06501196 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Kendall | Miami33176 | NCT04840602 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Kendall | Miami33176 | NCT06311227 | Map |
| FL | University of Miami | Miami33136 | NCT05442216 | Map |
| FL | University of Miami | Miami33136 | NCT05597306 | Map |
| FL | University of Miami | Miami33136 | NCT04988555 | Map |
| FL | University of Miami | Miami33136 | NCT06456463 | Map |
| FL | University of Miami | Miami33124 | NCT06634394 | Map |
| FL | University of Miami | Miami33136 | NCT06782542 | Map |
| FL | University of Miami | Miami33136 | NCT07007312 | Map |
| FL | University of Miami - Miller School of Medicine | Miami33136 | NCT03850574 | Map |
| FL | University of Miami - Sylvester Comprehensive Cancer Center | Miami33136 | NCT04256317 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT04840602 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT06311227 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT06317662 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT06504459 | Map |
| FL | University of Miami, Sylvester Comprehensive Cancer Center | Miami33136 | NCT05530421 | Map |
| FL | Mount Sinai Medical Center Campus | Miami Beach33140-2948 | NCT05963074 | Map |
| FL | University of Miami Sylvester Comprehensive Cancer Center at Sole Mia | North Miami33181 | NCT04840602 | Map |
| FL | The Oncology Institute | North Miami Beach33169 | NCT05963074 | Map |
| FL | Mid Florida Hematology Oncology | Orange32763 | NCT05963074 | Map |
| FL | Mid Florida Hematology And Oncology Center /ID# 269159 | Orange City32763 | NCT06428019 | Map |
| FL | AdventHealth Cancer Institute | Orlando32804 | NCT06456463 | Map |
| FL | AdventHealth Orlando | Orlando32803 | NCT05442216 | Map |
| FL | AdventHealth Orlando | Orlando32803 | NCT06317662 | Map |
| FL | Arnold Palmer Hospital for Children | Orlando32806 | NCT06317662 | Map |
| FL | Nemours Children's Hospital | Orlando32827 | NCT06317662 | Map |
| FL | Nemours Children's Hospital - Orlando | Orlando32827 | NCT05183035 | Map |
| FL | Orlando Health Cancer Institute | Orlando32806 | NCT06852222 | Map |
| FL | Memorial Hospital West | Pembroke Pines33028 | NCT05554393 | Map |
| FL | Memorial Hospital West | Pembroke Pines33028 | NCT05554406 | Map |
| FL | Memorial Hospital West | Pembroke Pines33028 | NCT05564390 | Map |
| FL | Memorial Hospital West | Pembroke Pines33028 | NCT06672146 | Map |
| FL | Memorial Hospital West ( Site 5410) | Pembroke Pines33028 | NCT05947851 | Map |
| FL | Nemours Children's Clinic - Pensacola | Pensacola32504 | NCT06317662 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Plantation | Plantation33324 | NCT04840602 | Map |
| FL | Comprehensive Hematology Oncology /ID# 267644 | St. Petersburg33709 | NCT06428019 | Map |
| FL | Johns Hopkins All Children's Hospital | St. Petersburg33701 | NCT06317662 | Map |
| FL | Moffit Cancer center | Tampa33612 | NCT06852222 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT06501196 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT06511882 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT06660368 | Map |
| FL | Moffitt Cancer Center & Research Institute | Tampa33612 | NCT07007312 | Map |
| FL | Saint Joseph's Hospital - Tampa | Tampa33607 | NCT05183035 | Map |
| FL | Saint Joseph's Hospital/Children's Hospital-Tampa | Tampa33607 | NCT06317662 | Map |
| FL | Saint Mary's Medical Center | West Palm Beach33407 | NCT06317662 | Map |
| FL | Cleveland Clinic Florida | Weston33331-3609 | NCT06846671 | Map |
| FL | Cleveland Clinic Florida | Weston33331 | NCT06852222 | Map |
| FL | Cleveland Clinic Florida | Weston33331-3609 | NCT06943872 | Map |
| GA | Phoebe Putney Memorial Hospital | Albany31701 | NCT05554393 | Map |
| GA | Phoebe Putney Memorial Hospital | Albany31701 | NCT05554406 | Map |
| GA | Phoebe Putney Memorial Hospital | Albany31701 | NCT05564390 | Map |
| GA | Phoebe Putney Memorial Hospital | Albany31701 | NCT06317649 | Map |
| GA | Children's Healthcare of Atlanta | Atlanta30322 | NCT05183035 | Map |
| GA | Children's Healthcare of Atlanta | Atlanta30329 | NCT06177067 | Map |
| GA | Children's Healthcare of Atlanta - Arthur M Blank Hospital | Atlanta30329 | NCT06317662 | Map |
| GA | Children's Healthcare of Atlanta at Arthur M. Blank Hospital | Atlanta30329 | NCT05292664 | Map |
| GA | Emory Healthcare - The Emory Clinic | Atlanta30308 | NCT05735184 | Map |
| GA | Emory University | Atlanta30308 | NCT03013998 | Map |
| GA | Emory University Winship Cancer Institute | Atlanta30322-1013 | NCT06846671 | Map |
| GA | Emory Winship Cancer Institute | Atlanta30322 | NCT04068597 | Map |
| GA | Northside Cancer Center | Atlanta30342 | NCT06846671 | Map |
| GA | The Blood and Marrow Transplant Group of Georgia (BMTGA) | Atlanta30342 | NCT03331198 | Map |
| GA | University of Emory - Winship Cancer Institute | Atlanta30322 | NCT04256317 | Map |
| GA | Winship Cancer Institute of Emory University /ID# 230643 | Atlanta30322 | NCT04895436 | Map |
| GA | Augusta University Medical Center | Augusta30912 | NCT05554406 | Map |
| GA | Augusta University Medical Center | Augusta30912 | NCT05564390 | Map |
| GA | Augusta University Medical Center | Augusta30912 | NCT06317649 | Map |
| GA | Augusta University Medical Center | Augusta30912 | NCT06672146 | Map |
| GA | Georgia Cancer Center at Augusta University | Augusta30912 | NCT05735184 | Map |
| GA | City of Hope - Atlanta | Newnan30265 | NCT04588922 | Map |
| GA | City of Hope Atlanta Cancer Center | Newnan30265 | NCT07218510 | Map |
| HI | Hawaii Cancer Care - Westridge | ‘Aiea96701 | NCT05554406 | Map |
| HI | Hawaii Cancer Care - Westridge | ‘Aiea96701 | NCT05564390 | Map |
| HI | Hawaii Cancer Care - Westridge | ‘Aiea96701 | NCT06317649 | Map |
| HI | Pali Momi Medical Center | ‘Aiea96701 | NCT05554406 | Map |
| HI | Pali Momi Medical Center | ‘Aiea96701 | NCT05564390 | Map |
| HI | Pali Momi Medical Center | ‘Aiea96701 | NCT06317649 | Map |
| HI | Hawaii Cancer Care Inc - Waterfront Plaza | Honolulu96813 | NCT05554406 | Map |
| HI | Hawaii Cancer Care Inc - Waterfront Plaza | Honolulu96813 | NCT05564390 | Map |
| HI | Hawaii Cancer Care Inc - Waterfront Plaza | Honolulu96813 | NCT06317649 | Map |
| HI | Kaiser Permanente Moanalua Medical Center | Honolulu96819 | NCT05564390 | Map |
| HI | Kaiser Permanente Moanalua Medical Center | Honolulu96819 | NCT06317649 | Map |
| HI | Kapi'olani Medical Center for Women and Children | Honolulu96826 | NCT05183035 | Map |
| HI | Kapiolani Medical Center for Women and Children | Honolulu96826 | NCT05554406 | Map |
| HI | Kapiolani Medical Center for Women and Children | Honolulu96826 | NCT05564390 | Map |
| HI | Kapiolani Medical Center for Women and Children | Honolulu96826 | NCT06317662 | Map |
| HI | Straub Clinic and Hospital | Honolulu96813 | NCT05554406 | Map |
| HI | Straub Clinic and Hospital | Honolulu96813 | NCT05564390 | Map |
| HI | Straub Clinic and Hospital | Honolulu96813 | NCT06317649 | Map |
| ID | Boise VA Medical Center | Boise83702 | NCT05963074 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT05554393 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT05554406 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT05564390 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT04269902 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT06317649 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT05554393 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT05554406 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT05564390 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT06317649 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT06317662 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT06672146 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT05554393 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT05554406 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT05564390 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT04269902 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT06317649 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT05554393 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT05554406 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT05564390 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT04269902 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT06317649 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT06672146 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT05554393 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT05554406 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT05564390 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT06317649 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT06672146 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT05554393 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT05554406 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT05564390 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT06317649 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT06672146 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT05554393 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT05554406 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT05564390 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT04840602 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT04269902 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT06317649 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT06672146 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT05554393 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT05554406 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT05564390 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT06317649 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT06672146 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT05554393 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT05554406 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT05564390 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT04269902 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT06317649 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT06672146 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT05554393 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT05554406 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT05564390 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT04269902 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT06317649 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT06672146 | Map |
| IL | Advocate Outpatient Center - Aurora | Aurora60506 | NCT05564390 | Map |
| IL | Rush-Copley Medical Center | Aurora60504 | NCT04269902 | Map |
| IL | Advocate Good Shepherd Hospital | Barrington60010 | NCT05564390 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT05554406 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT05564390 | Map |
| IL | OSF Saint Joseph Medical Center | Bloomington61701 | NCT05554406 | Map |
| IL | OSF Saint Joseph Medical Center | Bloomington61701 | NCT05564390 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT05554406 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT05564390 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT05554406 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT05564390 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT05554393 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT04840602 | Map |
| IL | Advocate Illinois Masonic Medical Center | Chicago60657 | NCT05564390 | Map |
| IL | Ann & Robert H Lurie Children's Hospital of Chicago | Chicago60611 | NCT05292664 | Map |
| IL | Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago60611 | NCT05183035 | Map |
| IL | Comer Children's Hospital | Chicago60637 | NCT05183035 | Map |
| IL | Lurie Children's Hospital-Chicago | Chicago60611 | NCT06317662 | Map |
| IL | Northwestern | Chicago60611 | NCT04988555 | Map |
| IL | Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion | Chicago60611 | NCT06501196 | Map |
| IL | Northwestern Memorial Hospital | Chicago60611 | NCT03331198 | Map |
| IL | Northwestern Memorial Hospital | Chicago60611 | NCT06419634 | Map |
| IL | Northwestern University | Chicago60611 | NCT05554393 | Map |
| IL | Northwestern University | Chicago60611 | NCT05554406 | Map |
| IL | Northwestern University | Chicago60611 | NCT05564390 | Map |
| IL | Northwestern University | Chicago60611 | NCT04269902 | Map |
| IL | Northwestern University | Chicago60611 | NCT03331198 | Map |
| IL | Northwestern University | Chicago60611 | NCT06317649 | Map |
| IL | Northwestern University | Chicago60611 | NCT06649812 | Map |
| IL | Northwestern University | Chicago60611 | NCT06672146 | Map |
| IL | Northwestern University | Chicago60611 | NCT06943872 | Map |
| IL | Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago60611 | NCT05735184 | Map |
| IL | University of Chicago | Chicago60637 | NCT03013998 | Map |
| IL | University of Chicago | Chicago60637 | NCT06456463 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05554393 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05554406 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05564390 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT04269902 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT06317662 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT06672146 | Map |
| IL | University of Chicago Medical Center | Chicago60637 | NCT04855695 | Map |
| IL | University of Chicago Medical Center | Chicago60637 | NCT03331198 | Map |
| IL | University Of Chicago Medical Center | Chicago60637 | NCT03331198 | Map |
| IL | University of Chicago Medicine | Chicago60637 | NCT06852222 | Map |
| IL | University of Chicago Medicine Comprehensive Cancer Center | Chicago60637 | NCT07294677 | Map |
| IL | University of Illinois | Chicago60612 | NCT05564390 | Map |
| IL | University of Illinois | Chicago60612 | NCT06317649 | Map |
| IL | University of Illinois | Chicago60612 | NCT06672146 | Map |
| IL | AMG Crystal Lake - Oncology | Crystal Lake60014 | NCT05564390 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT05564390 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT04840602 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT04269902 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT06317649 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT05554393 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT05554406 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT05564390 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT04840602 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT04269902 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT06317649 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT05554393 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT05554406 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT05564390 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT06317649 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT05564390 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT04269902 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT06317649 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT06649812 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT06672146 | Map |
| IL | Illinois CancerCare-Dixon | Dixon61021 | NCT05554406 | Map |
| IL | Illinois CancerCare-Dixon | Dixon61021 | NCT05564390 | Map |
| IL | Advocate Good Samaritan Hospital | Downers Grove60515 | NCT05564390 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT05564390 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT04840602 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT04269902 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT06317649 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT05554393 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT05554406 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT05564390 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT04840602 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT04269902 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT06317649 | Map |
| IL | Advocate Sherman Hospital | Elgin60123 | NCT05564390 | Map |
| IL | Elmhurst Memorial Hospital | Elmhurst60126 | NCT04269902 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT05554406 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT05564390 | Map |
| IL | NorthShore University HealthSystem-Evanston Hospital | Evanston60201 | NCT05554393 | Map |
| IL | NorthShore University HealthSystem-Evanston Hospital | Evanston60201 | NCT05554406 | Map |
| IL | NorthShore University HealthSystem-Evanston Hospital | Evanston60201 | NCT05564390 | Map |
| IL | NorthShore University HealthSystem-Evanston Hospital | Evanston60201 | NCT04269902 | Map |
| IL | NorthShore University HealthSystem-Evanston Hospital | Evanston60201 | NCT06317649 | Map |
| IL | NorthShore University HealthSystem-Evanston Hospital | Evanston60201 | NCT06672146 | Map |
| IL | Northwestern University | Evanston60208 | NCT03824483 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT05554406 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT05564390 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT05564390 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT04269902 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT06317649 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT06649812 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT06672146 | Map |
| IL | NorthShore University HealthSystem-Glenbrook Hospital | Glenview60026 | NCT05554393 | Map |
| IL | NorthShore University HealthSystem-Glenbrook Hospital | Glenview60026 | NCT05554406 | Map |
| IL | NorthShore University HealthSystem-Glenbrook Hospital | Glenview60026 | NCT05564390 | Map |
| IL | NorthShore University HealthSystem-Glenbrook Hospital | Glenview60026 | NCT04269902 | Map |
| IL | NorthShore University HealthSystem-Glenbrook Hospital | Glenview60026 | NCT06317649 | Map |
| IL | NorthShore University HealthSystem-Glenbrook Hospital | Glenview60026 | NCT06672146 | Map |
| IL | Northwestern Medicine Glenview Outpatient Center | Glenview60026 | NCT05564390 | Map |
| IL | Northwestern Medicine Glenview Outpatient Center | Glenview60026 | NCT04269902 | Map |
| IL | Northwestern Medicine Glenview Outpatient Center | Glenview60026 | NCT06317649 | Map |
| IL | Northwestern Medicine Glenview Outpatient Center | Glenview60026 | NCT06649812 | Map |
| IL | Northwestern Medicine Glenview Outpatient Center | Glenview60026 | NCT06672146 | Map |
| IL | Northwestern Medicine Grayslake Outpatient Center | Grayslake60030 | NCT05564390 | Map |
| IL | Northwestern Medicine Grayslake Outpatient Center | Grayslake60030 | NCT04269902 | Map |
| IL | Northwestern Medicine Grayslake Outpatient Center | Grayslake60030 | NCT06317649 | Map |
| IL | Northwestern Medicine Grayslake Outpatient Center | Grayslake60030 | NCT06649812 | Map |
| IL | Northwestern Medicine Grayslake Outpatient Center | Grayslake60030 | NCT06672146 | Map |
| IL | Ingalls Memorial Hospital | Harvey60426 | NCT04269902 | Map |
| IL | Advocate South Suburban Hospital | Hazel Crest60429 | NCT05564390 | Map |
| IL | NorthShore University HealthSystem-Highland Park Hospital | Highland Park60035 | NCT05554393 | Map |
| IL | NorthShore University HealthSystem-Highland Park Hospital | Highland Park60035 | NCT05554406 | Map |
| IL | NorthShore University HealthSystem-Highland Park Hospital | Highland Park60035 | NCT05564390 | Map |
| IL | NorthShore University HealthSystem-Highland Park Hospital | Highland Park60035 | NCT04269902 | Map |
| IL | NorthShore University HealthSystem-Highland Park Hospital | Highland Park60035 | NCT06317649 | Map |
| IL | NorthShore University HealthSystem-Highland Park Hospital | Highland Park60035 | NCT06672146 | Map |
| IL | Edward Hines Jr VA Hospital | Hines60141 | NCT05564390 | Map |
| IL | Edward Hines Jr VA Hospital | Hines60141 | NCT06317649 | Map |
| IL | Hope and Healing Cancer Services | Hinsdale60521 | NCT05963074 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT05554406 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT05564390 | Map |
| IL | Northwestern Medicine Lake Forest Hospital | Lake Forest60045 | NCT05564390 | Map |
| IL | Northwestern Medicine Lake Forest Hospital | Lake Forest60045 | NCT04269902 | Map |
| IL | Northwestern Medicine Lake Forest Hospital | Lake Forest60045 | NCT06317649 | Map |
| IL | Northwestern Medicine Lake Forest Hospital | Lake Forest60045 | NCT06649812 | Map |
| IL | Northwestern Medicine Lake Forest Hospital | Lake Forest60045 | NCT06672146 | Map |
| IL | AMG Libertyville - Oncology | Libertyville60048 | NCT05564390 | Map |
| IL | Condell Memorial Hospital | Libertyville60048 | NCT05564390 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT05554406 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT05564390 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT05564390 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT04840602 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT04269902 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT06317649 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT05554393 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT05554406 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT05564390 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT04269902 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT05735184 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT06317649 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT06672146 | Map |
| IL | SSM Health Good Samaritan | Mount Vernon62864 | NCT04269902 | Map |
| IL | Edward Hospital/Cancer Center | Naperville60540 | NCT04269902 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT05554393 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT05554406 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT04269902 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT06672146 | Map |
| IL | Illinois Cancer Specialists | Niles60714 | NCT06852222 | Map |
| IL | Illinois Cancer Specialists (Niles) Usor | Niles60714-5905 | NCT06943872 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT05554393 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT05554406 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT05564390 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT04840602 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT04269902 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT06317649 | Map |
| IL | Northwestern Medicine Oak Brook | Oak Brook60523 | NCT06649812 | Map |
| IL | Advocate Children's Hospital-Oak Lawn | Oak Lawn60453 | NCT06317662 | Map |
| IL | Advocate Christ Medical Center | Oak Lawn60453-2699 | NCT05564390 | Map |
| IL | Advocate Outpatient Center - Oak Lawn | Oak Lawn60453 | NCT05564390 | Map |
| IL | Northwestern Medicine Orland Park | Orland Park60462 | NCT05564390 | Map |
| IL | Northwestern Medicine Orland Park | Orland Park60462 | NCT06317649 | Map |
| IL | Northwestern Medicine Orland Park | Orland Park60462 | NCT06649812 | Map |
| IL | Northwestern Medicine Orland Park | Orland Park60462 | NCT06672146 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT05554393 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT05554406 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT04269902 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT06672146 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT05554406 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT05564390 | Map |
| IL | Advocate High Tech Medical Park | Palos Heights60463 | NCT05564390 | Map |
| IL | Advocate Children's Hospital-Park Ridge | Park Ridge60068 | NCT06317662 | Map |
| IL | Advocate Lutheran General Hospital | Park Ridge60068 | NCT05564390 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT05554406 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT05564390 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT05554406 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT05564390 | Map |
| IL | Methodist Medical Center of Illinois | Peoria61636 | NCT05554406 | Map |
| IL | Methodist Medical Center of Illinois | Peoria61636 | NCT05564390 | Map |
| IL | OSF Saint Francis Medical Center | Peoria61637 | NCT05554406 | Map |
| IL | OSF Saint Francis Medical Center | Peoria61637 | NCT05564390 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT05554406 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT05564390 | Map |
| IL | Edward Hospital/Cancer Center?Plainfield | Plainfield60585 | NCT04269902 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT05554406 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT05564390 | Map |
| IL | UW Health Carbone Cancer Center Rockford | Rockford61114 | NCT04269902 | Map |
| IL | Memorial Hospital East | Shiloh62269 | NCT06317649 | Map |
| IL | Memorial Hospital East | Shiloh62269 | NCT06649812 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT05554393 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT05554406 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT05564390 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT04840602 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT04269902 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT06317649 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT06317662 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT05554393 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT05554406 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT05564390 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT04840602 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT04269902 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT05963074 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT06317649 | Map |
| IL | Springfield Clinic - First /ID# 270145 | Springfield62702 | NCT06428019 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT05554393 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT05554406 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT05564390 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT04840602 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT06317649 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT05564390 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT04840602 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT04269902 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT06317649 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT05564390 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT04269902 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT06317649 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT06649812 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT06672146 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT05554406 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT05564390 | Map |
| IL | Rush-Copley Healthcare Center | Yorkville60560 | NCT04269902 | Map |
| IL | City of Hope - Chicago | Zion60099 | NCT04588922 | Map |
| IN | UChicago Medicine Northwest Indiana | Crown Point46307 | NCT05554393 | Map |
| IN | UChicago Medicine Northwest Indiana | Crown Point46307 | NCT05554406 | Map |
| IN | UChicago Medicine Northwest Indiana | Crown Point46307 | NCT04269902 | Map |
| IN | UChicago Medicine Northwest Indiana | Crown Point46307 | NCT06672146 | Map |
| IN | Northwest Cancer Center - Dyer Clinic /ID# 268478 | Dyer46311 | NCT06428019 | Map |
| IN | Community Health Network | Indianapolis46227 | NCT04068597 | Map |
| IN | Franciscan St. Francis Health - Indiana Blood and Marrow Transplantation (IBMT) | Indianapolis46237 | NCT03331198 | Map |
| IN | Indiana University School of Medicine | Indianapolis46202 | NCT05183035 | Map |
| IN | Indiana University/Melvin and Bren Simon Cancer Center | Indianapolis46202 | NCT05554406 | Map |
| IN | Indiana University/Melvin and Bren Simon Cancer Center | Indianapolis46202 | NCT05564390 | Map |
| IN | Indiana University/Melvin and Bren Simon Cancer Center | Indianapolis46202 | NCT04269902 | Map |
| IN | Indiana University/Melvin and Bren Simon Cancer Center | Indianapolis46202 | NCT06317649 | Map |
| IN | Riley Hospital for Children | Indianapolis46202 | NCT06317662 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT04840602 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT04269902 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT06649812 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT04840602 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT04269902 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT06649812 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT05564390 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT04269902 | Map |
| IA | Mercy Hospital | Cedar Rapids52403 | NCT06649812 | Map |
| IA | Oncology Associates at Mercy Medical Center | Cedar Rapids52403 | NCT06649812 | Map |
| IA | Physicians' Clinic of Iowa PC | Cedar Rapids52402 | NCT04269902 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT05564390 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT04269902 | Map |
| IA | Blank Children's Hospital | Des Moines50309 | NCT06317662 | Map |
| IA | Broadlawns Medical Center | Des Moines50314 | NCT04269902 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT05564390 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT04269902 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT05564390 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT04269902 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT05564390 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT04269902 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT05564390 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT04269902 | Map |
| IA | University of Iowa Health Care /ID# 267206 | Des Moines50314-3017 | NCT06428019 | Map |
| IA | McFarland Clinic - Trinity Cancer Center | Fort Dodge50501 | NCT04840602 | Map |
| IA | McFarland Clinic - Trinity Cancer Center | Fort Dodge50501 | NCT04269902 | Map |
| IA | McFarland Clinic - Trinity Cancer Center | Fort Dodge50501 | NCT06649812 | Map |
| IA | Iowa City VA Health Care System | Iowa City52246 | NCT05963074 | Map |
| IA | University of Iowa | Iowa City52246 | NCT07007312 | Map |
| IA | University of Iowa Health Care | Iowa City52242 | NCT07177079 | Map |
| IA | University of Iowa Hospitals & Clinics | Iowa City52242 | NCT05735184 | Map |
| IA | University of Iowa Stead Family Children's Hospital | Iowa City52242 | NCT05183035 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT05554393 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT05554406 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT05564390 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT06317649 | Map |
| IA | McFarland Clinic - Marshalltown | Marshalltown50158 | NCT04840602 | Map |
| IA | McFarland Clinic - Marshalltown | Marshalltown50158 | NCT04269902 | Map |
| IA | McFarland Clinic - Marshalltown | Marshalltown50158 | NCT06649812 | Map |
| IA | UI Healthcare Mission Cancer and Blood - Pella | Pella50219 | NCT05564390 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT05564390 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT04269902 | Map |
| IA | The Iowa Clinic PC | West Des Moines50266 | NCT05564390 | Map |
| KS | The University of Kansas Cancer Center ,Investigational Drug Services | Fairway66205 | NCT04227847 | Map |
| KS | The University of Kansas Clinical Research Center | Fairway66205 | NCT04227847 | Map |
| KS | The University of Kansas Medical Center Research Institute | Fairway66205 | NCT05735184 | Map |
| KS | University of Kansas | Fairway66205 | NCT06634394 | Map |
| KS | University of Kansas Clinical Research Center | Fairway66205 | NCT05554393 | Map |
| KS | University of Kansas Clinical Research Center | Fairway66205 | NCT05554406 | Map |
| KS | University of Kansas Clinical Research Center | Fairway66205 | NCT05564390 | Map |
| KS | University of Kansas Clinical Research Center | Fairway66205 | NCT03013998 | Map |
| KS | University of Kansas Clinical Research Center | Fairway66205 | NCT06317649 | Map |
| KS | University of Kansas Clinical Research Center | Fairway66205 | NCT06672146 | Map |
| KS | HaysMed | Hays67601 | NCT05564390 | Map |
| KS | HaysMed | Hays67601 | NCT04269902 | Map |
| KS | The University of Kansas Hospital | Kansas City66160 | NCT04227847 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT05554393 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT05554406 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT05564390 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT04269902 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT06311227 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT06317649 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT06672146 | Map |
| KS | University of Kansas Hospital Cambridge North Tower A | Kansas City66160 | NCT04227847 | Map |
| KS | University of Kansas Medical center Medical office building | Kansas City66160 | NCT04227847 | Map |
| KS | University of Kansas Medical Center Research Institute | Kansas City66160 | NCT04227847 | Map |
| KS | Lawrence Memorial Hospital | Lawrence66044 | NCT05564390 | Map |
| KS | Lawrence Memorial Hospital | Lawrence66044 | NCT04269902 | Map |
| KS | The University of Kansas Cancer Center - Olathe | Olathe66061 | NCT05564390 | Map |
| KS | The University of Kansas Cancer Center - Olathe | Olathe66061 | NCT04269902 | Map |
| KS | The University of Kansas Cancer Center - Indian Creek Campus | Overland Park66211 | NCT04227847 | Map |
| KS | The University of Kansas Cancer Center - Overland Park | Overland Park66210 | NCT04227847 | Map |
| KS | University of Kansas Cancer Center-Overland Park | Overland Park66210 | NCT05564390 | Map |
| KS | University of Kansas Cancer Center-Overland Park | Overland Park66210 | NCT04269902 | Map |
| KS | University of Kansas Cancer Center-Overland Park | Overland Park66210 | NCT06311227 | Map |
| KS | University of Kansas Hospital-Indian Creek Campus | Overland Park66211 | NCT05554393 | Map |
| KS | University of Kansas Hospital-Indian Creek Campus | Overland Park66211 | NCT05554406 | Map |
| KS | University of Kansas Hospital-Indian Creek Campus | Overland Park66211 | NCT05564390 | Map |
| KS | University of Kansas Hospital-Indian Creek Campus | Overland Park66211 | NCT06317649 | Map |
| KS | Salina Regional Health Center | Salina67401 | NCT05564390 | Map |
| KS | Salina Regional Health Center | Salina67401 | NCT04269902 | Map |
| KS | Cotton O'Neil Cancer Center / Stormont Vail Health | Topeka66606 | NCT06317649 | Map |
| KS | University of Kansas Health System Saint Francis Campus | Topeka66606 | NCT05564390 | Map |
| KS | University of Kansas Health System Saint Francis Campus | Topeka66606 | NCT04269902 | Map |
| KS | The University of Kansas Cancer Center | Westwood66205 | NCT04227847 | Map |
| KS | The University of Kansas Medical Center | Westwood66205 | NCT06445959 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT05554393 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT05554406 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT05564390 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT04269902 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT06311227 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT06317649 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT06672146 | Map |
| KY | University of Kentucky | Lexington40536 | NCT07007312 | Map |
| KY | University of Kentucky Markey Cancer Center | Lexington40536 | NCT06852222 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT05554393 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT05554406 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT05564390 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT06317649 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT06317662 | Map |
| KY | Norton Cancer Institute | Louisville40207 | NCT06852222 | Map |
| KY | Norton Cancer Institute - St. Matthews | Louisville40207 | NCT05735184 | Map |
| KY | Norton Cancer Institute, St. Matthews Campus | Louisville40207 | NCT04227847 | Map |
| KY | Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD | Louisville40207 | NCT04227847 | Map |
| KY | Norton Children's Hospital | Louisville40202 | NCT05183035 | Map |
| KY | Norton Children's Hospital | Louisville40202 | NCT06317662 | Map |
| KY | Norton Healthcare - Norton Cancer Institute | Louisville40202 | NCT03331198 | Map |
| KY | Norton Hospitals, Inc | Louisville40202 | NCT04227847 | Map |
| KY | Norton Women & Children's Hospital | Louisville40207 | NCT04227847 | Map |
| KY | The James Graham Brown Cancer Center at University of Louisville | Louisville40202 | NCT05554393 | Map |
| KY | The James Graham Brown Cancer Center at University of Louisville | Louisville40202 | NCT05554406 | Map |
| KY | The James Graham Brown Cancer Center at University of Louisville | Louisville40202 | NCT05564390 | Map |
| KY | The James Graham Brown Cancer Center at University of Louisville | Louisville40202 | NCT06317649 | Map |
| KY | The James Graham Brown Cancer Center at University of Louisville | Louisville40202 | NCT06672146 | Map |
| KY | University of Kentucky Markey Cancer Center | Louisville40202 | NCT05735184 | Map |
| KY | University of Louisville, Brown Cancer Center | Louisville40202 | NCT06943872 | Map |
| KY | UofL Health Brown Cancer Center | Louisville40202 | NCT06852222 | Map |
| KY | UofL Health Medical Center Northeast | Louisville40245 | NCT05554393 | Map |
| KY | UofL Health Medical Center Northeast | Louisville40245 | NCT05554406 | Map |
| KY | UofL Health Medical Center Northeast | Louisville40245 | NCT05564390 | Map |
| KY | UofL Health Medical Center Northeast | Louisville40245 | NCT06317649 | Map |
| KY | UofL Health Medical Center Northeast | Louisville40245 | NCT06672146 | Map |
| LA | LSU Health Baton Rouge-North Clinic | Baton Rouge70805 | NCT05554393 | Map |
| LA | LSU Health Baton Rouge-North Clinic | Baton Rouge70805 | NCT05554406 | Map |
| LA | LSU Health Baton Rouge-North Clinic | Baton Rouge70805 | NCT05564390 | Map |
| LA | LSU Health Baton Rouge-North Clinic | Baton Rouge70805 | NCT06317649 | Map |
| LA | Mary Bird Perkins Cancer Center | Baton Rouge70809 | NCT06852222 | Map |
| LA | Mary Bird Perkins Cancer Center | Baton Rouge70809-3738 | NCT06943872 | Map |
| LA | Our Lady of The Lake | Baton Rouge70808 | NCT05554393 | Map |
| LA | Our Lady of The Lake | Baton Rouge70808 | NCT05554406 | Map |
| LA | Our Lady of The Lake | Baton Rouge70808 | NCT05564390 | Map |
| LA | Our Lady of The Lake | Baton Rouge70808 | NCT06317649 | Map |
| LA | Our Lady of The Lake | Baton Rouge70808 | NCT06672146 | Map |
| LA | Our Lady of the Lake Hospital | Baton Rouge70808-4365 | NCT06846671 | Map |
| LA | Our Lady of the Lake Physician Group | Baton Rouge70808 | NCT05554393 | Map |
| LA | Our Lady of the Lake Physician Group | Baton Rouge70808 | NCT05554406 | Map |
| LA | Our Lady of the Lake Physician Group | Baton Rouge70808 | NCT05564390 | Map |
| LA | Our Lady of the Lake Physician Group | Baton Rouge70808 | NCT06317649 | Map |
| LA | Our Lady of the Lake Physician Group | Baton Rouge70808 | NCT06672146 | Map |
| LA | Ochsner MD Anderson Cancer Center | Jefferson70121 | NCT05735184 | Map |
| LA | Children's Hospital New Orleans | New Orleans70118 | NCT06317662 | Map |
| LA | Ochsner Medical Center Jefferson | New Orleans70121 | NCT06317662 | Map |
| LA | Ochsner Medical Center Jefferson | New Orleans70121 | NCT06649812 | Map |
| ME | Harold Alfond Center for Cancer Care | Augusta04330 | NCT04269902 | Map |
| ME | MaineHealth Cancer Care and IV Therapy - Brunswick | Brunswick04011 | NCT05564390 | Map |
| ME | MaineHealth Cancer Care and IV Therapy - Brunswick | Brunswick04011 | NCT04269902 | Map |
| ME | MaineHealth Cancer Care and IV Therapy - Brunswick | Brunswick04011 | NCT06317649 | Map |
| ME | MaineHealth Cancer Care and IV Therapy - Brunswick | Brunswick04011 | NCT06672146 | Map |
| ME | Mid Coast Hospital | Brunswick04011 | NCT05564390 | Map |
| ME | Mid Coast Hospital | Brunswick04011 | NCT04269902 | Map |
| ME | Mid Coast Hospital | Brunswick04011 | NCT06317649 | Map |
| ME | Mid Coast Hospital | Brunswick04011 | NCT06672146 | Map |
| ME | MaineHealth LincolnHealth Hospital | Damariscotta04543 | NCT04269902 | Map |
| ME | MaineHealth Maine Medical Center - Portland | Portland04102 | NCT05554393 | Map |
| ME | MaineHealth Maine Medical Center - Portland | Portland04102 | NCT05554406 | Map |
| ME | MaineHealth Maine Medical Center - Portland | Portland04102 | NCT05564390 | Map |
| ME | MaineHealth Maine Medical Center - Portland | Portland04102 | NCT04269902 | Map |
| ME | MaineHealth Maine Medical Center - Portland | Portland04102 | NCT06317649 | Map |
| ME | MaineHealth Maine Medical Center - Portland | Portland04102 | NCT06672146 | Map |
| ME | Maine Children's Cancer Program | Scarborough04074 | NCT06317662 | Map |
| ME | MaineHealth Maine Medical Center- Scarborough | Scarborough04074 | NCT05554393 | Map |
| ME | MaineHealth Maine Medical Center- Scarborough | Scarborough04074 | NCT05554406 | Map |
| ME | MaineHealth Maine Medical Center- Scarborough | Scarborough04074 | NCT05564390 | Map |
| ME | MaineHealth Maine Medical Center- Scarborough | Scarborough04074 | NCT04269902 | Map |
| ME | MaineHealth Maine Medical Center- Scarborough | Scarborough04074 | NCT06317649 | Map |
| ME | MaineHealth Maine Medical Center- Scarborough | Scarborough04074 | NCT06672146 | Map |
| ME | New England Cancer Specialists | Scarborough04074 | NCT05168930 | Map |
| ME | MaineHealth Cancer Care and IV Therapy - South Portland | South Portland04106 | NCT05554393 | Map |
| ME | MaineHealth Cancer Care and IV Therapy - South Portland | South Portland04106 | NCT05554406 | Map |
| ME | MaineHealth Cancer Care and IV Therapy - South Portland | South Portland04106 | NCT05564390 | Map |
| ME | MaineHealth Cancer Care and IV Therapy - South Portland | South Portland04106 | NCT04269902 | Map |
| ME | MaineHealth Cancer Care and IV Therapy - South Portland | South Portland04106 | NCT06317649 | Map |
| ME | MaineHealth Cancer Care and IV Therapy - South Portland | South Portland04106 | NCT06672146 | Map |
| MD | Johns Hopkins Main Center | Baltimore21287 | NCT04988555 | Map |
| MD | Johns Hopkins School of Medicine | Baltimore21205 | NCT05735184 | Map |
| MD | Johns Hopkins University | Baltimore21218 | NCT06284486 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT05554406 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT05564390 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT04269902 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT06317662 | Map |
| MD | Sibley Memorial Hospital | Baltimore20016 | NCT04988555 | Map |
| MD | Sinai Hospital of Baltimore | Baltimore21215 | NCT06317662 | Map |
| MD | University of Maryland | Baltimore21201 | NCT04988555 | Map |
| MD | University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore21201-1544 | NCT06943872 | Map |
| MD | University of Maryland Medical Center | Baltimore21201 | NCT03013998 | Map |
| MD | University of Maryland/Greenebaum Cancer Center | Baltimore21201 | NCT06311227 | Map |
| MD | American Oncology Partners of Maryland Pa | Bethesda20817-7847 | NCT06846671 | Map |
| MD | Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 266445 | Bethesda20817 | NCT06428019 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT03986034 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT03223610 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT06649812 | Map |
| MD | NCI - Center for Cancer Research | Bethesda20892 | NCT06311227 | Map |
| MD | The Center for Cancer and Blood Disorders (CCBD) | Bethesda20817 | NCT04068597 | Map |
| MD | Walter Reed National Military Medical Center | Bethesda20889-5600 | NCT05554393 | Map |
| MD | Walter Reed National Military Medical Center | Bethesda20889-5600 | NCT05554406 | Map |
| MD | Walter Reed National Military Medical Center | Bethesda20889-5600 | NCT05564390 | Map |
| MD | Walter Reed National Military Medical Center | Bethesda20889-5600 | NCT04269902 | Map |
| MD | Walter Reed National Military Medical Center | Bethesda20889-5600 | NCT06317649 | Map |
| MD | Maryland Oncology Hematology - Silver Spring /ID# 267557 | Silver Spring20904 | NCT06428019 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT05554406 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT05564390 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT04855695 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT04227847 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT03331198 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT05168930 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06317649 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06456463 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06510309 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT07374029 | Map |
| MA | Boston Medical Center | Boston02118 | NCT05451771 | Map |
| MA | Brigham and Women's Hospital | Boston02215 | NCT06152809 | Map |
| MA | Brigham and Women's Hospital | Boston02115 | NCT07148180 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT03113643 | Map |
| MA | Dana Farber Cancer Institute | Boston02115 | NCT06852222 | Map |
| MA | Dana Farber Cancer Institute | Boston02215-5418 | NCT06943872 | Map |
| MA | Dana Farber Cancer Institute (Data Collection and Specimen Analysis) | Boston02115 | NCT07231952 | Map |
| MA | Dana Farber Cancer Institute (DFCI) | Boston02114 | NCT06456463 | Map |
| MA | Dana Farber/Mass General Brigham Cancer Care, Inc | Boston02215 | NCT04227847 | Map |
| MA | Dana-Farber Cancer Center | Boston02215 | NCT06284486 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05292664 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05554393 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05554406 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05564390 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT04855695 | Map |
| MA | Dana-Farber Cancer Institute | Boston02114 | NCT04256317 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT04269902 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT03471260 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05168930 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05183035 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06152809 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06317649 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06317662 | Map |
| MA | Dana-Farber Cancer Institute | Boston02115 | NCT06644183 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT07148180 | Map |
| MA | Dana-Farber Cancer Institute /ID# 230061 | Boston02215 | NCT04895436 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT04988555 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT04227847 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT05735184 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT03331198 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT06419634 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT06456463 | Map |
| MA | Massachusetts General Hospital (Data Collection and Specimen Analysis) | Boston02114 | NCT03824483 | Map |
| MA | Massachusetts General Hospital Cancer Center | Boston02114 | NCT04560322 | Map |
| MA | Tufts Medical Center | Boston02111 | NCT05554393 | Map |
| MA | Tufts Medical Center | Boston02111 | NCT05554406 | Map |
| MA | Tufts Medical Center | Boston02111 | NCT05564390 | Map |
| MA | Tufts Medical Center | Boston02111 | NCT04269902 | Map |
| MA | Tufts Medical Center | Boston02111 | NCT06317649 | Map |
| MA | Tufts Medical Center | Boston02111 | NCT06672146 | Map |
| MA | Lahey Hospital and Medical Center | Burlington01805 | NCT05554393 | Map |
| MA | Lahey Hospital and Medical Center | Burlington01805 | NCT05554406 | Map |
| MA | Lahey Hospital and Medical Center | Burlington01805 | NCT06317649 | Map |
| MA | Lahey Medical Center-Peabody | Peabody01960 | NCT05554393 | Map |
| MA | Lahey Medical Center-Peabody | Peabody01960 | NCT05554406 | Map |
| MA | Lahey Medical Center-Peabody | Peabody01960 | NCT06317649 | Map |
| MA | South Shore Hospital | South Weymouth02190 | NCT05168930 | Map |
| MA | Tufts Medical Center Cancer Center Stoneham | Stoneham02180 | NCT04269902 | Map |
| MA | UMass Chan Medical School | Worcester01655 | NCT05735184 | Map |
| MA | UMass Memorial Medical Center - University Campus | Worcester01655 | NCT05564390 | Map |
| MA | UMass Memorial Medical Center - University Campus | Worcester01655 | NCT06317662 | Map |
| MA | UMass Memorial Medical Center /ID# 270023 | Worcester01655 | NCT06428019 | Map |
| MA | University of Massachusetts | Worcester01605 | NCT07007312 | Map |
| MI | C S Mott Children's Hospital | Ann Arbor48109 | NCT06317662 | Map |
| MI | C.S. Mott Children's Hospital | Ann Arbor48109-4259 | NCT05183035 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT05554406 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT05564390 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT04840602 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT04269902 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT03523975 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT07007312 | Map |
| MI | University of Michigan Comprehensive Cancer Center | Ann Arbor48109 | NCT05735184 | Map |
| MI | University of Michigan Comprehensive Cancer Center | Ann Arbor48109-5362 | NCT03331198 | Map |
| MI | University Of Michigan Comprehensive Cancer Center | Ann Arbor48109 | NCT03331198 | Map |
| MI | Bronson Battle Creek | Battle Creek49017 | NCT04269902 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT05554393 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT05554406 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT05564390 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT04840602 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT04269902 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT06317649 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT06672146 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT06917911 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT04840602 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT04269902 | Map |
| MI | Henry Ford Cancer Institute-Downriver | Brownstown48183 | NCT04269902 | — |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT05554393 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT05554406 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT05564390 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT04840602 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT04269902 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT06317649 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT06672146 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT06917911 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT04840602 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT04269902 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT04840602 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT04269902 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT05554393 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT05554406 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT05564390 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT04840602 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT04269902 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT06317649 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT06672146 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT06917911 | Map |
| MI | Hematology Oncology Consultants-Clarkston | Clarkston48346 | NCT04840602 | Map |
| MI | Hematology Oncology Consultants-Clarkston | Clarkston48346 | NCT04269902 | Map |
| MI | Henry Ford Macomb Hospital-Clinton Township | Clinton Township48038 | NCT05554393 | Map |
| MI | Henry Ford Macomb Hospital-Clinton Township | Clinton Township48038 | NCT05554406 | Map |
| MI | Henry Ford Macomb Hospital-Clinton Township | Clinton Township48038 | NCT05564390 | Map |
| MI | Henry Ford Macomb Hospital-Clinton Township | Clinton Township48038 | NCT04840602 | Map |
| MI | Henry Ford Macomb Hospital-Clinton Township | Clinton Township48038 | NCT04269902 | Map |
| MI | Henry Ford Macomb Hospital-Clinton Township | Clinton Township48038 | NCT06317649 | Map |
| MI | Henry Ford Macomb Hospital-Clinton Township | Clinton Township48038 | NCT06672146 | Map |
| MI | Henry Ford Medical Center-Fairlane | Dearborn48126 | NCT04269902 | Map |
| MI | Barbara Ann Karmanos Cancer Institute | Detroit48201 | NCT03331198 | Map |
| MI | Children's Hospital of Michigan | Detroit48201 | NCT05183035 | Map |
| MI | Henry Ford Health Saint John Hospital | Detroit48236 | NCT04269902 | Map |
| MI | Henry Ford Health System | Detroit48202 | NCT06852222 | Map |
| MI | Henry Ford Health System Brigitte Harris Cancer Pavillion | Detroit48202 | NCT06456463 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT05554393 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT05554406 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT05564390 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT04840602 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT04269902 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT06317649 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT06672146 | Map |
| MI | Henry Ford Hospital /ID# 270973 | Detroit48202 | NCT06428019 | Map |
| MI | Karmanos Cancer Institute | Detroit48201 | NCT04227847 | Map |
| MI | Karmanos Cancer Institute | Detroit48201 | NCT05735184 | Map |
| MI | Wayne State University School of Medicine | Detroit48201 | NCT07007312 | Map |
| MI | Wayne State University/Karmanos Cancer Institute | Detroit48201 | NCT05554406 | Map |
| MI | Wayne State University/Karmanos Cancer Institute | Detroit48201 | NCT05564390 | Map |
| MI | Henry Ford River District Hospital | East China Township48054 | NCT04269902 | — |
| MI | OSF Saint Francis Hospital and Medical Group | Escanaba49829 | NCT06672146 | Map |
| MI | Karmanos Cancer Institute Weisberg Cancer Treatment Center | Farmington Hills48334 | NCT04227847 | Map |
| MI | Weisberg Cancer Treatment Center | Farmington Hills48334 | NCT05554406 | Map |
| MI | Weisberg Cancer Treatment Center | Farmington Hills48334 | NCT05564390 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT05554393 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT05554406 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT05564390 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT04840602 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT04269902 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT06317649 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT06672146 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT05554393 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT05554406 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT05564390 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT04840602 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT04269902 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT06317649 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT06672146 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT05554393 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT05554406 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT05564390 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT04840602 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT04269902 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT06317649 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids49503 | NCT04269902 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital | Grand Rapids49503 | NCT06317662 | Map |
| MI | The Cancer and Hematology Centers | Grand Rapids49503-2563 | NCT06943872 | Map |
| MI | Trinity Health Grand Rapids Hospital | Grand Rapids49503 | NCT04269902 | Map |
| MI | Henry Ford Saint John Hospital - Academic | Grosse Pointe Woods48236 | NCT04269902 | Map |
| MI | Henry Ford Saint John Hospital - Van Elslander | Grosse Pointe Woods48236 | NCT04269902 | Map |
| MI | Allegiance Health | Jackson49201 | NCT05554393 | Map |
| MI | Allegiance Health | Jackson49201 | NCT05554406 | Map |
| MI | Allegiance Health | Jackson49201 | NCT05564390 | Map |
| MI | Allegiance Health | Jackson49201 | NCT04269902 | Map |
| MI | Allegiance Health | Jackson49201 | NCT06317649 | Map |
| MI | Allegiance Health | Jackson49201 | NCT06672146 | Map |
| MI | Beacon Kalamazoo Cancer Center | Kalamazoo49009 | NCT04269902 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT04269902 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT06317662 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT04269902 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT04840602 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT04269902 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT05554393 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT05554406 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT05564390 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT04840602 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT04269902 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT06317649 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT06672146 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT06917911 | Map |
| MI | Henry Ford Saint John Hospital - Macomb Medical | Macomb48044 | NCT04269902 | Map |
| MI | Trinity Health Muskegon Hospital | Muskegon49444 | NCT04269902 | Map |
| MI | Corewell Health Lakeland Hospitals - Niles Hospital | Niles49120 | NCT04269902 | Map |
| MI | Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores49444 | NCT04269902 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT05554393 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT05554406 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT05564390 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT04840602 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT04269902 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT06317649 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT06672146 | Map |
| MI | Michigan Healthcare Professionals Pontiac | Pontiac48341 | NCT04840602 | Map |
| MI | Michigan Healthcare Professionals Pontiac | Pontiac48341 | NCT04269902 | Map |
| MI | Newland Medical Associates-Pontiac | Pontiac48341 | NCT04840602 | Map |
| MI | Newland Medical Associates-Pontiac | Pontiac48341 | NCT04269902 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT05554393 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT05554406 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT05564390 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT04840602 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT04269902 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT06317649 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT06672146 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT06917911 | Map |
| MI | Corewell Health Reed City Hospital | Reed City49677 | NCT04269902 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT04840602 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT04269902 | Map |
| MI | Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center | Saint Joseph49085 | NCT04269902 | Map |
| MI | Henry Ford Health Providence Southfield Hospital | Southfield48075 | NCT04269902 | Map |
| MI | MyMichigan Medical Center Tawas | Tawas City48764 | NCT04840602 | Map |
| MI | MyMichigan Medical Center Tawas | Tawas City48764 | NCT04269902 | Map |
| MI | Munson Medical Center | Traverse City49684 | NCT04269902 | Map |
| MI | Henry Ford Health Warren Hospital | Warren48093 | NCT04269902 | Map |
| MI | Henry Ford Warren Hospital - GLCMS | Warren48093 | NCT04269902 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT05554393 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT05554406 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT05564390 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT04840602 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT04269902 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT06317649 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT06672146 | Map |
| MI | Henry Ford Wyandotte Hospital | Wyandotte48192 | NCT04269902 | Map |
| MI | University of Michigan Health - West | Wyoming49519 | NCT04269902 | Map |
| MI | Huron Gastroenterology PC | Ypsilanti48106 | NCT04840602 | Map |
| MI | Huron Gastroenterology PC | Ypsilanti48106 | NCT04269902 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT05554393 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT05554406 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT05564390 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT04840602 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT04269902 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT06317649 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT06672146 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT06917911 | Map |
| MI | Trinity Health Michigan Heart - Ann Arbor Campus | Ypsilanti48106 | NCT06852222 | Map |
| MN | Essentia Health Saint Joseph's Medical Center | Brainerd56401 | NCT06649812 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT05554393 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT05554406 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT05564390 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT04269902 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT06317649 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT06672146 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT05554393 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT05554406 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT05564390 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT04269902 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT06317649 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT06649812 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT06672146 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT05554393 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT05554406 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT05564390 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT04269902 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT06317649 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT06649812 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT06672146 | Map |
| MN | St. Lukes Hospital of Duluth /ID# 250021 | Duluth55805 | NCT04895436 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT05554393 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT05554406 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT05564390 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT06317649 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT06672146 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT05554393 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT05554406 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT05564390 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT04269902 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT06317649 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT06649812 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT06672146 | Map |
| MN | Saint John's Hospital - Healtheast | Maplewood55109 | NCT04269902 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT05554393 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT05554406 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT05564390 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT06317649 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT06672146 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT04840602 | Map |
| MN | Masonic Cancer Center | Minneapolis55455 | NCT05183035 | Map |
| MN | Minneapolis VA Medical Center | Minneapolis55417 | NCT04269902 | Map |
| MN | Minnesota Oncology Hematology P A | Minneapolis55404 | NCT05963074 | Map |
| MN | University of Minnesota | Minneapolis55455 | NCT05735184 | Map |
| MN | University of Minnesota | Minneapolis55455 | NCT07007312 | Map |
| MN | University of Minnesota/Masonic Cancer Center | Minneapolis55455 | NCT06317662 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT03331198 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT03331198 | Map |
| MN | Mayo Clinic - Rochester | Rochester55905 | NCT05735184 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT05388006 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT05554406 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT05564390 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT04840602 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT05910801 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT06042725 | Map |
| MN | Mayo Clinic Rochester | Rochester55905 | NCT05451771 | Map |
| MN | Mayo Clinic Rochester | Rochester55902 | NCT05091424 | Map |
| MN | Mayo Clinic Rochester | Rochester55905-0001 | NCT06943872 | Map |
| MN | Coborn Cancer Center at Saint Cloud Hospital | Saint Cloud56303 | NCT04269902 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT05554393 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT05554406 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT05564390 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT04840602 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT04269902 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT06317649 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT06672146 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT05554393 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT05554406 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT05564390 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT04840602 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT06317649 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT06672146 | Map |
| MN | United Hospital | Saint Paul55102 | NCT05554393 | Map |
| MN | United Hospital | Saint Paul55102 | NCT05554406 | Map |
| MN | United Hospital | Saint Paul55102 | NCT05564390 | Map |
| MN | United Hospital | Saint Paul55102 | NCT06317649 | Map |
| MN | United Hospital | Saint Paul55102 | NCT06672146 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT05554393 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT05554406 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT04269902 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT06317649 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT06649812 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT06672146 | Map |
| MN | Saint Francis Regional Medical Center | Shakopee55379 | NCT04269902 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT05554393 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT05554406 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT05564390 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT04269902 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT06317649 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT06649812 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT06672146 | Map |
| MN | Ridgeview Medical Center | Waconia55387 | NCT04269902 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Golden Triangle | Columbus39705 | NCT05554393 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Golden Triangle | Columbus39705 | NCT05554406 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Golden Triangle | Columbus39705 | NCT05564390 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Golden Triangle | Columbus39705 | NCT04269902 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Golden Triangle | Columbus39705 | NCT06317649 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Golden Triangle | Columbus39705 | NCT06917911 | Map |
| MS | Baptist Cancer Center-Grenada | Grenada38901 | NCT05554393 | Map |
| MS | Baptist Cancer Center-Grenada | Grenada38901 | NCT05554406 | Map |
| MS | Baptist Cancer Center-Grenada | Grenada38901 | NCT05564390 | Map |
| MS | Baptist Cancer Center-Grenada | Grenada38901 | NCT04269902 | Map |
| MS | Baptist Cancer Center-Grenada | Grenada38901 | NCT06317649 | Map |
| MS | Baptist Cancer Center-Grenada | Grenada38901 | NCT06917911 | Map |
| MS | Hattiesburg Clinic /ID# 233443 | Hattiesburg39401 | NCT04895436 | Map |
| MS | University of Mississippi Medical Center | Jackson39216 | NCT05183035 | Map |
| MS | University of Mississippi Medical Center | Jackson39216 | NCT06317662 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Union County | New Albany38652 | NCT05554393 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Union County | New Albany38652 | NCT05554406 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Union County | New Albany38652 | NCT05564390 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Union County | New Albany38652 | NCT04269902 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Union County | New Albany38652 | NCT06317649 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Union County | New Albany38652 | NCT06917911 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Oxford | Oxford38655 | NCT05554393 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Oxford | Oxford38655 | NCT05554406 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Oxford | Oxford38655 | NCT05564390 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Oxford | Oxford38655 | NCT06317649 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Oxford | Oxford38655 | NCT06917911 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Desoto | Southhaven38671 | NCT05554393 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Desoto | Southhaven38671 | NCT05554406 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Desoto | Southhaven38671 | NCT05564390 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Desoto | Southhaven38671 | NCT04269902 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Desoto | Southhaven38671 | NCT06317649 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Desoto | Southhaven38671 | NCT06917911 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT04840602 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT04269902 | Map |
| MO | Saint Luke's Hospital | Chesterfield63017 | NCT04269902 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT05554393 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT05554406 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT05564390 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT06317649 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT06649812 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT05554393 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT05554406 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT05564390 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT06317649 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT06649812 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT05564390 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT04269902 | Map |
| MO | Children's Mercy Hospital of Kansas City | Kansas City64108 | NCT06177067 | Map |
| MO | Children's Mercy Hospitals and Clinics | Kansas City64108 | NCT06317662 | Map |
| MO | Kansas City VA Medical Center, Kansas City, MO | Kansas City64128-2226 | NCT06520098 | Map |
| MO | Kansas City Veterans Affairs Medical Center | Kansas City64128 | NCT04269902 | Map |
| MO | Research Medical Center | Kansas City64132 | NCT05963074 | Map |
| MO | Saint Lukes Hospital of Kansas City /ID# 267270 | Kansas City64111 | NCT06428019 | Map |
| MO | The Children's Mercy Hospital - Adele Hall Campus | Kansas City64108 | NCT05183035 | Map |
| MO | The University of Kansas Cancer Center - Medical Oncology Clinic | Kansas City64116 | NCT04227847 | Map |
| MO | The University of Kansas Cancer Center - Radiation Oncology Clinic | Kansas City64116 | NCT04227847 | Map |
| MO | The University of Kansas Cancer Center -North | Kansas City64154 | NCT04227847 | Map |
| MO | University Health Truman Medical Center | Kansas City64108 | NCT05564390 | Map |
| MO | University Health Truman Medical Center | Kansas City64108 | NCT04269902 | Map |
| MO | University of Kansas Cancer Center - Briarcliff | Kansas City64116 | NCT05564390 | Map |
| MO | University of Kansas Cancer Center - Briarcliff | Kansas City64116 | NCT04269902 | Map |
| MO | University of Kansas Cancer Center - Briarcliff | Kansas City64116 | NCT06311227 | Map |
| MO | University of Kansas Cancer Center - North | Kansas City64154 | NCT05564390 | Map |
| MO | University of Kansas Cancer Center - North | Kansas City64154 | NCT04269902 | Map |
| MO | University of Kansas Cancer Center - North | Kansas City64154 | NCT06311227 | Map |
| MO | The University of Kansas Cancer Center - Lee's Summit | Lee's Summit64064 | NCT04227847 | Map |
| MO | University of Kansas Cancer Center - Lee's Summit | Lee's Summit64064 | NCT05564390 | Map |
| MO | University of Kansas Cancer Center - Lee's Summit | Lee's Summit64064 | NCT04269902 | Map |
| MO | University of Kansas Cancer Center - Lee's Summit | Lee's Summit64064 | NCT06311227 | Map |
| MO | Phelps Health Delbert Day Cancer Institute | Rolla65401 | NCT04269902 | Map |
| MO | Heartland Regional Medical Center | Saint Joseph64506 | NCT05564390 | Map |
| MO | Heartland Regional Medical Center | Saint Joseph64506 | NCT04840602 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT05564390 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT04269902 | Map |
| MO | Oncology Hematology Associates | Springfield65807-5288 | NCT06846671 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT04269902 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT06317662 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT04840602 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT04269902 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT05564390 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT04269902 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT05554393 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT05554406 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT05564390 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT06317649 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT06649812 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT05554393 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT05554406 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT05564390 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT06317649 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT06649812 | Map |
| MO | Washington University - Siteman Cancer Center | St Louis63110 | NCT06456463 | Map |
| MO | Washington University in St Louis | St Louis63130 | NCT06852222 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT05554393 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT05554406 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT05564390 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06317649 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06317662 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06649812 | Map |
| MO | Washington University School of Medicine in St. Louis | St Louis63110 | NCT05183035 | Map |
| MO | Washington University School of Medicine, Siteman Cancer Center | St Louis63108 | NCT06419634 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT05564390 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT04269902 | Map |
| MO | BJC Outpatient Center at Sunset Hills | Sunset Hills63127 | NCT05564390 | Map |
| MO | BJC Outpatient Center at Sunset Hills | Sunset Hills63127 | NCT04269902 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT05554393 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT05554406 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT05564390 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT04269902 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT06317649 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT06672146 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT05554393 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT05554406 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT05564390 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT04269902 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT06317649 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT06672146 | Map |
| MT | Saint Vincent Frontier Cancer Center | Billings59102 | NCT04840602 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT05554393 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT05554406 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT05564390 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT04269902 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT06317649 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT06672146 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT05554393 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT05554406 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT05564390 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT04269902 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT06317649 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT06672146 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT05554393 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT05554406 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT05564390 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT04269902 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT06317649 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT06672146 | Map |
| MT | Community Medical Center | Missoula59804 | NCT05554393 | Map |
| MT | Community Medical Center | Missoula59804 | NCT05554406 | Map |
| MT | Community Medical Center | Missoula59804 | NCT05564390 | Map |
| MT | Community Medical Center | Missoula59804 | NCT04269902 | Map |
| MT | Community Medical Center | Missoula59804 | NCT06317649 | Map |
| MT | Community Medical Center | Missoula59804 | NCT06672146 | Map |
| MT | Saint Patrick Hospital - Community Hospital | Missoula59802 | NCT05564390 | Map |
| NE | Nebraska Medicine-Bellevue | Bellevue68123 | NCT05554393 | Map |
| NE | Nebraska Medicine-Bellevue | Bellevue68123 | NCT05554406 | Map |
| NE | Nebraska Medicine-Bellevue | Bellevue68123 | NCT05564390 | Map |
| NE | Nebraska Medicine-Bellevue | Bellevue68123 | NCT06649812 | Map |
| NE | Children's Hospital and Medical Center of Omaha | Omaha68114 | NCT06317662 | Map |
| NE | Nebraska Cancer Specialists | Omaha68130 | NCT04068597 | Map |
| NE | Nebraska Cancer Specialists | Omaha68130 | NCT06115135 | Map |
| NE | Nebraska Medicine-Village Pointe | Omaha68118 | NCT05554393 | Map |
| NE | Nebraska Medicine-Village Pointe | Omaha68118 | NCT05554406 | Map |
| NE | Nebraska Medicine-Village Pointe | Omaha68118 | NCT05564390 | Map |
| NE | Nebraska Medicine-Village Pointe | Omaha68118 | NCT06649812 | Map |
| NE | Oncology Hematology West, Pc Dba Nebraska Cancer Specialists | Omaha68130-2042 | NCT06846671 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT05554393 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT05554406 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT05564390 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT03331198 | Map |
| NE | University of Nebraska Medical Center | Omaha68198-6846 | NCT04068597 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT06649812 | Map |
| NE | University Of Nebraska Medical Center | Omaha68198 | NCT03331198 | Map |
| NV | Alliance for Childhood Diseases dba Cure 4 The Kids Foundation | Las Vegas89135 | NCT05183035 | Map |
| NV | Alliance for Childhood Diseases/Cure 4 the Kids Foundation | Las Vegas89135 | NCT06317662 | Map |
| NV | OptumCare Cancer Care at Charleston | Las Vegas89102 | NCT05554393 | Map |
| NV | OptumCare Cancer Care at Charleston | Las Vegas89102 | NCT05554406 | Map |
| NV | OptumCare Cancer Care at Charleston | Las Vegas89102 | NCT05564390 | Map |
| NV | OptumCare Cancer Care at Charleston | Las Vegas89102 | NCT04269902 | Map |
| NV | OptumCare Cancer Care at Charleston | Las Vegas89102 | NCT06317649 | Map |
| NV | OptumCare Cancer Care at Fort Apache | Las Vegas89183 | NCT05554393 | Map |
| NV | OptumCare Cancer Care at Fort Apache | Las Vegas89183 | NCT05554406 | Map |
| NV | OptumCare Cancer Care at Fort Apache | Las Vegas89183 | NCT05564390 | Map |
| NV | OptumCare Cancer Care at Fort Apache | Las Vegas89183 | NCT04269902 | Map |
| NV | OptumCare Cancer Care at Fort Apache | Las Vegas89183 | NCT06317649 | Map |
| NH | Dartmouth Hitchcock Medical Center | Lebanon03756 | NCT06852222 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT05554393 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT05564390 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT04269902 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT06317649 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT06317662 | Map |
| NJ | Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities) | Basking Ridge07920 | NCT07392242 | Map |
| NJ | Memorial Sloan Kettering at Basking Ridge | Basking Ridge07920 | NCT03824483 | Map |
| NJ | Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) | Basking Ridge07920 | NCT06773208 | Map |
| NJ | Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) | Basking Ridge07920 | NCT06903702 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT05554393 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT05554406 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT05564390 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT04840602 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT04269902 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT06317649 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT06672146 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT07231952 | Map |
| NJ | Memorial Sloan-Kettering Cancer Center (MSKCC) - Basking Ridge | Basking Ridge07920 | NCT03331198 | Map |
| NJ | Cooper Hospital University Medical Center | Camden08103 | NCT05554406 | Map |
| NJ | Cooper Hospital University Medical Center | Camden08103 | NCT05564390 | Map |
| NJ | Cooper Hospital University Medical Center | Camden08103 | NCT04269902 | Map |
| NJ | Astera Cancer Care | Edison08820 | NCT03331198 | Map |
| NJ | Hunterdon Hematology Oncology | Flemington08822 | NCT05963074 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601 | NCT05735184 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601 | NCT03331198 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601 | NCT06317662 | Map |
| NJ | Hackensack University Medical Center, HMH | Hackensack07601 | NCT05183035 | Map |
| NJ | John Theurer Cancer Center | Hackensack07601-2191 | NCT03331198 | Map |
| NJ | John Theurer Cancer Center - Hackensack Meridian Health | Hackensack07601 | NCT06456463 | Map |
| NJ | John Theurer Cancer Center / Hackensack University | Hackensack07601 | NCT04256317 | Map |
| NJ | John Theurer Cancer Center at Hackensack University Medical Center | Hackensack07601 | NCT06419634 | Map |
| NJ | John Theurer Cancer Center at Hackensack University Medical Center | Hackensack07601 | NCT06852222 | Map |
| NJ | Regional Cancer Care Associates /ID# 244620 | Hackensack07601-7015 | NCT04895436 | Map |
| NJ | Jersey City Medical Center | Jersey City07302 | NCT04269902 | Map |
| NJ | Monmouth Medical Center Southern Campus | Lakewood08701 | NCT04269902 | Map |
| NJ | Saint Barnabas Medical Center | Livingston07039 | NCT05554393 | Map |
| NJ | Saint Barnabas Medical Center | Livingston07039 | NCT05554406 | Map |
| NJ | Saint Barnabas Medical Center | Livingston07039 | NCT05564390 | Map |
| NJ | Saint Barnabas Medical Center | Livingston07039 | NCT06317649 | Map |
| NJ | Saint Barnabas Medical Center | Livingston07039 | NCT06672146 | Map |
| NJ | Monmouth Medical Center | Long Branch07740 | NCT05554393 | Map |
| NJ | Monmouth Medical Center | Long Branch07740 | NCT05554406 | Map |
| NJ | Monmouth Medical Center | Long Branch07740 | NCT05564390 | Map |
| NJ | Monmouth Medical Center | Long Branch07740 | NCT04269902 | Map |
| NJ | Monmouth Medical Center | Long Branch07740 | NCT06317649 | Map |
| NJ | Monmouth Medical Center | Long Branch07740 | NCT06672146 | Map |
| NJ | Memoral Sloan Kettering Monmouth | Middletown07748 | NCT07231952 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT05554393 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT05554406 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT05564390 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT04840602 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT04269902 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT03824483 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT06317649 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT06672146 | Map |
| NJ | Memorial Sloan Kettering Monmouth (All Protocol Activities) | Middletown07748 | NCT06773208 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Consent and Follow-up) | Middletown07748 | NCT06903702 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT06903702 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT07392242 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT05554393 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT05554406 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT05564390 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT04840602 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT04269902 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT06317649 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT06672146 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT07231952 | Map |
| NJ | Memorial Sloan Kettering Bergen (All Protocol Activities) | Montvale07645 | NCT06773208 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT06903702 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT07392242 | Map |
| NJ | Atlantic Health | Morristown07960 | NCT04988555 | Map |
| NJ | Atlantic Health System / Morristown Medical Center | Morristown07960 | NCT03331198 | Map |
| NJ | Morristown Medical Center | Morristown07960 | NCT05183035 | Map |
| NJ | Morristown Medical Center | Morristown07960 | NCT06317662 | Map |
| NJ | Rutgers Biomedical and Health Sciences | New Brunswick08903 | NCT07007312 | Map |
| NJ | Rutgers Cancer Institute | New Brunswick08903 | NCT05735184 | Map |
| NJ | Rutgers Cancer Institute | New Brunswick08901 | NCT06456463 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT05554393 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT05554406 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT05564390 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08901 | NCT04988555 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT04269902 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT03331198 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT06317649 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT06672146 | Map |
| NJ | Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital | New Brunswick08903 | NCT06317662 | Map |
| NJ | The Valley Hospital - Luckow Pavilion | Paramus07652 | NCT05554393 | Map |
| NJ | The Valley Hospital - Luckow Pavilion | Paramus07652 | NCT05554406 | Map |
| NJ | The Valley Hospital - Luckow Pavilion | Paramus07652 | NCT05564390 | Map |
| NJ | The Valley Hospital - Luckow Pavilion | Paramus07652 | NCT06317649 | Map |
| NJ | Saint Joseph's Regional Medical Center | Paterson07503 | NCT06317662 | Map |
| NJ | Valley Health System Ridgewood Campus | Ridgewood07450 | NCT05554393 | Map |
| NJ | Valley Health System Ridgewood Campus | Ridgewood07450 | NCT05554406 | Map |
| NJ | Valley Health System Ridgewood Campus | Ridgewood07450 | NCT05564390 | Map |
| NJ | Valley Health System Ridgewood Campus | Ridgewood07450 | NCT06317649 | Map |
| NJ | Sidney Kimmel Comprehensive Cancer Center Washington Twp | Sewell08080 | NCT06943872 | Map |
| NJ | Community Medical Center | Toms River08755 | NCT05554393 | Map |
| NJ | Community Medical Center | Toms River08755 | NCT05554406 | Map |
| NJ | Community Medical Center | Toms River08755 | NCT05564390 | Map |
| NJ | Community Medical Center | Toms River08755 | NCT04269902 | Map |
| NJ | Community Medical Center | Toms River08755 | NCT06317649 | Map |
| NJ | Community Medical Center | Toms River08755 | NCT06672146 | Map |
| NJ | MD Anderson Cancer Center at Cooper-Voorhees | Voorhees Township08043 | NCT04269902 | Map |
| NM | University of New Mexico | Albuquerque87131 | NCT07007312 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT05554393 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT05554406 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT05564390 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT04269902 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT06317649 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT06672146 | Map |
| NM | Memorial Medical Center-Las Cruces | Las Cruces88011 | NCT04269902 | Map |
| NM | Presbyterian Rust Medical Center/Jorgensen Cancer Center | Rio Rancho87124 | NCT04269902 | Map |
| NM | Christus St Vincent Regional Cancer Center | Santa Fe87505 | NCT06943872 | Map |
| NY | Albany Medical Center | Albany12208 | NCT06317662 | Map |
| NY | Roswell Park | Buffalo14263 | NCT06445959 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT05442216 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT05554393 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT05554406 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT05564390 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT06317649 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT06317662 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14203 | NCT06456463 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT06501196 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT06672146 | Map |
| NY | Roswell Park Comprehensive Cancer Center | Buffalo14203 | NCT04988555 | Map |
| NY | Roswell Park Comprehensive Cancer Center | Buffalo14263 | NCT04256317 | Map |
| NY | Roswell Park Comprehensive Cancer Center | Buffalo14203 | NCT05735184 | Map |
| NY | Roswell Park Comprehensive Cancer Center | Buffalo14263 | NCT06852222 | Map |
| NY | State University of New York at Buffalo | Buffalo14263 | NCT07007312 | Map |
| NY | Hematology Oncology Associates of CNY at Camillus | Camillus13031 | NCT04269902 | Map |
| NY | Memorial Sloan Kettering Cancer Center - Suffolk (Limited Protocol Activities) | Commack11725 | NCT06903702 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT05554393 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT05554406 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT05564390 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT04840602 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT04269902 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT03824483 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT06317649 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT06672146 | Map |
| NY | Memorial Sloan Kettering Suffolk - Commack | Commack11725 | NCT07231952 | Map |
| NY | Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities) | Commack11725 | NCT07392242 | Map |
| NY | Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities) | Commack11725 | NCT06773208 | Map |
| NY | Hematology Oncology Associates of Central New York-East Syracuse | East Syracuse13057 | NCT04269902 | Map |
| NY | Glens Falls Hospital | Glens Falls12801 | NCT04269902 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT05554406 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT04840602 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT04269902 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT03824483 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT06672146 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT07231952 | Map |
| NY | Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison10604 | NCT06773208 | Map |
| NY | Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison10604 | NCT06903702 | Map |
| NY | Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison10604 | NCT07392242 | Map |
| NY | Northwell Health/Center for Advanced Medicine | Lake Success11042 | NCT05554406 | Map |
| NY | Northwell Health/Center for Advanced Medicine | Lake Success11042 | NCT06317649 | Map |
| NY | North Shore University Hospital | Manhasset11030 | NCT05554406 | Map |
| NY | North Shore University Hospital | Manhasset11030 | NCT06317649 | Map |
| NY | North Shore University Hospital | Manhasset11030 | NCT06456463 | Map |
| NY | New York University Langone Hospital - Long Island | Mineola11501 | NCT04256317 | Map |
| NY | The Steven and Alexandra Cohen Children's Medical Center of New York | New Hyde Park11040 | NCT06317662 | Map |
| NY | Zuckerberg Cancer Center | New Hyde Park11042 | NCT07163793 | Map |
| NY | Columbia University | New York10032 | NCT07007312 | Map |
| NY | Columbia University Irving Medical Center | New York10032 | NCT04227847 | Map |
| NY | Columbia University Irving Medical Center | New York10032 | NCT05183035 | Map |
| NY | Columbia University Irving Medical Center | New York10032 | NCT06456463 | Map |
| NY | Columbia University Medical Center | New York10032 | NCT05735184 | Map |
| NY | CUIMC Research Pharmacy | New York10032 | NCT04227847 | Map |
| NY | Icahn School of Medicine at Mount Sinai | New York10029 | NCT04256317 | Map |
| NY | Icahn School of Medicine at Mount Sinai | New York10003 | NCT07007312 | Map |
| NY | Icahn School of Medicine at Mount Sinai | New York10029 | NCT07320235 | Map |
| NY | Icahn School of Medicine at Mount Sinai /ID# 266328 | New York10029 | NCT06428019 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT06317662 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05554393 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05554406 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05564390 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT04840602 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT04269902 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT03824483 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT03013998 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06284486 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06317649 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06317662 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06501196 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06672146 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06903702 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT07231952 | Map |
| NY | Memorial Sloan Kettering Cancer Center - New York | New York10065 | NCT05183035 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT06773208 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT07392242 | Map |
| NY | Memorial Sloan Kettering Cancer Center Mskcc | New York10065-6800 | NCT06846671 | Map |
| NY | Memorial Sloan Kettering Cancer Center Mskcc | New York10065-6800 | NCT06943872 | Map |
| NY | Memorial Sloan- Kettering Cancer Center | New York10065 | NCT06177067 | Map |
| NY | Mount Sinai - Ruttenberg Treatment Center | New York10029 | NCT05735184 | Map |
| NY | Mount Sinai Hospital | New York10029 | NCT05554393 | Map |
| NY | Mount Sinai Hospital | New York10029 | NCT05554406 | Map |
| NY | Mount Sinai Hospital | New York10029 | NCT05564390 | Map |
| NY | New York - Presbyterian / Weill Cornell Medicine | New York10021 | NCT05735184 | Map |
| NY | New York Presbyterian - Weill Cornell | New York10065 | NCT06852222 | Map |
| NY | New York Presbyterian Hospital/Columbia University Irving Medical Center | New York10032 | NCT05451771 | Map |
| NY | NYP/Weill Cornell Medical Center | New York10065 | NCT06317662 | Map |
| NY | NYU Langone Health | New York10016 | NCT06456463 | Map |
| NY | Perlmutter Cancer Center - 34th Street | New York10016 | NCT04256317 | Map |
| NY | The New York and Presbyterian Hospital | New York10032 | NCT04227847 | Map |
| NY | Weill Cornell Medical Center | New York10065 | NCT07007312 | Map |
| NY | Weill Cornell Medical College | New York10065 | NCT03331198 | Map |
| NY | Hematology Oncology Associates of Rockland | Nyack10960 | NCT05963074 | Map |
| NY | Upstate Cancer Center at Oswego | Oswego13126 | NCT04269902 | Map |
| NY | Cohen Children's Medical Center | Queens11040 | NCT05183035 | Map |
| NY | Rochester General Hospital | Rochester14621 | NCT05564390 | Map |
| NY | University of Rochester | Rochester14642 | NCT05554393 | Map |
| NY | University of Rochester | Rochester14642 | NCT05554406 | Map |
| NY | University of Rochester | Rochester14642 | NCT05564390 | Map |
| NY | University of Rochester | Rochester14642 | NCT04840602 | Map |
| NY | University of Rochester | Rochester14642 | NCT04269902 | Map |
| NY | University of Rochester | Rochester14642 | NCT06317649 | Map |
| NY | University of Rochester | Rochester14642 | NCT06317662 | Map |
| NY | University of Rochester | Rochester14642 | NCT06672146 | Map |
| NY | University of Rochester Medical Center | Rochester14642 | NCT06852222 | Map |
| NY | Memorial Sloan Kettering Nassau (All Protocol Activities) | Rockville Centre11553 | NCT06773208 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited Protocol Activites) | Rockville Centre11553 | NCT07392242 | Map |
| NY | Stony Brook University | Stony Brook11794-8160 | NCT03331198 | Map |
| NY | Stony Brook University Hospital | Stony Brook11794 | NCT05735184 | Map |
| NY | Stony Brook University Medical Center | Stony Brook11794 | NCT05554393 | Map |
| NY | Stony Brook University Medical Center | Stony Brook11794 | NCT05554406 | Map |
| NY | Stony Brook University Medical Center | Stony Brook11794 | NCT05564390 | Map |
| NY | Stony Brook University Medical Center | Stony Brook11794 | NCT06317649 | Map |
| NY | State University of New York Upstate Medical University | Syracuse13210 | NCT05554406 | Map |
| NY | State University of New York Upstate Medical University | Syracuse13210 | NCT05564390 | Map |
| NY | State University of New York Upstate Medical University | Syracuse13210 | NCT04269902 | Map |
| NY | State University of New York Upstate Medical University | Syracuse13210 | NCT06317649 | Map |
| NY | State University of New York Upstate Medical University | Syracuse13210 | NCT06317662 | Map |
| NY | SUNY Upstate Medical Center-Community Campus | Syracuse13215 | NCT04269902 | Map |
| NY | Einstein-Montefiore Medical Center | The Bronx10467 | NCT06852222 | Map |
| NY | Montefiore Einstein Cancer Center and Children's Hospital at Montefiore (CHAM) | The Bronx10467 | NCT05342584 | Map |
| NY | Montefiore Medical Center | The Bronx10467 | NCT04256317 | Map |
| NY | Montefiore Medical Center | The Bronx10467 | NCT05986240 | Map |
| NY | Montefiore Medical Center | The Bronx10467 | NCT05184842 | Map |
| NY | Montefiore Medical Center | The Bronx10467 | NCT07283094 | Map |
| NY | Montefiore Medical Center - Moses Campus | The Bronx10467 | NCT05554393 | Map |
| NY | Montefiore Medical Center - Moses Campus | The Bronx10467 | NCT05554406 | Map |
| NY | Montefiore Medical Center - Moses Campus | The Bronx10467 | NCT05564390 | Map |
| NY | Montefiore Medical Center - Moses Campus | The Bronx10467 | NCT06317662 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT05554393 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT05554406 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT05564390 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT04840602 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT04269902 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT03824483 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT06672146 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT07231952 | Map |
| NY | New York Medical College | Valhalla10595 | NCT06317662 | Map |
| NY | Upstate Cancer Center at Verona | Verona13478 | NCT04269902 | Map |
| NY | Wilmot Cancer Institute at Webster | Webster14580 | NCT04269902 | Map |
| NY | Clinical Research Alliance, Inc | Westbury11590-5119 | NCT06846671 | Map |
| NY | Clinical Research Alliance, Inc | Westbury11590-5119 | NCT06943872 | Map |
| NY | White Plains Hospital | White Plains10601 | NCT05184842 | Map |
| NC | UNC Hospital | Chapel Hill27514 | NCT04988555 | Map |
| NC | UNC Hospitals, University of North Carolina at Chapel Hill | Chapel Hill27514 | NCT05401097 | Map |
| NC | UNC Hospitals, University of North Carolina at Chapel Hill | Chapel Hill27514 | NCT03013998 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT05564390 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT04269902 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT06317649 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT06317662 | Map |
| NC | UNC School of Medicine, Division of Hematology | Chapel Hill27599 | NCT04588922 | Map |
| NC | University of North Carolina /ID# 233313 | Chapel Hill27514 | NCT04895436 | Map |
| NC | University of North Carolina at Chapel Hill | Chapel Hill27599 | NCT05442216 | Map |
| NC | University of North Carolina At Chapel Hill | Chapel Hill27514-4220 | NCT06943872 | Map |
| NC | University of North Carolina, Chapel Hill | Chapel Hill27514 | NCT07007312 | Map |
| NC | Atrium Health | Charlotte28204 | NCT06852222 | Map |
| NC | Atrium Health /ID# 267219 | Charlotte28204-2963 | NCT06428019 | Map |
| NC | Carolina Oncology Specialists | Charlotte28207 | NCT06852222 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT05554393 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT05554406 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT05564390 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT04840602 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT06317649 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT06317662 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT06672146 | Map |
| NC | Levine Cancer Center | Charlotte28204-2990 | NCT06943872 | Map |
| NC | Novant Health Charlotte | Charlotte28204 | NCT06852222 | Map |
| NC | Novant Health Presbyterian Medical Center | Charlotte28204 | NCT05554393 | Map |
| NC | Novant Health Presbyterian Medical Center | Charlotte28204 | NCT05564390 | Map |
| NC | Novant Health Presbyterian Medical Center | Charlotte28204 | NCT06456463 | Map |
| NC | Novant Health Presbyterian Medical Center /ID# 230201 | Charlotte28204 | NCT04895436 | Map |
| NC | Southeastern Medical Oncology Center-Clinton | Clinton28328 | NCT04840602 | Map |
| NC | Southeastern Medical Oncology Center-Clinton | Clinton28328 | NCT04269902 | Map |
| NC | Duke Blood Cancer Center | Durham27705 | NCT05735184 | Map |
| NC | Duke University | Durham27705 | NCT04988555 | Map |
| NC | Duke University | Durham27705 | NCT04256317 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT05554393 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT05554406 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT05564390 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT04269902 | Map |
| NC | Duke University Medical Center | Durham27705 | NCT03331198 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT03331198 | Map |
| NC | Duke University Medical Center | Durham27705 | NCT03850574 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06317649 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06317662 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06649812 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06672146 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT07007312 | Map |
| NC | Durham VA Medical Center, Durham, NC | Durham27705-3875 | NCT06520098 | Map |
| NC | Levine Cancer Institute-Gaston | Gastonia28054 | NCT04840602 | Map |
| NC | Southeastern Medical Oncology Center-Goldsboro | Goldsboro27534 | NCT04840602 | Map |
| NC | Southeastern Medical Oncology Center-Goldsboro | Goldsboro27534 | NCT04269902 | Map |
| NC | East Carolina University | Greenville27834 | NCT05554393 | Map |
| NC | East Carolina University | Greenville27834 | NCT05554406 | Map |
| NC | East Carolina University | Greenville27834 | NCT05564390 | Map |
| NC | East Carolina University | Greenville27834 | NCT04269902 | Map |
| NC | East Carolina University | Greenville27834 | NCT06317649 | Map |
| NC | East Carolina University | Greenville27834 | NCT06317662 | Map |
| NC | East Carolina University | Greenville27834 | NCT06672146 | Map |
| NC | Margaret R Pardee Memorial Hospital | Hendersonville28791 | NCT04269902 | Map |
| NC | University of North Carolina-Hillsborough Campus | Hillsborough27278 | NCT04269902 | Map |
| NC | Southeastern Medical Oncology Center-Jacksonville | Jacksonville28546 | NCT04840602 | Map |
| NC | Southeastern Medical Oncology Center-Jacksonville | Jacksonville28546 | NCT04269902 | Map |
| NC | ECU Health Oncology Kinston | Kinston28501 | NCT04269902 | Map |
| NC | Atrium Health Union/LCI-Union | Monroe28112 | NCT04840602 | Map |
| NC | Novant Health New Hanover Regional Medical Center | Wilmington28401 | NCT05564390 | Map |
| NC | Atrium Health Wake Forest Baptist | Winston-Salem27157 | NCT06943872 | Map |
| NC | Atrium Health Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem27157 | NCT05442216 | Map |
| NC | Atrium Health Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem27157 | NCT06382168 | Map |
| NC | Atrium Health Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem27157 | NCT06852222 | Map |
| NC | Atrium Health Wake Forest Baptist Medical Center /ID# 273142 | Winston-Salem27157 | NCT06428019 | Map |
| NC | Atrium Wake Forest Baptist Medical Center | Winston-Salem27157 | NCT04988555 | Map |
| NC | Novant Health Derrick L Davis Cancer Center | Winston-Salem27103 | NCT06456463 | Map |
| NC | Novant Health Forsyth Medical Center | Winston-Salem27103 | NCT05554393 | Map |
| NC | Novant Health Forsyth Medical Center | Winston-Salem27103 | NCT05564390 | Map |
| NC | Novant Health Forsyth Medical Center /ID# 249533 | Winston-Salem27103 | NCT04895436 | Map |
| NC | Novant Health Winston Salem | Winston-Salem27106 | NCT06852222 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT05554393 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT05554406 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT05564390 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT06317649 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT06317662 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT06672146 | Map |
| ND | Essentia Health Cancer Center-South University Clinic | Fargo58103 | NCT06649812 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT06317662 | Map |
| OH | Children's Hospital Medical Center of Akron | Akron44308 | NCT06317662 | Map |
| OH | Strecker Cancer Center-Belpre | Belpre45714 | NCT04269902 | Map |
| OH | Gabrail Cancer Center | Canton44718 | NCT06634394 | Map |
| OH | Gabrail Cancer Center | Canton44718 | NCT06852222 | Map |
| OH | Cincinnati Children's Hospital Medical Center | Cincinnati45229 | NCT03826992 | Map |
| OH | Cincinnati Children's Hospital Medical Center | Cincinnati45229 | NCT06177067 | Map |
| OH | Cincinnati Children's Hospital Medical Center | Cincinnati45229 | NCT06317662 | Map |
| OH | Cincinnati Children's Hospital Medical Center | Cincinnati45229 | NCT06863259 | Map |
| OH | Oncology Hematology Care | Cincinnati45242 | NCT05963074 | Map |
| OH | Oncology Hematology Care | Cincinnati45226 | NCT06634394 | Map |
| OH | Oncology Hematology Care | Cincinnati45226 | NCT06852222 | Map |
| OH | Oncology Hematology Care Clinical Trials, Llc | Cincinnati45245-1995 | NCT06943872 | Map |
| OH | University of Cincinnati | Cincinnati45219 | NCT07014917 | Map |
| OH | University of Cincinnati Medical Center | Cincinnati45219 | NCT03013998 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT05554393 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT05554406 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT05564390 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT05834244 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT06317649 | Map |
| OH | Cleveland Clinic | Cleveland44195 | NCT04227847 | Map |
| OH | Cleveland Clinic | Cleveland44195 | NCT06852222 | Map |
| OH | Cleveland Clinic Cancer Center/Fairview Hospital | Cleveland44111 | NCT04269902 | Map |
| OH | Cleveland Clinic Foundation | Cleveland44195 | NCT04269902 | Map |
| OH | Cleveland Clinic Foundation | Cleveland44195 | NCT06456463 | Map |
| OH | Cleveland Clinic Main Campus /ID# 271292 | Cleveland44195 | NCT06428019 | Map |
| OH | Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center | Cleveland44106 | NCT06129734 | Map |
| OH | Cleveland Clinic Taussig Cancer Institute | Cleveland44195 | NCT05735184 | Map |
| OH | Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center | Cleveland44195 | NCT03471260 | Map |
| OH | Rainbow Babies and Childrens Hospital | Cleveland44106 | NCT06317662 | Map |
| OH | University Hospitals | Cleveland44106-1716 | NCT06846671 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT04227847 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT05735184 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT03331198 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT06852222 | Map |
| OH | University Hospitals Seidman Cancer Center (Case Western) | Cleveland44106-5061 | NCT03331198 | Map |
| OH | University Hospitals Seidman Cancer, Case Comprehensive Cancer Center | Cleveland44106 | NCT06129734 | Map |
| OH | Nationwide Children's Hospital | Columbus43205 | NCT05183035 | Map |
| OH | Ohio State University | Columbus43210 | NCT03013998 | Map |
| OH | Ohio State University | Columbus43210 | NCT07007312 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05336812 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05401097 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05554406 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05564390 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT04269902 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT06317649 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT06466122 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT06649812 | Map |
| OH | Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute | Columbus43210 | NCT04256317 | Map |
| OH | The James Cancer Hospital and Solove Research Institute | Columbus43210 | NCT05735184 | Map |
| OH | The James Cancer Hospital and Solove Research Institute | Columbus43210 | NCT05091424 | Map |
| OH | The Mark H Zangmeister Center | Columbus43219 | NCT04269902 | Map |
| OH | The Ohio State University /ID# 230439 | Columbus43210 | NCT04895436 | Map |
| OH | The Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT04988555 | Map |
| OH | The Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT03331198 | Map |
| OH | The Ohio State University Wexner Medical Center | Columbus43210 | NCT03850574 | Map |
| OH | The Ohio State University Wexner Medical Center - James Cancer Hosp | Columbus43210 | NCT06501196 | Map |
| OH | The Ohio State University Wexner Medical Center/James Cancer Hospital | Columbus43210 | NCT04227847 | Map |
| OH | Dayton Children's Hospital | Dayton45404 | NCT06317662 | Map |
| OH | Dayton Physician Network | Dayton45415 | NCT06846671 | Map |
| OH | Marietta Memorial Hospital | Marietta45750 | NCT04269902 | Map |
| OH | Memorial Hospital | Marysville43040 | NCT04269902 | Map |
| OH | Hillcrest Hospital Cancer Center | Mayfield Heights44124 | NCT04269902 | Map |
| OH | Licking Memorial Hospital | Newark43055 | NCT04840602 | Map |
| OH | Licking Memorial Hospital | Newark43055 | NCT04269902 | Map |
| OH | Southern Ohio Medical Center | Portsmouth45662 | NCT04269902 | Map |
| OH | Springfield Regional Cancer Center | Springfield45504 | NCT04269902 | Map |
| OH | ProMedica Flower Hospital | Sylvania43560 | NCT04269902 | Map |
| OH | ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital | Toledo43606 | NCT06317662 | Map |
| OH | Genesis Healthcare System Cancer Care Center | Zanesville43701 | NCT04269902 | Map |
| OK | OU Health Stephenson Cancer Center | Oklahoma City73104 | NCT05735184 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05554393 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05554406 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05564390 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT04269902 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT06317649 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT06317662 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT06649812 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT06672146 | Map |
| OK | University of Oklahoma Health Sciences Center (Stephenson Cancer Center) | Oklahoma City73104 | NCT03331198 | Map |
| OK | University of Oklahoma Peggy and Charles Stephenson Cancer Center | Oklahoma City73104 | NCT03331198 | Map |
| OK | Oklahoma Cancer Specialists and Research Institute /ID# 267643 | Tulsa74146 | NCT06428019 | Map |
| OK | Saint Francis Children's Hospital | Tulsa74136 | NCT06390319 | Map |
| OR | Saint Charles Health System | Bend97701 | NCT04269902 | Map |
| OR | Clackamas Radiation Oncology Center | Clackamas97015 | NCT04269902 | Map |
| OR | Oncology Associates of Oregon | Eugene97401 | NCT04988555 | Map |
| OR | Oncology Associates of Oregon Willamette Valley Cancer Center | Eugene97401 | NCT06846671 | Map |
| OR | Oncology Associates of Oregon Willamette Valley Cancer Center | Eugene97401 | NCT06943872 | Map |
| OR | Willamette Valley Cancer Institute | Eugene97401 | NCT07007312 | Map |
| OR | Willamette Valley Cancer Institute and Research Center | Eugene97401 | NCT05963074 | Map |
| OR | Willamette Valley Cancer Institute and Research Center /ID# 266326 | Eugene97401 | NCT06428019 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT05564390 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT04840602 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT04269902 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT06317649 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT06649812 | Map |
| OR | Saint Alphonsus Cancer Care Center-Ontario | Ontario97914 | NCT05554393 | Map |
| OR | Saint Alphonsus Cancer Care Center-Ontario | Ontario97914 | NCT05554406 | Map |
| OR | Saint Alphonsus Cancer Care Center-Ontario | Ontario97914 | NCT05564390 | Map |
| OR | Saint Alphonsus Cancer Care Center-Ontario | Ontario97914 | NCT04269902 | Map |
| OR | Saint Alphonsus Cancer Care Center-Ontario | Ontario97914 | NCT06317649 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT05564390 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT04840602 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT04269902 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT06317649 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT06649812 | Map |
| OR | Doernbecher Children's Hospital | Portland97239 | NCT05183035 | Map |
| OR | OHSU Knight Cancer Institute | Portland97239 | NCT05963074 | Map |
| OR | OHSU Knight Cancer Institute | Portland97239 | NCT03874052 | Map |
| OR | OHSU Knight Cancer Institute | Portland97239 | NCT06357182 | Map |
| OR | OHSU Knight Cancer Institute | Portland97239 | NCT06504459 | Map |
| OR | OHSU Knight Cancer Institute | Portland97239 | NCT07228273 | Map |
| OR | Oregon Health & Science University | Portland97239 | NCT03013998 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT04256317 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT03471260 | Map |
| OR | Oregon Health and Science University ( Site 5425) | Portland97239-3011 | NCT05947851 | Map |
| OR | Providence Oncology and Hematology Care Clinic Westside | Portland97225 | NCT06852222 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT05554393 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT05554406 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT05564390 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT04840602 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT04269902 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT06317649 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT06649812 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT06852222 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT05554393 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT05554406 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT05564390 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT04840602 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT04269902 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT06317649 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT06649812 | Map |
| OR | Oregon Oncology Specialists | Salem97301 | NCT04256317 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT05554393 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT05554406 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT05564390 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT04269902 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT06317649 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT06317662 | Map |
| PA | Lehigh Valley Hospital - Muhlenberg | Bethlehem18017 | NCT04269902 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT05554393 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT05554406 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT05564390 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT04269902 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT06317649 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT06317662 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT06672146 | Map |
| PA | Penn State Milton S Hershey Medical Center | Hershey17033-0850 | NCT05554393 | Map |
| PA | Penn State Milton S Hershey Medical Center | Hershey17033-0850 | NCT05554406 | Map |
| PA | Penn State Milton S Hershey Medical Center | Hershey17033-0850 | NCT05564390 | Map |
| PA | Penn State Milton S Hershey Medical Center | Hershey17033-0850 | NCT06317649 | Map |
| PA | Penn State Milton S Hershey Medical Center | Hershey17033 | NCT06943872 | Map |
| PA | Lewistown Hospital | Lewistown17044 | NCT05554393 | Map |
| PA | Lewistown Hospital | Lewistown17044 | NCT05554406 | Map |
| PA | Lewistown Hospital | Lewistown17044 | NCT05564390 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT05183035 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT06177067 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT06317662 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT06852222 | Map |
| PA | Hospital of the University of Pennsylvania | Philadelphia19104 | NCT05735184 | Map |
| PA | Jefferson Torresdale Hospital | Philadelphia19114 | NCT04269902 | Map |
| PA | Penn Medicine - Abramson Cancer Center Perelman | Philadelphia19104 | NCT04068597 | Map |
| PA | Penn Medicine Abramson Cancer Center | Philadelphia19104 | NCT05442216 | Map |
| PA | Pennsylvania Oncology Hematolo /ID# 249637 | Philadelphia19106 | NCT04895436 | Map |
| PA | Sidney Kimmel Comprehensive Cancer Center | Philadelphia19107 | NCT04988555 | Map |
| PA | Sydney Kimmel (Thomas Jefferson University) | Philadelphia19107 | NCT06456463 | Map |
| PA | Thomas Jefferson University | Philadelphia19107 | NCT03331198 | Map |
| PA | Thomas Jefferson University | Philadelphia19107 | NCT06852222 | Map |
| PA | Thomas Jefferson University | Philadelphia19107-4216 | NCT06943872 | Map |
| PA | Thomas Jefferson University - Clinical Research Institute | Philadelphia19107 | NCT03331198 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT05554406 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT05564390 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT04269902 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT06649812 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT06672146 | Map |
| PA | University of Pennsylvania | Philadelphia19104 | NCT07007312 | Map |
| PA | University of Pennsylvania - Perelman Center for Advanced Medicine | Philadelphia19104 | NCT03331198 | Map |
| PA | University of Pennsylvania Perelman Center for Advanced Medicine | Philadelphia19104 | NCT03331198 | Map |
| PA | University of Pennsylvania/Abramson Cancer Center | Philadelphia19104 | NCT05554406 | Map |
| PA | University of Pennsylvania/Abramson Cancer Center | Philadelphia19104 | NCT05564390 | Map |
| PA | University of Pennsylvania/Abramson Cancer Center | Philadelphia19104 | NCT06317649 | Map |
| PA | Allegheny Health Network | Pittsburgh15224 | NCT04988555 | Map |
| PA | Children's Hospital of Pittsburgh of UPMC | Pittsburgh15224 | NCT06317662 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT05554393 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT05554406 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT05564390 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT06317649 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT06672146 | Map |
| PA | University of Pittsburgh Medical Center | Pittsburgh15260 | NCT06852222 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT03331198 | Map |
| PA | Upmc Hillman Cancer Center(Univ of Pittsburgh) | Pittsburgh15232-1309 | NCT06943872 | Map |
| PA | West Penn Hospital | Pittsburgh15224 | NCT06846671 | Map |
| PA | Reading Hospital | West Reading19611 | NCT05554393 | Map |
| PA | Reading Hospital | West Reading19611 | NCT05554406 | Map |
| PA | Reading Hospital | West Reading19611 | NCT05564390 | Map |
| PA | Reading Hospital | West Reading19611 | NCT06317649 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT05554393 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT05554406 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT05564390 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT04269902 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT06317649 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT06672146 | Map |
| PA | Cancer Care Associates of York | York17403-5049 | NCT06846671 | Map |
| RI | Lifespan Cancer Institute - Providence /ID# 266550 | Providence02903 | NCT06428019 | Map |
| RI | Lifespan Health System Rhode Island Hospital | Providence46278 | NCT05442216 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT05554406 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT05564390 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT06317649 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT06317662 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT06672146 | Map |
| SC | Prisma Health Cancer Institute - Spartanburg | Boiling Springs29316 | NCT05554393 | Map |
| SC | Prisma Health Cancer Institute - Spartanburg | Boiling Springs29316 | NCT05554406 | Map |
| SC | Prisma Health Cancer Institute - Spartanburg | Boiling Springs29316 | NCT05564390 | Map |
| SC | Prisma Health Cancer Institute - Spartanburg | Boiling Springs29316 | NCT04269902 | Map |
| SC | Prisma Health Cancer Institute - Spartanburg | Boiling Springs29316 | NCT06317649 | Map |
| SC | Prisma Health Cancer Institute - Spartanburg | Boiling Springs29316 | NCT06672146 | Map |
| SC | Hollings Cancer Center | Charleston29425 | NCT04227847 | Map |
| SC | Hollings Cancer Center | Charleston29425 | NCT04256317 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT05564390 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT04988555 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT04269902 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT06317649 | Map |
| SC | Medical University of South Carolina- Ashley River Tower | Charleston29425 | NCT04227847 | Map |
| SC | Medical University of South Carolina- Investigational Drug Services | Charleston29425 | NCT04227847 | Map |
| SC | Medical University of South Carolina- University Hospital | Charleston29425 | NCT04227847 | Map |
| SC | Ralph H Johnson VA Medical Center | Charleston29401 | NCT04269902 | Map |
| SC | Prisma Health Richland Hospital | Columbia29203 | NCT05183035 | Map |
| SC | Prisma Health Richland Hospital | Columbia29203 | NCT06317662 | Map |
| SC | Prisma Health Cancer Institute - Easley | Easley29640 | NCT05554393 | Map |
| SC | Prisma Health Cancer Institute - Easley | Easley29640 | NCT05554406 | Map |
| SC | Prisma Health Cancer Institute - Easley | Easley29640 | NCT05564390 | Map |
| SC | Prisma Health Cancer Institute - Easley | Easley29640 | NCT04269902 | Map |
| SC | Prisma Health Cancer Institute - Easley | Easley29640 | NCT06317649 | Map |
| SC | Prisma Health Cancer Institute - Easley | Easley29640 | NCT06672146 | Map |
| SC | BI-LO Charities Children's Cancer Center | Greenville29605 | NCT06317662 | Map |
| SC | Bon Secours St. Francis Cancer Center | Greenville29607 | NCT04588922 | Map |
| SC | Prisma Health Cancer Institute - Butternut | Greenville29605 | NCT05554393 | Map |
| SC | Prisma Health Cancer Institute - Butternut | Greenville29605 | NCT05554406 | Map |
| SC | Prisma Health Cancer Institute - Butternut | Greenville29605 | NCT05564390 | Map |
| SC | Prisma Health Cancer Institute - Butternut | Greenville29605 | NCT04269902 | Map |
| SC | Prisma Health Cancer Institute - Butternut | Greenville29605 | NCT06317649 | Map |
| SC | Prisma Health Cancer Institute - Butternut | Greenville29605 | NCT06672146 | Map |
| SC | Prisma Health Cancer Institute - Eastside | Greenville29615 | NCT05554393 | Map |
| SC | Prisma Health Cancer Institute - Eastside | Greenville29615 | NCT05554406 | Map |
| SC | Prisma Health Cancer Institute - Eastside | Greenville29615 | NCT05564390 | Map |
| SC | Prisma Health Cancer Institute - Eastside | Greenville29615 | NCT04269902 | Map |
| SC | Prisma Health Cancer Institute - Eastside | Greenville29615 | NCT06317649 | Map |
| SC | Prisma Health Cancer Institute - Eastside | Greenville29615 | NCT06672146 | Map |
| SC | Prisma Health Cancer Institute - Faris | Greenville29605 | NCT05554393 | Map |
| SC | Prisma Health Cancer Institute - Faris | Greenville29605 | NCT05554406 | Map |
| SC | Prisma Health Cancer Institute - Faris | Greenville29605 | NCT05564390 | Map |
| SC | Prisma Health Cancer Institute - Faris | Greenville29605 | NCT04269902 | Map |
| SC | Prisma Health Cancer Institute - Faris | Greenville29605 | NCT06317649 | Map |
| SC | Prisma Health Cancer Institute - Faris | Greenville29605 | NCT06672146 | Map |
| SC | Prisma Health Cancer Institute - Greer | Greer29650 | NCT05554393 | Map |
| SC | Prisma Health Cancer Institute - Greer | Greer29650 | NCT05554406 | Map |
| SC | Prisma Health Cancer Institute - Greer | Greer29650 | NCT05564390 | Map |
| SC | Prisma Health Cancer Institute - Greer | Greer29650 | NCT04269902 | Map |
| SC | Prisma Health Cancer Institute - Greer | Greer29650 | NCT06317649 | Map |
| SC | Prisma Health Cancer Institute - Greer | Greer29650 | NCT06672146 | Map |
| SC | Prisma Health Cancer Institute - Seneca | Seneca29672 | NCT05554393 | Map |
| SC | Prisma Health Cancer Institute - Seneca | Seneca29672 | NCT05554406 | Map |
| SC | Prisma Health Cancer Institute - Seneca | Seneca29672 | NCT05564390 | Map |
| SC | Prisma Health Cancer Institute - Seneca | Seneca29672 | NCT04269902 | Map |
| SC | Prisma Health Cancer Institute - Seneca | Seneca29672 | NCT06317649 | Map |
| SC | Prisma Health Cancer Institute - Seneca | Seneca29672 | NCT06672146 | Map |
| SD | Sanford Cancer Center Oncology Clinic | Sioux Falls57104 | NCT05564390 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT05564390 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT06317662 | Map |
| TN | Tennessee Oncology Greco Hainsworth Centers For Research Chattanooga | Chattanooga37404 | NCT06943872 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Collierville | Collierville38017 | NCT05554393 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Collierville | Collierville38017 | NCT05554406 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Collierville | Collierville38017 | NCT05564390 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Collierville | Collierville38017 | NCT06317649 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Collierville | Collierville38017 | NCT06917911 | Map |
| TN | Ballad Health Cancer Care - Kingsport | Kingsport37660 | NCT04269902 | Map |
| TN | East Tennessee Childrens Hospital | Knoxville37916 | NCT06317662 | Map |
| TN | University of Tennessee | Knoxville37920 | NCT06852222 | Map |
| TN | University of Tennessee - Knoxville | Knoxville37920 | NCT05554406 | Map |
| TN | University of Tennessee - Knoxville | Knoxville37920 | NCT05564390 | Map |
| TN | University of Tennessee - Knoxville | Knoxville37920 | NCT06317649 | Map |
| TN | Baptist Clinical Research Institute | Memphis38120 | NCT07007312 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Memphis | Memphis38120 | NCT05554393 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Memphis | Memphis38120 | NCT05554406 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Memphis | Memphis38120 | NCT05564390 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Memphis | Memphis38120 | NCT04269902 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Memphis | Memphis38120 | NCT06317649 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Memphis | Memphis38120 | NCT06917911 | Map |
| TN | Saint Jude Children's Research Hospital | Memphis38105 | NCT06317662 | Map |
| TN | St. Jude Children's Research Hospital | Memphis38105-3678 | NCT05183035 | Map |
| TN | St. Jude Children's Research Hospital | Memphis38105 | NCT06177067 | Map |
| TN | St. Jude Children's Research Hospital | Memphis38105 | NCT06390319 | Map |
| TN | Monroe Carell Jr. Children's Hospital at Vanderbilt | Nashville37232 | NCT05183035 | Map |
| TN | Sarah Cannon Research Institute | Nashville37203 | NCT06501196 | Map |
| TN | Sarah Cannon Research Institute - Tennessee Oncology | Nashville37203 | NCT03331198 | Map |
| TN | Sarah Cannon, the Cancer Institute of HCA Healthcare | Nashville37203 | NCT06456463 | Map |
| TN | Tennessee Oncology | Nashville37203 | NCT06456463 | Map |
| TN | Tennessee Oncology | Nashville37205 | NCT06943872 | Map |
| TN | Tennessee Oncology | Nashville37203 | NCT07007312 | Map |
| TN | The Children's Hospital at TriStar Centennial | Nashville37203 | NCT06317662 | Map |
| TN | TriStar Bone Marrow Transplant | Nashville37203 | NCT05735184 | Map |
| TN | TriStar Centennial Medical Center | Nashville37203 | NCT04988555 | Map |
| TN | TriStar Centennial Medical Center | Nashville37203 | NCT07007312 | Map |
| TN | Vanderbilt Ingram Cancer Center | Nashville37232 | NCT06852222 | Map |
| TN | Vanderbilt University Medical Center | Nashville37232 | NCT04256317 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT06317662 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37203 | NCT06399640 | Map |
| TX | Dell Children's Medical Center of Central Texas | Austin78723 | NCT06317662 | Map |
| TX | Sarah Cannon Research Institute - St. David's South Austin Medical Center / Texas Oncology South Austin | Austin78704 | NCT05735184 | Map |
| TX | Texas Oncology - Austin Midtown /ID# 268152 | Austin78705 | NCT06428019 | Map |
| TX | Texas Oncology-Austin Midtown | Austin78705 | NCT07007312 | Map |
| TX | Driscoll Children's Hospital | Corpus Christi78411 | NCT06317662 | Map |
| TX | Baylor Research Institute | Dallas75204 | NCT04227847 | Map |
| TX | Baylor Scott & White Health | Dallas75246 | NCT04588922 | Map |
| TX | Baylor Scott & White Health | Dallas75246 | NCT06456463 | Map |
| TX | Baylor University Medical Center | Dallas75246 | NCT04227847 | Map |
| TX | Baylor University Medical Center | Dallas75246 | NCT03331198 | Map |
| TX | Baylor University Medical Center | Dallas75246 | NCT06852222 | Map |
| TX | Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy | Dallas75246 | NCT04227847 | Map |
| TX | Harold C. Simmons Comprehensive Cancer Center | Dallas75235 | NCT05183035 | Map |
| TX | Medical City Dallas Hospital | Dallas75230 | NCT06317662 | Map |
| TX | Texas Oncology Baylorcharles A Sammons Cancer Center | Dallas75246-2003 | NCT06943872 | Map |
| TX | Texas Oncology-Presbyterian Cancer Center | Dallas75231 | NCT07007312 | Map |
| TX | University of Texas - Southwestern Medical Center /ID# 266528 | Dallas75235 | NCT06428019 | Map |
| TX | University of Texas Southwestern | Dallas75390 | NCT03013998 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390 | NCT04256317 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390 | NCT03331198 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390 | NCT06634394 | Map |
| TX | UT Southwestern - Simmons Cancer Center | Dallas75235 | NCT05735184 | Map |
| TX | UT Southwestern Medical Center at Dallas | Dallas75235 | NCT05401097 | Map |
| TX | UT Southwestern/Simmons Cancer Center | Dallas75390 | NCT06177067 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT06317662 | Map |
| TX | STCC at DHR Health Institute for Research and Development | Edinburg78539 | NCT04269902 | Map |
| TX | El Paso Children's Hospital | El Paso79905 | NCT06317662 | Map |
| TX | Cook Children's Medical Center | Fort Worth76104 | NCT06177067 | Map |
| TX | Cook Children's Medical Center | Fort Worth76104 | NCT06317662 | Map |
| TX | Texas Oncology-Fort Worth Cancer Center | Fort Worth76104 | NCT05963074 | Map |
| TX | Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston77030 | NCT05554393 | Map |
| TX | Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston77030 | NCT05564390 | Map |
| TX | Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston77030 | NCT06317649 | Map |
| TX | Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston77030 | NCT06317662 | Map |
| TX | Ben Taub General Hospital | Houston77030 | NCT05554393 | Map |
| TX | Ben Taub General Hospital | Houston77030 | NCT05564390 | Map |
| TX | Ben Taub General Hospital | Houston77030 | NCT06317649 | Map |
| TX | Houston Methodist Hospital | Houston77030 | NCT04227847 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05360160 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05365035 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05529069 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05536349 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT04708054 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT04774393 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT04216524 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT03471260 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT03586609 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT03629171 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT02392572 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT03661307 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT00501826 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT02115295 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT03128879 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT03214562 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT04140487 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT04169737 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05010122 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05010772 | Map |
| TX | M.D. Anderson Cancer Center | Houston77030 | NCT05834244 | Map |
| TX | M.D. Anderson Cancer Center, Department of Leukemia | Houston77030 | NCT05986240 | Map |
| TX | MD Anderson | Houston77091 | NCT04588922 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT04256317 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT05735184 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT03113643 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06191978 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06284486 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06397027 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06445959 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06448013 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06466395 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06548230 | Map |
| TX | MD Anderson Cancer Center | Houston77090 | NCT06561074 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06634394 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06852222 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06967610 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT07032727 | Map |
| TX | MDACC | Houston77030 | NCT04988555 | Map |
| TX | Texas Children's Cancer and Hematology Center | Houston77030 | NCT07059975 | Map |
| TX | Texas Children's Hospital | Houston77030 | NCT05183035 | Map |
| TX | The University of Texas - MD Anderson Cancer Center | Houston77030 | NCT03331198 | Map |
| TX | The University of Texas M.D. Anderson Cancer Center | Houston77030 | NCT06501196 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT05963074 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT03331198 | Map |
| TX | University of Texas | Houston77030 | NCT07007312 | Map |
| TX | University of Texas MD Anderson Cancer Center | Houston77030 | NCT06419634 | Map |
| TX | University of Texas MD Anderson Cancer Center | Houston77030 | NCT06456463 | Map |
| TX | MD Anderson Cancer Center | Huston77030 | NCT03850574 | — |
| TX | Children's Hospital of San Antonio | San Antonio78207 | NCT06317662 | Map |
| TX | Methodist Children's Hospital of South Texas | San Antonio78229 | NCT06317662 | Map |
| TX | Texas Oncology - San Antonio Medical Center | San Antonio78240 | NCT07007312 | Map |
| TX | Texas Oncology San Antonio Medical Center Usor | San Antonio78240-5251 | NCT06943872 | Map |
| TX | Texas Oncology-Gulf Coast | The Woodlands77380 | NCT05963074 | Map |
| TX | Texas Oncology - Northeast | Tyler75702 | NCT06852222 | Map |
| TX | Texas Oncology Tyler | Tyler75702-7522 | NCT06846671 | Map |
| TX | Texas Oncology Tyler | Tyler75702-7522 | NCT06943872 | Map |
| UT | Community Cancer Trials of Utah | Ogden84405 | NCT05963074 | Map |
| UT | George E Wahlen Department of Veterans Affairs Medical Center | Salt Lake City84148 | NCT05564390 | Map |
| UT | George E Wahlen Department of Veterans Affairs Medical Center | Salt Lake City84148 | NCT06317649 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT04988555 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT05861050 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT03331198 | Map |
| UT | Huntsman Cancer Institute at The University of Utah | Salt Lake City84112 | NCT05091424 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT05554393 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT05554406 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT05564390 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT04269902 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT06317649 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT06672146 | Map |
| UT | Intermountain Healthcare | Salt Lake City84143 | NCT04988555 | Map |
| UT | Primary Children's Hospital | Salt Lake City84113 | NCT05183035 | Map |
| VT | University of Vermont and State Agricultural College | Burlington05405 | NCT05554393 | Map |
| VT | University of Vermont and State Agricultural College | Burlington05405 | NCT05554406 | Map |
| VT | University of Vermont and State Agricultural College | Burlington05405 | NCT05564390 | Map |
| VT | University of Vermont and State Agricultural College | Burlington05405 | NCT06317649 | Map |
| VT | University of Vermont and State Agricultural College | Burlington05405 | NCT06649812 | Map |
| VT | University of Vermont Cancer Center | Burlington05401 | NCT06382168 | Map |
| VT | University of Vermont Medical Center | Burlington05401 | NCT05554393 | Map |
| VT | University of Vermont Medical Center | Burlington05401 | NCT05554406 | Map |
| VT | University of Vermont Medical Center | Burlington05401 | NCT05564390 | Map |
| VT | University of Vermont Medical Center | Burlington05401 | NCT06317649 | Map |
| VT | University of Vermont Medical Center | Burlington05401 | NCT06649812 | Map |
| VT | University of Vermont Medical Center | Burlington05401 | NCT07007312 | Map |
| VA | Ballad Health Cancer Care - Bristol | Bristol24201 | NCT04269902 | Map |
| VA | University of Virginia | Charlottesville22908 | NCT04988555 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT05554393 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT05554406 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT05564390 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22903 | NCT03523975 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT06317649 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT06317662 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22911 | NCT06382168 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT06649812 | Map |
| VA | University of Virginia School of Medicine | Charlottesville22903 | NCT07007312 | Map |
| VA | Inova Schar Cancer Institute | Fairfax22031 | NCT05554393 | Map |
| VA | Inova Schar Cancer Institute | Fairfax22031 | NCT05554406 | Map |
| VA | Inova Schar Cancer Institute | Fairfax22031 | NCT05564390 | Map |
| VA | Virginia Cancer Specialists | Fairfax22031 | NCT04988555 | Map |
| VA | Virginia Cancer Specialists - Fairfax /ID# 268155 | Fairfax22031 | NCT06428019 | Map |
| VA | Inova Fairfax Hospital | Falls Church22042 | NCT05554393 | Map |
| VA | Inova Fairfax Hospital | Falls Church22042 | NCT05554406 | Map |
| VA | Inova Fairfax Hospital | Falls Church22042 | NCT05564390 | Map |
| VA | Virginia Cancer Specialists | Manassas20110 | NCT05963074 | Map |
| VA | Virginia Cancer Specialists | Manassas20110 | NCT07007312 | Map |
| VA | Children's Hospital of The King's Daughters | Norfolk23507 | NCT06317662 | Map |
| VA | Virginia Oncology Associates | Norfolk23502 | NCT04988555 | Map |
| VA | Ballad Health Cancer Care - Norton | Norton24273 | NCT04269902 | Map |
| VA | Children's Hospital of Richmond at Virginia Commonwealth University | Richmond23219 | NCT05183035 | Map |
| VA | VCU Massey Cancer Center at Stony Point | Richmond23235 | NCT04269902 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT05564390 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT04840602 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT04269902 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT06317649 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT06317662 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT06649812 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT06672146 | Map |
| VA | Virginia Commonwealth University - Massey Cancer Center | Richmond23298 | NCT06852222 | Map |
| VA | Carilion Children's | Roanoke24014 | NCT06317662 | Map |
| VA | Virginia Oncology Associates | Virginia Beach23456 | NCT05963074 | Map |
| WA | FHCC Overlake | Bellevue98004 | NCT04269902 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT05554393 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT05554406 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT05564390 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT04840602 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT04269902 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT06317649 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT06672146 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT05554393 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT05554406 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT05564390 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT04840602 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT04269902 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT06317649 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT06672146 | Map |
| WA | Kadlec Clinic Hematology and Oncology | Kennewick99336 | NCT04269902 | Map |
| WA | FHCC at EvergreenHealth | Kirkland98034 | NCT04269902 | Map |
| WA | Vista Oncology - East Olympia /ID# 267337 | Olympia98506 | NCT06428019 | Map |
| WA | FHCC at Northwest Hospital | Seattle98133 | NCT04269902 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT04797767 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT04941716 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT05564390 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT04269902 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT06317649 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT06501196 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT06852222 | Map |
| WA | Fred Hutchinson Cancer Research Center | Seattle98109 | NCT03331198 | Map |
| WA | Fred Hutchinson Cancer Research Center | Seattle98109-4433 | NCT07277231 | Map |
| WA | Seattle Cancer Care Alliance | Seattle98109 | NCT04256317 | Map |
| WA | Seattle Cancer Center Alliance | Seattle98109 | NCT03331198 | Map |
| WA | Seattle Children's Hospital | Seattle98105 | NCT05183035 | Map |
| WA | Seattle Children's Hospital | Seattle98105 | NCT06317662 | Map |
| WA | Swedish Cancer Institute | Seattle98104 | NCT04227847 | Map |
| WA | Swedish Cancer Institute | Seattle98104 | NCT06852222 | Map |
| WA | Swedish Medical Center | Seattle98122 | NCT04227847 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT05554393 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT05554406 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT05564390 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT04840602 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT04269902 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT06317649 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT06649812 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT06672146 | Map |
| WA | University of Washington Medical Center - Montlake | Seattle98195 | NCT05564390 | Map |
| WA | University of Washington Medical Center - Montlake | Seattle98195 | NCT04269902 | Map |
| WA | University of Washington Medical Center - Montlake | Seattle98195 | NCT06317649 | Map |
| WA | VA Puget Sound Health Care System Seattle Division, Seattle, WA | Seattle98108-1532 | NCT06520098 | Map |
| WA | VA Puget Sound Healthcare System | Seattle98108 | NCT05963074 | Map |
| WA | Medical Oncology Associates, PS ( Site 5406) | Spokane99208 | NCT05947851 | Map |
| WA | Providence Sacred Heart Medical Center and Children's Hospital | Spokane99204 | NCT06317662 | Map |
| WA | Northwest Medical Specialties Tacoma /ID# 266327 | Tacoma98405 | NCT06428019 | Map |
| WA | Northwest Cancer Specialist, Pc(Us Oncology Research) | Vancouver98684-6930 | NCT06943872 | Map |
| WA | Northwest Cancer Specialists PC | Vancouver98684 | NCT05963074 | Map |
| WV | West Virginia University School of Medicine /ID# 267645 | Morgantown26506 | NCT06428019 | Map |
| WV | WVU Medicine Wheeling Hospital | Wheeling26003 | NCT07007312 | Map |
| WI | ThedaCare Regional Cancer Center | Appleton54911 | NCT05554406 | Map |
| WI | ThedaCare Regional Cancer Center | Appleton54911 | NCT05564390 | Map |
| WI | ThedaCare Regional Cancer Center | Appleton54911 | NCT04840602 | Map |
| WI | ThedaCare Regional Cancer Center | Appleton54911 | NCT06317649 | Map |
| WI | ThedaCare Regional Medical Center - Appleton | Appleton54911 | NCT05554406 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT05554393 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT05554406 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT05564390 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT04269902 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT06317649 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT06649812 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT06672146 | Map |
| WI | Aurora Cancer Care-Southern Lakes VLCC | Burlington53105 | NCT05564390 | Map |
| WI | Aurora Saint Luke's South Shore | Cudahy53110 | NCT05564390 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT05564390 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT04269902 | Map |
| WI | Aurora Health Care Germantown Health Center | Germantown53022 | NCT05564390 | Map |
| WI | Aurora Cancer Care-Grafton | Grafton53024 | NCT05564390 | Map |
| WI | Aurora BayCare Medical Center | Green Bay54311 | NCT05564390 | Map |
| WI | Bellin Memorial Hospital | Green Bay54301 | NCT04269902 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT05554393 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT05554406 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT05564390 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT06317649 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT06672146 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT05554393 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT05554406 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT05564390 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT06317649 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT06317662 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT06672146 | Map |
| WI | Mercyhealth Hospital and Cancer Center - Janesville | Janesville53548 | NCT05564390 | Map |
| WI | Mercyhealth Hospital and Cancer Center - Janesville | Janesville53548 | NCT06649812 | Map |
| WI | Aurora Cancer Care-Kenosha South | Kenosha53142 | NCT05564390 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT05554393 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT05554406 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT05564390 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT04840602 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT06317649 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT06649812 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT06672146 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT06917911 | Map |
| WI | University of Wisconsin | Madison53792 | NCT07007312 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison53718 | NCT05554406 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison53718 | NCT05564390 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison53718 | NCT04269902 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison53718 | NCT06317649 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT05554406 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT05564390 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT04269902 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT06317649 | Map |
| WI | University of Wisconsin Clinical Science Center | Madison53792 | NCT06501196 | Map |
| WI | University of Wisconsin Hospital and Clinics | Madison53792 | NCT05735184 | Map |
| WI | William S Middleton VA Medical Center | Madison53705 | NCT05564390 | Map |
| WI | William S Middleton VA Medical Center | Madison53705 | NCT06317649 | Map |
| WI | William S Middleton VA Medical Center | Madison53705 | NCT06672146 | Map |
| WI | Aurora Bay Area Medical Group-Marinette | Marinette54143 | NCT05564390 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT05564390 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT04269902 | Map |
| WI | Froedtert Menomonee Falls Hospital | Menomonee Falls53051 | NCT05564390 | Map |
| WI | Froedtert Menomonee Falls Hospital | Menomonee Falls53051 | NCT06649812 | Map |
| WI | Aurora Cancer Care-Milwaukee | Milwaukee53209 | NCT05564390 | Map |
| WI | Aurora Saint Luke's Medical Center | Milwaukee53215 | NCT05564390 | Map |
| WI | Aurora Sinai Medical Center | Milwaukee53233 | NCT05564390 | Map |
| WI | Children's Hospital of Wisconsin | Milwaukee53226 | NCT06317662 | Map |
| WI | Children's Wisconsin | Milwaukee53226 | NCT05317403 | Map |
| WI | Froedtert & Medical College of Wisconsin | Milwaukee53226 | NCT04256317 | Map |
| WI | Froedtert & Medical College of Wisconsin | Milwaukee53226 | NCT07007312 | Map |
| WI | Froedtert Hospital & the Medical College of Wisconsin | Milwaukee53226 | NCT05451771 | Map |
| WI | Froedtert Hospital BMT Medical College of Wisconsin | Milwaukee53226 | NCT03331198 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT05554393 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT05554406 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT05564390 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT03331198 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT06317649 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT06649812 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT06672146 | Map |
| WI | Medical College of Wisconsin Cancer Center | Milwaukee53226 | NCT05735184 | Map |
| WI | Zablocki Veterans Administration Medical Center | Milwaukee53295 | NCT04269902 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT05564390 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT04269902 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT05564390 | Map |
| WI | Froedtert and MCW Moorland Reserve Health Center | New Berlin53151 | NCT05564390 | Map |
| WI | Froedtert and MCW Moorland Reserve Health Center | New Berlin53151 | NCT06649812 | Map |
| WI | Cancer Center of Western Wisconsin | New Richmond54017 | NCT04269902 | Map |
| WI | Drexel Town Square Health Center | Oak Creek53154 | NCT05564390 | Map |
| WI | Drexel Town Square Health Center | Oak Creek53154 | NCT06649812 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT05564390 | Map |
| WI | Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls54154 | NCT05564390 | Map |
| WI | Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls54154 | NCT06317649 | Map |
| WI | Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls54154 | NCT06672146 | Map |
| WI | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh54904 | NCT05564390 | Map |
| WI | Aurora Cancer Care-Racine | Racine53406 | NCT05564390 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT05564390 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT04269902 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT05564390 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT06317649 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT06672146 | Map |
| WI | Sheboygan Physicians Group | Sheboygan53081 | NCT06672146 | Map |
| WI | Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan53081 | NCT05564390 | Map |
| WI | Essentia Health-Spooner Clinic | Spooner54801 | NCT06649812 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT05554393 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT05554406 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT05564390 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT04269902 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT06317649 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT06672146 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT05564390 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT06317649 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT06672146 | Map |
| WI | Aurora Medical Center in Summit | Summit53066 | NCT05564390 | — |
| WI | Essentia Health Saint Mary's Hospital - Superior | Superior54880 | NCT06649812 | Map |
| WI | Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers54241 | NCT05564390 | Map |
| WI | ProHealth Waukesha Memorial Hospital | Waukesha53188 | NCT05564390 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT05564390 | Map |
| WI | Aurora Cancer Care-Milwaukee West | Wauwatosa53226 | NCT05564390 | Map |
| WI | Aurora West Allis Medical Center | West Allis53227 | NCT05564390 | Map |
| WI | Froedtert West Bend Hospital/Kraemer Cancer Center | West Bend53095 | NCT05564390 | Map |
| WI | Froedtert West Bend Hospital/Kraemer Cancer Center | West Bend53095 | NCT06649812 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT05554393 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT05554406 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT05564390 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT04269902 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT06317649 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT06672146 | Map |
Venetoclax clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | terminated | withdrawn | suspended | not yet recruiting | unknown | no longer available | available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Early P1 | 1 | 2 | 2 | 1 | 6 | |||||||
| P1 | 41 | 27 | 1 | 45 | 27 | 7 | 5 | 3 | 2 | 158 | ||
| P1/P2 | 44 | 20 | 13 | 23 | 9 | 1 | 7 | 8 | 125 | |||
| P2 | 119 | 50 | 37 | 17 | 10 | 1 | 19 | 16 | 269 | |||
| P2/P3 | 10 | 2 | 1 | 1 | 5 | 19 | ||||||
| P3 | 17 | 16 | 13 | 4 | 7 | 2 | 59 | |||||
| P4 | 2 | 1 | 2 | 5 | ||||||||
| N/A | 20 | 3 | 1 | 6 | 1 | 2 | 9 | 2 | 1 | 45 |
Recruiting Venetoclax clinical trials (303)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05725200 | EVIDENTStudy to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer | P2 | Metastatic Colorectal Cancer | 40 | Sep 2022 |
| NCT05947851 | VRA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). | P3 | Leukemia, Lymphocytic, Chronic, B-Cell | 735 | Aug 2023 |
| NCT07320235 | IMAGINEImetelstat Combinations in Relapsed AML | P1 | Relapsed Acute Myeloid Leukemia | 36 | Jan 2026 |
| NCT06390319 | ALLAdding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) | P2 | T-cell Acute Lymphoblastic Leukemia | 100 | Dec 2024 |
| NCT07604233 | Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML | P1/P2 | Myeloid Leukemia | 30 | Nov 2026 |
| NCT06967610 | PVOPhase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). | P2 | Chronic Lymphocytic Leukemia | 40 | Jul 2025 |
| NCT07520006 | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies | P1/P2 | B-cell Lymphoma | 150 | May 2026 |
| NCT05099471 | VIWA-1Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia | P2 | Waldenstrom Macroglobulinemia | 80 | Mar 2025 |
| NCT04523428 | REVEALREtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) | P2 | CLL/SLL | 60 | Dec 2020 |
| NCT05791409 | AETHERVenetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL | P1/P2 | CLL/SLL | 112 | Apr 2024 |
| NCT07175415 | HEM-iSMART EHEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | P1/P2 | Acute Lymphoblastic Leukemia | 42 | Oct 2026 |
| NCT06644183 | IOA-244Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) | P1/P2 | Leukemia | 64 | Mar 2025 |
| NCT07581002 | REVIVALA Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) | P2/P3 | Acute Myeloid Leukemia | 660 | Jul 2026 |
| NCT07014917 | ESR-23-22182Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL | P2 | Chronic Lymphocytic Leukemia | 62 | Dec 2025 |
| NCT06991920 | Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage | N/A | Adult ALL | 50 | Jun 2026 |
| NCT07294677 | CAVALRYCApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL | P1/P2 | Leukemia | 104 | Mar 2026 |
| NCT06558604 | GLOASISPhase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma | P2 | Lymphoma, Mantle-Cell | 100 | Feb 2025 |
| NCT04628026 | Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 | P3 | Acute Myeloid Leukemia | 650 | Sep 2022 |
| NCT05091424 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | P1 | Chronic Lymphocytic Leukemia | 137 | Mar 2022 |
| NCT05745714 | HEM-iSMART CHEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | P1/P2 | Acute Lymphoblastic Leukemia, in Relapse | 26 | Oct 2025 |
| NCT07425808 | FIT-AMLFLT3-ITD Targeted Therapy in Fit AML Patients | P2/P3 | AML (Acute Myeloid Leukemia) | 230 | Dec 2026 |
| NCT05751044 | HEM-iSMART BHEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | P1/P2 | Acute Lymphoblastic Leukemia | 26 | Oct 2025 |
| NCT02416388 | BIG-1Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR | P2/P3 | Acute Myeloid Leukemia (AML) | 3,100 | Jan 2015 |
| NCT07513129 | Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma | P1 | T-cell Acute Lymphoblastic Leukemia | 18 | Sep 2026 |
| NCT06561074 | T-ALLA Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) | P2 | T-cell Acute Lymphoblastic Leukemia | 22 | Sep 2025 |
| NCT06943872 | CELESTIAL-RRCLLA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) | P3 | Chronic Lymphocytic Leukemia | 630 | Jun 2025 |
| NCT06466395 | A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias | P1 | Refractory Acute Leukemia | 22 | Feb 2025 |
| NCT07277231 | BGB-11417A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia | P3 | Chronic Lymphocytic Leukemia | 500 | Jan 2026 |
| NCT07007312 | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | P3 | Acute Myeloid Leukemia (AML) | 1,300 | Sep 2025 |
| NCT06510309 | Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma | P2 | Lymphoma | 33 | Feb 2026 |
| NCT07007052 | TAGVENPhase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients | P2 | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | 33 | Dec 2025 |
| NCT05431257 | LD-VenExAzacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling | P2 | Acute Myeloid Leukemia | 117 | May 2022 |
| NCT07059975 | UPDATE AMLUPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML | Early P1 | Acute Myeloid Leukemia | 36 | Oct 2025 |
| NCT04941716 | Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial | P2 | Recurrent Chronic Lymphocytic Leukemia | 20 | May 2023 |
| NCT05442216 | TAGALONGTagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents | P2 | Acute Myeloid Leukemia | 53 | May 2024 |
| NCT07238686 | Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS | P2 | Myelodysplastic Syndromes | 40 | Jun 2025 |
| NCT07078591 | Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML | P2 | Acute Myeloid Leukemia | 50 | Jun 2025 |
| NCT06855810 | CCCG-TALL-2025Newly-diagnosed Pediatric T-cell ALL Protocol | P2/P3 | Acute Lymphoblastic Leukemia | 610 | Mar 2025 |
| NCT06764238 | CCCG-I/HR-ALLNewly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol | P2/P3 | Acute Lymphoblastic Leukemia ALL | 1,800 | Jan 2025 |
| NCT06810778 | PTCLDuvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | P1/P2 | T-cell-prolymphocytic Leukemia | 12 | May 2025 |
| NCT05183035 | AMLVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | P3 | Acute Myeloid Leukemia | 130 | Oct 2022 |
| NCT07539818 | Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML | P3 | AML | 788 | Apr 2026 |
| NCT07082452 | SEVENAZAA Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction | P3 | Leukemia, B-Cell, Chronic | 262 | Sep 2025 |
| NCT07311746 | Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia | P1/P2 | T-cell Prolymphocytic Leukemia | 36 | Jun 2026 |
| NCT07407140 | VAG-3+7-GVAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML | P3 | AML, Adult | 300 | Apr 2026 |
| NCT07148180 | A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax | P1/P2 | Acute Myeloid Leukaemia (AML) | 31 | Feb 2026 |
| NCT06520098 | Benefit VAA Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | P2 | Chronic Lymphocytic Leukemia | 100 | Oct 2025 |
| NCT06448013 | A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia | P1 | Acute Myeloid Leukemia | 22 | Mar 2025 |
| NCT06397027 | A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias | P1 | Refractory Acute Leukemia | 22 | Dec 2024 |
| NCT05910801 | V-MINDTafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | P2 | Recurrent Mantle Cell Lymphoma | 100 | Jan 2024 |
| NCT06841952 | Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia | N/A | AML, Adult | 158 | Feb 2025 |
| NCT07374029 | Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML | P1 | Acute Myeloid Leukemia | 30 | Feb 2026 |
| NCT06598384 | VA as Maintenance Therapy Post Allo-HSCT in MDS and AML | P2 | Acute Myeloid Leukemia | 40 | Sep 2024 |
| NCT06419634 | ORM-6151Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | P1 | Acute Myeloid Leukemia | 105 | May 2024 |
| NCT07159620 | Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients | P2 | Adult T-cell Leukemia/Lymphoma | 27 | Sep 2025 |
| NCT06471946 | VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS | P1/P2 | Higher-risk Myelodysplastic Syndromes | 54 | Oct 2024 |
| NCT07511062 | Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML | P1 | Acute Myeloid Leukemia | 32 | Aug 2026 |
| NCT03868722 | Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment | P2/P3 | CLL | 212 | Oct 2019 |
| NCT05292664 | Venetoclax Basket Trial for High Risk Hematologic Malignancies | P1 | Myelodysplastic Syndromes, de Novo | 30 | Mar 2023 |
| NCT07396480 | Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial | P3 | Venentoclax | 186 | Mar 2026 |
| NCT05404906 | AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission | P2/P3 | Acute Myeloid Leukemia (AML) in Remission | 124 | Jun 2022 |
| NCT02115295 | Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia | P2 | Acute Biphenotypic Leukemia | 508 | May 2014 |
| NCT07478991 | VENP-A-QUIAzacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) | P3 | Acute Myeloid Leukemia, Adult | 376 | Mar 2026 |
| NCT06696183 | SEQUENCEGilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment | P2 | AML - Acute Myeloid Leukemia | 60 | Apr 2025 |
| NCT05735184 | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | P1 | Acute Myeloid Leukemia | 420 | Jul 2023 |
| NCT07153497 | Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) | P2 | Acute Myeloid Leukemia | 132 | May 2026 |
| NCT06972641 | Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation | P2/P3 | AML | 126 | Jun 2025 |
| NCT05986240 | Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML | P1 | AML/MDS | 38 | May 2024 |
| NCT07493161 | Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL | N/A | Ph+ ALL | 110 | Apr 2026 |
| NCT05530421 | SELVEDgeSelinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma | P2 | Relapsed and Refractory Multiple Myeloma | 33 | Mar 2023 |
| NCT07522801 | ALL-TARGETA Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL | P2 | LAL | 93 | Sep 2026 |
| NCT07454226 | ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL | N/A | Ph-Like | 92 | May 2026 |
| NCT07495631 | Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia | N/A | Acute Lymphoblastic Leukemia, Adult | 43 | Apr 2026 |
| NCT07283094 | FHD-286FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia | P1 | Acute Myeloid Leukemia | 33 | Feb 2026 |
| NCT06846671 | CaDAnCe-302A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors | P3 | CLL | 250 | Apr 2025 |
| NCT06456463 | TRILLIUMA Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy | P2 | Acute Myeloid Leukemia | 83 | Jan 2025 |
| NCT07407660 | Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax | P3 | Acute Myeloid Leukemia | 250 | Feb 2026 |
| NCT07481175 | INITIATEInhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study) | P1 | HIV-1 | 38 | Apr 2026 |
| NCT07154264 | TAI-SHAN10A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) | P2 | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 66 | Sep 2025 |
| NCT06084819 | Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | P2 | Relapsed/Refractory Acute Myeloid Leukemia | 200 | Aug 2023 |
| NCT07358195 | Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation | Early P1 | Kidney Failure Chronic | 3 | Jul 2026 |
| NCT07060001 | Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker | P2 | Acute Myeloid Leukemia (AML) | 112 | Apr 2026 |
| NCT07177079 | HDAHigh-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML) | P1 | Acute Myeloid Leukemia | 30 | Mar 2026 |
| NCT07052422 | VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT | P2/P3 | Older Patients | 160 | Jul 2025 |
| NCT06221683 | GMCAIIClinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML | P2 | AML, Childhood | 500 | Jan 2024 |
| NCT06548230 | MDSA Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | P1/P2 | Myelodysplastic Syndrome(MDS) | 40 | Mar 2025 |
| NCT07228273 | Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia | P2 | Acute Myeloid Leukemia | 102 | Dec 2025 |
| NCT06852222 | cAMeLot-2A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | P3 | Leukemia, Myeloid, Acute | 600 | Jun 2025 |
| NCT07014462 | DLIT-AMLA Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML | P1 | AML - Acute Myeloid Leukemia | 20 | Sep 2025 |
| NCT07047183 | Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes | P2 | Myelodysplastic Neoplasms | 46 | Jul 2025 |
| NCT06445959 | Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib | P1/P2 | Mutant IDH1 Inhibitor Olutasidenib | 78 | Aug 2024 |
| NCT05401097 | IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) | P2 | Acute Myeloid Leukemia | 125 | Sep 2022 |
| NCT07218510 | Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial | P2 | Chronic Lymphocytic Leukemia | 33 | Jan 2026 |
| NCT07032727 | Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations | P2 | Targeted Therapy | 68 | Sep 2025 |
| NCT07437950 | Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | P2 | Acute Myeloid Leukemia | 126 | Oct 2026 |
| NCT07023588 | Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease | P2 | Acute Myeloid Leukemia (AML) | 70 | Jun 2025 |
| NCT02966756 | A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | P2 | Chronic Lymphocytic Leukemia (CLL) | 110 | Oct 2017 |
| NCT07024706 | MAVRiCPhase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab | P2 | Chronic Lymphocytic Leukemia (CLL) | 80 | Jan 2026 |
| NCT06317649 | AMLVenetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | P2 | Acute Myeloid Leukemia | 147 | Sep 2024 |
| NCT05564390 | MYELOMATCHMYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | P2 | Acute Myeloid Leukemia | 2,000 | Jun 2024 |
| NCT07582159 | Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | P2 | Chronic Lymphocytic Leukemia | 35 | Dec 2026 |
| NCT06516978 | A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL | P2 | Diffuse Large B Cell Lymphoma | 528 | Oct 2024 |
| NCT07469046 | VAH vs VA in Newly Diagnosed Elderly AML | P3 | Acute Myeloid Leukemia (AML) | 308 | Apr 2026 |
| NCT06782542 | OLUVENAZAOlutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy | P2 | Acute Myeloid Leukemia | 16 | Mar 2026 |
| NCT07507825 | VHAGExploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) | P2 | Acute Myeloid Leukemia (AML) | 61 | Mar 2026 |
| NCT07075016 | EVOLVE 1Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy | P3 | Acute Myeloid Leukemia | 227 | Aug 2025 |
| NCT05287568 | CC-486 and Venetoclax for Acute Myeloid Leukemia | P1 | AML | 35 | Dec 2022 |
| NCT05963074 | TAILORA Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia | P2 | Leukemia, Lymphocytic, Chronic, B-Cell | 320 | May 2024 |
| NCT07490288 | Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML | N/A | AML | 27 | May 2026 |
| NCT04560322 | Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL | P2 | Chronic Lymphocytic Leukemia | 40 | Oct 2020 |
| NCT07439211 | GAVELAssessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia | P1 | Leukemia, Myeloid | 48 | Jul 2026 |
| NCT04895436 | ReVenGStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | P2 | Chronic Lymphocytic Leukemia (CLL) | 75 | Mar 2022 |
| NCT06863259 | Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL | P1 | B-cell Acute Lymphoblastic Leukemia | 28 | May 2025 |
| NCT07514832 | VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial | P2 | AML (Acute Myeloid Leukemia) | 48 | Apr 2026 |
| NCT06317662 | Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | P2 | Acute Leukemia of Ambiguous Lineage | 153 | Jun 2025 |
| NCT06470841 | CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML | P2 | Acute Myeloid Leukemia | 85 | Sep 2024 |
| NCT06387121 | Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL | P2 | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 53 | Apr 2024 |
| NCT06191978 | ASTX727A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) | P1 | Acute Myeloid Leukemia | 40 | Mar 2024 |
| NCT05853965 | BELI(E)VECombination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma | P1/P2 | Multiple Myeloma | 45 | Jun 2023 |
| NCT05342584 | Venetoclax AMLVenetoclax Plus Intensive Chemotherapy in AML and Advanced MDS | P1 | Acute Myeloid Leukemia | 99 | May 2022 |
| NCT04797767 | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms | P1/P2 | Acute Biphenotypic Leukemia | 62 | Feb 2022 |
| NCT03013998 | Study of Biomarker-Based Treatment of Acute Myeloid Leukemia | P1/P2 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | 3,000 | Nov 2016 |
| NCT07264010 | Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study | P2/P3 | Acute Myeloid Leukaemia (AML) | 87 | Dec 2025 |
| NCT06284486 | A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib | P1/P2 | Acute Myeloid Leukemia | 8 | Sep 2024 |
| NCT06757855 | Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML | P1/P2 | CML,Blast Phase | 29 | Jan 2025 |
| NCT06042725 | MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma | P1 | Multiple Myeloma | 100 | Mar 2024 |
| NCT06651229 | A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms | P1 | Leukemia, Myeloid, Acute | 155 | Mar 2025 |
| NCT06557421 | STOP VENDe-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients | P2 | Acute Myeloid Leukemia | 50 | Feb 2026 |
| NCT04256317 | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | P2/P3 | Myelodysplastic Syndromes | 316 | May 2020 |
| NCT07486726 | Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia | P1/P2 | Acute Myeloid Leukemia (AML) | 112 | Mar 2026 |
| NCT07163793 | Pilot Study of Reduced Venetoclax Exposure | P2 | Acute Myeloid Leukemia in Remission | 41 | Oct 2024 |
| NCT06686108 | Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention | P2 | T-cell Acute Lymphoblastic Leukemia | 59 | Oct 2024 |
| NCT05168930 | ZANU-VENZanubrutinib and Venetoclax in CLL (ZANU-VEN) | P2 | Chronic Lymphocytic Leukemia (CLL) | 45 | Feb 2022 |
| NCT06611839 | IDH1-AML-2024Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML | P1/P2 | AML | 23 | Oct 2025 |
| NCT06635681 | DAV-AML-2024Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML | P2 | AML (Acute Myelogenous Leukemia) | 380 | Sep 2024 |
| NCT04269902 | CLLTesting Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | P3 | Chronic Lymphocytic Leukemia | 247 | Mar 2021 |
| NCT05904106 | VINCENTVenetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML | P2 | Acute Myeloid Leukemia | 146 | Apr 2024 |
| NCT04140487 | Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm | P1/P2 | Recurrent Acute Myeloid Leukemia | 97 | Dec 2019 |
| NCT06712121 | Venetoclax and Decitabine in R/R T-ALL | P2 | T Lymphoblastic Leukemia/Lymphoma | 28 | Jan 2025 |
| NCT06511882 | Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD | P2 | Acute Myeloid Leukemia | 37 | Nov 2024 |
| NCT07132684 | Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients | P3 | AML, Adult | 240 | Aug 2025 |
| NCT07183878 | Ven-BUCYVenetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study) | N/A | Acute Myeloid Leukemia | 138 | Aug 2025 |
| NCT06544109 | Ven APLVenetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients | P2/P3 | Acute Promyelocytic Leukemia | 98 | Aug 2023 |
| NCT07605949 | RAVENRevumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML | P2 | Leukemia Acute Myeloid | 88 | Jul 2026 |
| NCT07387471 | WMStudy to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) | P2 | Waldenstrom Macroglobulinemia | 14 | Mar 2026 |
| NCT06668558 | VERDIVenetoclax + Azacitidine in Patients With Acute Myeloid Leukemia | P2 | Acute Myeloid Leukemia | 29 | Dec 2024 |
| NCT06536010 | Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML | N/A | Acute Myeloid Leukemia | 50 | Nov 2021 |
| NCT04227847 | A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies | P1 | Myelodysplastic Syndrome | 178 | Aug 2020 |
| NCT06483906 | Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML. | P2 | Acute Myeloid Leukemia | 56 | Jul 2024 |
| NCT06537843 | VenCMSafety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia | P2 | Acute Myeloid Leukemia | 100 | Dec 2023 |
| NCT06742463 | VHAG in Treating R/R T-ALL/LBL | P2 | Acute T Lymphpblastic Leukemia/Lymphoma | 50 | Dec 2024 |
| NCT06481241 | Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL | N/A | Philadelphia Chromosome Negative ALL | 77 | Jun 2024 |
| NCT05834244 | ADVENT-AMLA Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) | P1 | Acute Myeloid Leukemia | 32 | Oct 2023 |
| NCT07133997 | Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia | P1 | Recurrent B Acute Lymphoblastic Leukemia | 26 | Jun 2026 |
| NCT06481228 | Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL | N/A | Philadelphia Positive Acute Lymphoblastic Leukemia | 82 | Jun 2024 |
| NCT05197192 | A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL | P3 | Chronic Lymphocytic Leukemia | 202 | Apr 2022 |
| NCT06954987 | Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | P2 | Acute Myeloid Leukemia | 244 | Jul 2026 |
| NCT07012447 | Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations | P2 | Early T Acute Lymphoblastic Leukemia | 32 | Apr 2025 |
| NCT06504459 | Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML | P2 | Acute Monocytic Leukemia | 40 | Jan 2025 |
| NCT07131059 | MRD-positive AML Clinical Study | N/A | AML, Adult | 120 | May 2024 |
| NCT05536349 | CLLTime-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) | P2 | Leukemia | 60 | Dec 2022 |
| NCT07231952 | WMA Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) | P2 | Waldenstrom Macroglobulinemia | 40 | Nov 2025 |
| NCT06634394 | APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | P1 | Acute Myeloid Leukemia (AML) | 39 | Oct 2024 |
| NCT06428019 | TLSA Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | P3 | Chronic Lymphocytic Leukemia | 170 | Aug 2024 |
| NCT06014489 | HO171A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML | P2 | AML, Adult | 142 | Jan 2024 |
| NCT04840602 | Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma | P2 | Lymphoplasmacytic Lymphoma | 92 | Jan 2022 |
| NCT05805098 | VHAVenetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML | P2/P3 | Acute Myeloid Leukemia | 60 | Mar 2023 |
| NCT06571825 | RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR | P4 | Acute Myeloid Leukemia | 118 | Jul 2024 |
| NCT06958705 | Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy | P2 | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | 79 | Dec 2025 |
| NCT07392242 | A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia | P2 | Acute Myeloid Leukemia | 45 | Jan 2026 |
| NCT03826992 | CPX-351Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia | P1 | Leukemia | 21 | Dec 2018 |
| NCT05807932 | FLAMSAVenetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML | P1/P2 | Myelodysplastic Syndromes | 38 | Jun 2023 |
| NCT05010122 | ASTX727ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | P1/P2 | Acute Myeloid Leukemia | 42 | Jul 2021 |
| NCT06765928 | Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT | P2 | MDS | 73 | Jan 2025 |
| NCT03661307 | Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | P1/P2 | Acute Myeloid Leukemia | 73 | Oct 2018 |
| NCT07557056 | Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P2 | Chronic Lymphocytic Leukemia | 25 | May 2026 |
| NCT07255872 | A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia | P2/P3 | Acute Myeloid Leukemia | 216 | Mar 2026 |
| NCT07486479 | Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | P3 | Acute Myeloid Leukemia (AML) | 204 | Mar 2026 |
| NCT07451912 | Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML | P1/P2 | Acute Myeloid Leukemia (AML) | 29 | Sep 2025 |
| NCT06783790 | Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT | P2 | AML (Acute Myelogenous Leukemia) | 20 | Jan 2025 |
| NCT07514936 | Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | P2 | Newly Diagnosed Acute Myeloid Leukemia (AML) | 120 | Nov 2024 |
| NCT05554393 | Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | P2 | Acute Myeloid Leukemia | 153 | Sep 2024 |
| NCT06621199 | Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML | P2 | Acute Myeloid Leukemia | 42 | Jul 2024 |
| NCT06621212 | Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML | P2 | Relapsed/Refractory Acute Myeloid Leukaemia | 72 | Jul 2024 |
| NCT06115135 | A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma | P2 | Multiple Myeloma in Relapse | 39 | Jun 2024 |
| NCT06429098 | Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML | P2 | Acute Myeloid Leukemia | 40 | Jan 2024 |
| NCT05365035 | A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts | P2 | Myelodysplastic Syndromes | 60 | Sep 2022 |
| NCT04988555 | DSP-5336A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | P1/P2 | Leukemia, Myeloid, Acute | 606 | Feb 2022 |
| NCT04708054 | Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS | P2/P3 | Acute Myeloid Leukemia | 324 | Oct 2021 |
| NCT04855695 | Avo In R/R And Previously Untreated MCL | P1/P2 | Mantle Cell Lymphoma | 72 | Jul 2021 |
| NCT04588922 | Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | P1/P2 | Hematologic Malignancies | 160 | May 2021 |
| NCT03874052 | Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | P1 | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | 51 | Aug 2019 |
| NCT06754267 | Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL | P2 | Precursor B-Cell Acute Lymphoblastic Leukemia | 36 | Dec 2024 |
| NCT06386302 | Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia | N/A | AML | 184 | Aug 2024 |
| NCT06232694 | Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML | N/A | Acute Myeloid Leukemia | 54 | Jan 2024 |
| NCT04758975 | VALUABLEVenetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) | P2 | Chronic Lymphocytic Leukemia (CLL) | 55 | Sep 2022 |
| NCT05660473 | Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia | P2 | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 100 | Aug 2022 |
| NCT06328179 | Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. | N/A | Acute Myeloid Leukemia | 34 | May 2022 |
| NCT06390306 | The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP | — | Chronic Myeloid Leukemia | 30 | Jul 2024 |
| NCT03223610 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | P1/P2 | Lymphoma | 155 | Feb 2018 |
| NCT07044687 | SCStudy to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India | P4 | Acute Myeloid Leukemia | 100 | Jul 2025 |
| NCT06660368 | BCL2i CLAG-M in R/R Acute Myeloid Leukemia | P2 | Relapsed or Refractory Acute Myeloid Leukemia (AML) | 52 | Nov 2024 |
| NCT06429449 | Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia | P1 | Leukemia | 30 | Jul 2024 |
| NCT06152809 | CIML NK Cells With Venetoclax for AML | P1 | Acute Myeloid Leukemia | 10 | Feb 2024 |
| NCT04774393 | Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | P1/P2 | Acute Myeloid Leukemia | 84 | May 2021 |
| NCT03331198 | CLLStudy Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | P1/P2 | Leukemia, Lymphocytic, Chronic, B-Cell | 320 | Nov 2017 |
| NCT06917911 | GOTesting the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) | P2 | Core Binding Factor Acute Myeloid Leukemia | 162 | Feb 2027 |
| NCT06643962 | Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy | N/A | Leukemia | 83 | Oct 2024 |
| NCT06232655 | Cladribine Venetoclax in Monocytic AML | P2 | Acute Myeloid Leukemia | 20 | Feb 2024 |
| NCT06399640 | Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia | P1 | Relapsed Myelodysplastic Syndrome | 60 | Aug 2024 |
| NCT05939180 | VA vs DA for Newly Diagnosed Hig-risk AML | P2/P3 | Acute Myeloid Leukemia | 116 | Apr 2024 |
| NCT03471260 | Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies | P1/P2 | Acute Myeloid Leukemia | 96 | Mar 2018 |
| NCT03214562 | Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia | P1/P2 | High Risk Myelodysplastic Syndrome | 116 | Sep 2017 |
| NCT06649812 | Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma | P2 | High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements | 120 | Oct 2025 |
| NCT07244367 | Maintenance Venetoclax in AML Fit Patients | N/A | Acute Myeloid Leukaemia (AML) | 80 | Sep 2025 |
| NCT06237192 | MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients | N/A | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 200 | Apr 2023 |
| NCT06561880 | FLT3AML-2024The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation | P1/P2 | FLT3 Gene Mutation | 66 | Oct 2024 |
| NCT06554626 | Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL | P2 | Precursor B-Cell Lymphoblastic Leukemia | 20 | Aug 2024 |
| NCT06129734 | Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant | P1/P2 | Myeloid Malignancy | 20 | Jul 2025 |
| NCT06536959 | VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS | P2 | Relapsed Acute Myeloid Leukemia | 67 | Jul 2024 |
| NCT06496308 | Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment | P3 | Mantle Cell Lymphoma (MCL) | 78 | Jul 2024 |
| NCT03969446 | Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory | P1 | Acute Myeloid Leukemia | 54 | May 2020 |
| NCT06903702 | A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia | P2 | Acute Myeloid Leukemia | 100 | Jun 2025 |
| NCT06746519 | BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia | P1/P2 | Acute Myeloid Leukemia | 135 | Dec 2024 |
| NCT06652685 | Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia | P2 | Acute Myeloid Leukemia (AML) | 218 | Oct 2024 |
| NCT06451861 | Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML | P2 | Acute Myeloid Leukemia | 240 | Aug 2024 |
| NCT06501196 | A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome | P1 | Leukemia | 170 | Jun 2024 |
| NCT05305859 | VCAVenetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML | P2 | Leukemia, Myeloid, Acute | 30 | Jan 2022 |
| NCT03523975 | Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma | P1/P2 | Mantle Cell Lymphoma | 28 | Dec 2018 |
| NCT06471738 | Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma | P2 | Ann Arbor Stage II Follicular Lymphoma | 30 | Jul 2024 |
| NCT03113643 | AMLSL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | P1 | Acute Myeloid Leukemia | 72 | Jun 2017 |
| NCT03128879 | Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL | P2 | Chronic Lymphocytic Leukemia | 90 | Jun 2017 |
| NCT06311227 | Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia | P2 | Recurrent Hairy Cell Leukemia | 20 | Dec 2024 |
| NCT06372717 | A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS | P1 | Acute Myeloid Leukemia Refractory | 100 | Jun 2024 |
| NCT06387420 | A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia | P1/P2 | ACUTE MYELOID LEUKEMIA; AML | 180 | Apr 2024 |
| NCT06177067 | Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | P1 | Refractory Acute Myeloid Leukemia | 24 | Apr 2024 |
| NCT05736965 | SAVA Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia | P2 | AML, Adult | 58 | Feb 2023 |
| NCT03850574 | TUSCANYClinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia | P1/P2 | Leukemia, Myeloid, Acute | 240 | Mar 2019 |
| NCT03586609 | Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia | P2 | Acute Myeloid Leukemia | 145 | Oct 2018 |
| NCT05529069 | Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients | P2 | Mantle Cell Lymphoma | 30 | Jan 2023 |
| NCT06393985 | Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL | P2 | B-cell Acute Lymphoblastic Leukemia | 30 | Apr 2024 |
| NCT06672146 | Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) | P2 | Acute Myeloid Leukemia | 93 | May 2025 |
| NCT05554406 | Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | P2 | Acute Myeloid Leukemia | 335 | Sep 2024 |
| NCT06361329 | Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL | P3 | ETP-ALL | 81 | Apr 2024 |
| NCT06192979 | Optimize First-line Treatment for AL Amyloidosis With t (11; 14) | N/A | Amyloidosis; Systemic | 41 | Jan 2024 |
| NCT06156579 | VenSwitchCombination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML | P2 | AML | 27 | Nov 2023 |
| NCT05184842 | Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML | P2 | Myelodysplastic Syndromes | 91 | Mar 2022 |
| NCT04068597 | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | P1/P2 | Haematological Malignancy | 250 | Aug 2019 |
| NCT05736978 | AVSAdaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results | P2 | AML | 58 | Mar 2023 |
| NCT05628623 | ERASETesting the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment | P2 | Leukemia, Myeloid, Acute | 184 | Oct 2024 |
| NCT03824483 | CLLStudy of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) | P2 | Chronic Lymphocytic Leukemia (CLL) | 230 | Feb 2019 |
| NCT05388006 | Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P2 | Chronic Lymphocytic Leukemia | 27 | Jan 2023 |
| NCT05861050 | Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | P1/P2 | Blastoid Variant Mantle Cell Lymphoma | 50 | Aug 2023 |
| NCT07044544 | Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies | P1 | Myeloid Malignancy | 20 | Jul 2025 |
| NCT06773208 | AMLA Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML) | P2 | Acute Myeloid Leukemia (AML) | 30 | Jan 2025 |
| NCT05317403 | Venetoclax to Augment Epigenetic Modification and Chemotherapy | P1 | Acute Myeloid Leukemia, in Relapse | 40 | Mar 2023 |
| NCT06763341 | A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | P1 | Recurrent Acute Myeloid Leukemia | 12 | Jul 2025 |
| NCT06990321 | Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia | P3 | Acute Myeloid Leukemia (AML) | 68 | Jun 2025 |
| NCT07007949 | a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia | P2 | Acute Myeloid Leukemia | 42 | Jun 2025 |
| NCT06466122 | LOXO-305Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi | P2 | Chronic Lymphocytic Leukemia | 30 | Nov 2024 |
| NCT05074355 | Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms | P2 | Myeloproliferative Neoplasm | 40 | Nov 2023 |
| NCT04790045 | LymBIOLymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens | P4 | Chronic Lymphocytic Leukemia | 30 | Nov 2023 |
| NCT05603884 | AMLVCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | P2 | Leukemia, Myeloid, Acute | 66 | Dec 2022 |
| NCT05506332 | Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia | P1 | Acute Myeloid Leukemia, in Relapse | 10 | Jul 2022 |
| NCT05211570 | AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | P1/P2 | Acute Myeloid Leukemia Refractory | 78 | Jun 2022 |
| NCT05010772 | Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | P1 | Acute Myeloid Leukemia | 125 | Oct 2021 |
| NCT04581512 | Study to Evaluate the Safety and Tolerability of EP0042 | P1/P2 | Acute Myeloid Leukemia | 70 | Nov 2020 |
| NCT04216524 | Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm | P2 | Blastic Plasmacytoid Dendritic Cell Neoplasm | 40 | May 2020 |
| NCT03629171 | Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia | P2 | Recurrent Acute Myeloid Leukemia | 52 | Oct 2018 |
| NCT06394011 | Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients | P2 | Intermediate Risk Acute Myeloid Leukemia | 60 | Feb 2024 |
| NCT06324994 | Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma. | P2 | Mantle Cell Lymphoma | 10 | May 2024 |
| NCT05668026 | AMBERAdministration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART | P1/P2 | HIV-1-infection | 18 | Apr 2024 |
| NCT06220162 | VAC Regimen for AML Patients Who Failed to Response to VA Regimen | P2 | Acute Myeloid Leukemia | 32 | Feb 2024 |
| NCT05360160 | ASTX727A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) | P1/P2 | Acute Myeloid Leukemia | 43 | Oct 2022 |
| NCT05376111 | Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients | P2 | T-cell Acute Lymphoblastic Leukemia | 28 | Apr 2022 |
| NCT02392572 | ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome | P1/P2 | Recurrent Acute Lymphoblastic Leukemia | 120 | Nov 2015 |
| NCT05597306 | VenBomVenetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia | P1 | Acute Myeloid Leukemia | 18 | Nov 2022 |
| NCT06082934 | Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia | P1/P2 | Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia | 30 | Nov 2023 |
| NCT05657652 | CAV Regimen for R/R Ph- B-ALL | N/A | Acute Lymphoblastic Leukemia | 36 | Oct 2022 |
| NCT05336812 | Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia | P2 | Chronic Lymphocytic Leukemia | 52 | Sep 2022 |
| NCT00501826 | Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | P2 | T Acute Lymphoblastic Leukemia | 160 | Jul 2007 |
| NCT06629818 | Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14) | P2 | Light Chain (AL) Amyloidosis | 36 | Oct 2024 |
| NCT06191263 | RIVER-81Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML | P2 | Acute Myeloid Leukemia | 98 | Jan 2024 |
| NCT05451771 | Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis | P1/P2 | AL Amyloidosis | 53 | Oct 2022 |
| NCT05566054 | VACVenetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia | P2 | Acute Monocytic Leukemia | 92 | Mar 2022 |
| NCT06928376 | A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients | P2 | Acute Myeloid Leukemia | 160 | Apr 2024 |
| NCT05554419 | Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) | P2 | Acute Myeloid Leukemia | 184 | Jul 2026 |
| NCT06697327 | Daunorubicin + Cytarabine + Venetoclax in de Novo AML | N/A | Leukemia, Myeloid, Acute | 94 | Feb 2025 |
| NCT05054465 | ITALLI001A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL | P1/P2 | Acute Lymphoblastic Leukemia | 48 | Oct 2021 |
| NCT04169737 | Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P2 | Recurrent Chronic Lymphocytic Leukemia | 168 | Jul 2020 |
| NCT03986034 | CLLEarly Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | P2 | Chronic Lymphocytic Leukemia | 75 | Jun 2019 |
| NCT06382168 | DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia | P1/P2 | Leukemia, Myeloid, Acute | 39 | Jun 2024 |
| NCT06434662 | Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML | P2 | Relapsed/Refractory Acute Myeloid Leukaemia | 34 | Feb 2024 |
| NCT06265545 | Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia | N/A | AML | 120 | Feb 2024 |
| NCT06357182 | Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia | P1 | Acute Myeloid Leukemia | 24 | Aug 2024 |
| NCT07039877 | Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients | P2 | Acute Lymphobkastic Leukemia | 12 | Jan 2025 |
| NCT03557619 | A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies | P1 | Hematologic Malignancies | 12 | Jul 2019 |
| NCT05901974 | Venetoclax Combined With Azactidine in the Treatment of ALAL | P2 | Acute Leukemia of Ambiguous Lineage | 23 | Jul 2023 |
| NCT06045819 | PREDICLAXRelation Between Venetoclax Plasma Concentration and Remission in Adults with Acute Myeloid Leukemia (PREDICLAX) | — | Adult Acute Myeloid Leukemia | 100 | Apr 2024 |
| NCT05881265 | Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia | P2 | APL | 30 | May 2023 |
| NCT06763666 | CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML | P4 | Relapsed/Refractory AML | 172 | Feb 2025 |
| NCT05841771 | Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies. | P2 | Hypomethylating Agent | 78 | Jan 2023 |
| NCT04905810 | Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure | P2 | Acute Myeloid Leukemia | 20 | Feb 2022 |
Venetoclax clinical trials by indication
Acute Myeloid Leukemia (147)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05955261 | — | P2 | suspended | A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia |
| NCT07581002 | REVIVAL | P2/P3 | not yet recruiting | A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) |
| NCT04628026 | — | P3 | recruiting | Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 |
| NCT05431257 | LD-VenEx | P2 | recruiting | Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling |
| NCT07059975 | UPDATE AML | Early P1 | recruiting | UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML |
| NCT05442216 | TAGALONG | P2 | recruiting | Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents |
| NCT07078591 | — | P2 | recruiting | Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML |
| NCT05183035 | AML | P3 | recruiting | Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) |
| + 139 more, see All trials below. | ||||
Chronic Lymphocytic Leukemia (53)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06967610 | PVO | P2 | recruiting | Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). |
| NCT07014917 | ESR-23-22182 | P2 | recruiting | Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL |
| NCT05091424 | — | P1 | recruiting | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia |
| NCT06943872 | CELESTIAL-RRCLL | P3 | recruiting | A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) |
| NCT07277231 | BGB-11417 | P3 | recruiting | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia |
| NCT06520098 | Benefit VA | P2 | recruiting | A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
| NCT05677919 | — | P2 | active not recruiting | Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia |
| NCT04843904 | SAVE | P1 | active not recruiting | Safe Accelerated Venetoclax Escalation in CLL |
| + 45 more, see All trials below. | ||||
Acute Myeloid Leukemia (AML) (29)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02416388 | BIG-1 | P2/P3 | recruiting | Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR |
| NCT07007312 | — | P3 | recruiting | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML |
| NCT03613532 | — | P1 | active not recruiting | Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN |
| NCT07060001 | — | P2 | not yet recruiting | Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker |
| NCT07023588 | — | P2 | recruiting | Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease |
| NCT07469046 | — | P3 | not yet recruiting | VAH vs VA in Newly Diagnosed Elderly AML |
| NCT07507825 | VHAG | P2 | not yet recruiting | Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) |
| NCT07486726 | — | P1/P2 | not yet recruiting | Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia |
| + 21 more, see All trials below. | ||||
Leukemia, Myeloid, Acute (24)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06852222 | cAMeLot-2 | P3 | recruiting | A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) |
| NCT06651229 | — | P1 | recruiting | A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms |
| NCT04988555 | DSP-5336 | P1/P2 | recruiting | A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) |
| NCT06384261 | — | P2 | active not recruiting | A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy |
| NCT05305859 | VCA | P2 | recruiting | Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML |
| NCT06770257 | — | P2 | withdrawn | Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy |
| NCT04150887 | ELEVATE | P1 | active not recruiting | Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia |
| NCT03850574 | TUSCANY | P1/P2 | recruiting | Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia |
| + 16 more, see All trials below. | ||||
Chronic Lymphocytic Leukemia (CLL) (15)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02966756 | — | P2 | recruiting | A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| NCT07024706 | MAVRiC | P2 | not yet recruiting | Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab |
| NCT04895436 | ReVenG | P2 | recruiting | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) |
| NCT05168930 | ZANU-VEN | P2 | recruiting | Zanubrutinib and Venetoclax in CLL (ZANU-VEN) |
| NCT03580928 | AVO | P2 | active not recruiting | Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL |
| NCT04758975 | VALUABLE | P2 | recruiting | Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) |
| NCT04419519 | — | P2 | active not recruiting | Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax |
| NCT03824483 | CLL | P2 | recruiting | Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) |
| + 7 more, see All trials below. | ||||
AML (12)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07539818 | — | P3 | not yet recruiting | Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML |
| NCT06972641 | — | P2/P3 | recruiting | Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation |
| NCT05287568 | — | P1 | recruiting | CC-486 and Venetoclax for Acute Myeloid Leukemia |
| NCT07490288 | — | N/A | recruiting | Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML |
| NCT06611839 | IDH1-AML-2024 | P1/P2 | recruiting | Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML |
| NCT06744556 | — | P2 | active not recruiting | HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML |
| NCT06386302 | — | N/A | recruiting | Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia |
| NCT06156579 | VenSwitch | P2 | recruiting | Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML |
| + 4 more, see All trials below. | ||||
Leukemia (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06644183 | IOA-244 | P1/P2 | recruiting | Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) |
| NCT07294677 | CAVALRY | P1/P2 | recruiting | CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL |
| NCT03319901 | — | P1/P2 | active not recruiting | Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL |
| NCT05536349 | CLL | P2 | recruiting | Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) |
| NCT03826992 | CPX-351 | P1 | recruiting | Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia |
| NCT06429449 | — | P1 | recruiting | Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia |
| NCT06643962 | — | N/A | recruiting | Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy |
| NCT06501196 | — | P1 | recruiting | A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome |
| + 3 more, see All trials below. | ||||
Mantle Cell Lymphoma (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04802590 | — | P2 | active not recruiting | Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma |
| NCT06522386 | GATE1 | P2 | active not recruiting | GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma |
| NCT04855695 | — | P1/P2 | recruiting | Avo In R/R And Previously Untreated MCL |
| NCT03523975 | — | P1/P2 | recruiting | Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma |
| NCT05529069 | — | P2 | recruiting | Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients |
| NCT03710772 | — | P2 | active not recruiting | Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma |
| NCT06324994 | — | P2 | not yet recruiting | Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma. |
| NCT05025423 | — | P2 | terminated | Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma |
| + 2 more, see All trials below. | ||||
Recurrent Acute Myeloid Leukemia (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04140487 | — | P1/P2 | recruiting | Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm |
| NCT05222984 | — | P1 | active not recruiting | Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax |
| NCT06763341 | — | P1 | recruiting | A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
| NCT03629171 | — | P2 | recruiting | Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia |
| NCT05799079 | — | P2 | terminated | Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant |
| NCT04487106 | — | P2 | completed | Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome |
| NCT04655391 | — | P1 | withdrawn | Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation |
| NCT03390296 | OX40 | P1/P2 | completed | OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia |
| + 1 more, see All trials below. | ||||
Multiple Myeloma (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03314181 | — | P2 | active not recruiting | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma |
| NCT05853965 | BELI(E)VE | P1/P2 | recruiting | Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma |
| NCT06042725 | — | P1 | recruiting | MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma |
| NCT03539744 | — | P3 | active not recruiting | A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. |
| NCT02899052 | MM | P2 | active not recruiting | Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) |
| NCT03312530 | — | P1/P2 | completed | A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma |
| NCT02951117 | — | P1 | withdrawn | A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment |
| NCT03567616 | — | P2 | terminated | A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma |
| + 1 more, see All trials below. | ||||
Acute Lymphoblastic Leukemia (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07175415 | HEM-iSMART E | P1/P2 | not yet recruiting | HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies |
| NCT05751044 | HEM-iSMART B | P1/P2 | recruiting | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies |
| NCT06855810 | CCCG-TALL-2025 | P2/P3 | recruiting | Newly-diagnosed Pediatric T-cell ALL Protocol |
| NCT05657652 | — | N/A | recruiting | CAV Regimen for R/R Ph- B-ALL |
| NCT05054465 | ITALLI001 | P1/P2 | not yet recruiting | A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL |
| NCT05386576 | ALL | Early P1 | active not recruiting | A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) |
| NCT05268003 | — | P2 | terminated | A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia |
| NCT06087419 | — | P1/P2 | unknown | A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients |
AML, Adult (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07407140 | VAG-3+7-G | P3 | not yet recruiting | VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML |
| NCT06841952 | — | N/A | not yet recruiting | Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia |
| NCT07132684 | — | P3 | recruiting | Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients |
| NCT07131059 | — | N/A | recruiting | MRD-positive AML Clinical Study |
| NCT06014489 | HO171 | P2 | recruiting | A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML |
| NCT05736965 | SAV | P2 | recruiting | A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia |
| NCT05503355 | — | P1/P2 | unknown | A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML |
| NCT05177731 | — | P3 | active not recruiting | Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML |
Follicular Lymphoma (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03980171 | LEVERAGE | P1/P2 | active not recruiting | Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma |
| NCT04599634 | VENOM | P1 | completed | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies |
| NCT04722601 | — | P1/P2 | terminated | A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma |
| NCT03113422 | PrE0403 | P2 | completed | Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy |
| NCT03276468 | — | P2 | completed | Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas |
| NCT02877550 | — | P1 | completed | Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients |
| NCT03135262 | FL | P1/P2 | terminated | A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) |
| NCT02187861 | GDC-0199 | P2 | completed | A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL) |
Myelodysplastic Syndromes (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07238686 | — | P2 | recruiting | Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS |
| NCT04256317 | — | P2/P3 | recruiting | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) |
| NCT05201066 | MBG453 | P2 | active not recruiting | Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. |
| NCT05807932 | FLAMSA | P1/P2 | recruiting | Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML |
| NCT05365035 | — | P2 | recruiting | A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts |
| NCT05184842 | — | P2 | recruiting | Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML |
| NCT06109064 | — | P2 | unknown | Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDS |
Leukemia, Lymphocytic, Chronic, B-Cell (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05947851 | VR | P3 | recruiting | A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). |
| NCT03462719 | GLOW | P3 | active not recruiting | A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
| NCT05963074 | TAILOR | P2 | recruiting | A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia |
| NCT05650723 | CLL | P2 | active not recruiting | Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab |
| NCT03331198 | CLL | P1/P2 | recruiting | Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) |
| NCT02639910 | COSMOS | P2 | completed | Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi |
| NCT03343678 | — | P1 | withdrawn | This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax |
Lymphoma (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06510309 | — | P2 | recruiting | Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma |
| NCT04739813 | — | P1 | active not recruiting | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma |
| NCT03223610 | — | P1/P2 | recruiting | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma |
| NCT05371054 | VVIP | P1/P2 | completed | Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies |
| NCT03530683 | PF-07901801 | P1 | terminated | A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma |
| NCT01742988 | CUDC-907 | P1 | completed | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma |
T-cell Acute Lymphoblastic Leukemia (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06390319 | ALL | P2 | recruiting | Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) |
| NCT07513129 | — | P1 | not yet recruiting | Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma |
| NCT06561074 | T-ALL | P2 | recruiting | A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) |
| NCT06686108 | — | P2 | recruiting | Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention |
| NCT05376111 | — | P2 | recruiting | Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients |
Waldenstrom Macroglobulinemia (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05099471 | VIWA-1 | P2 | recruiting | Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia |
| NCT05734495 | — | P2 | active not recruiting | Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia |
| NCT07387471 | WM | P2 | recruiting | Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) |
| NCT07231952 | WM | P2 | recruiting | A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) |
| NCT04273139 | — | P2 | active not recruiting | Ibrutinib + Venetoclax in Untreated WM |
CLL (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06073821 | BGB-11417 | P3 | active not recruiting | Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) |
| NCT03868722 | — | P2/P3 | recruiting | Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment |
| NCT06846671 | CaDAnCe-302 | P3 | recruiting | A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors |
| NCT04639362 | — | P2 | active not recruiting | CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD. |
| NCT05209308 | CORAL | P2 | withdrawn | Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL |
Acute Myeloid Leukemia, Adult (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07478991 | VENP-A-QUI | P3 | not yet recruiting | Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) |
| NCT06449482 | — | P1/P2 | terminated | Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy |
| NCT04752527 | — | P2 | unknown | Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features |
| NCT04454580 | — | N/A | unknown | Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy |
Myeloid Malignancy (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06129734 | — | P1/P2 | recruiting | Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant |
| NCT07044544 | — | P1 | recruiting | Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies |
| NCT05455294 | — | P1 | active not recruiting | Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms |
| NCT04214860 | — | P1 | completed | APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies |
Chronic Myeloid Leukemia (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05768711 | AVENHIR | P2 | active not recruiting | Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) |
| NCT06390306 | — | N/A | recruiting | The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP |
| NCT05701215 | VARIANT | P2 | active not recruiting | Venetoclax After TKI to Target Persisting Stem Cells in CML |
| NCT03455517 | VeRitAs | P2 | completed | Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia |
Chronic Myelomonocytic Leukemia (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05600894 | — | P2 | active not recruiting | Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm |
| NCT04655755 | — | P1/P2 | active not recruiting | Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia |
| NCT04160052 | — | P1/P2 | terminated | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome |
| NCT06085638 | — | P1/P2 | withdrawn | Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia |
Recurrent Plasma Cell Myeloma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05391750 | — | P1 | active not recruiting | Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma |
| NCT03399539 | — | P1 | completed | Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma |
| NCT03856112 | — | P1/P2 | withdrawn | Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma |
| NCT03701321 | — | P1/P2 | withdrawn | Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma |
Chronic Lymphoid Leukemia (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03766763 | — | P2 | active not recruiting | Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A |
| NCT04608318 | CLL17 | P3 | active not recruiting | Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) |
| NCT04515238 | CLL2-BZAG | P2 | active not recruiting | Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL |
| NCT03787264 | CLL2-BAAG | P2 | completed | Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL |
Acute Myeloid Leukaemia (AML) (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07148180 | — | P1/P2 | recruiting | A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax |
| NCT07264010 | — | P2/P3 | not yet recruiting | Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study |
| NCT07244367 | — | N/A | recruiting | Maintenance Venetoclax in AML Fit Patients |
Relapsed Acute Myeloid Leukemia (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07320235 | IMAGINE | P1 | recruiting | Imetelstat Combinations in Relapsed AML |
| NCT06536959 | — | P2 | recruiting | VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS |
| NCT05362942 | — | P2 | unknown | Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia |
B-cell Acute Lymphoblastic Leukemia (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06863259 | — | P1 | recruiting | Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL |
| NCT06393985 | — | P2 | recruiting | Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL |
| NCT05016947 | — | P1 | active not recruiting | Venetoclax Plus Inotuzumab for B-ALL |
AML (Acute Myelogenous Leukemia) (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06635681 | DAV-AML-2024 | P2 | recruiting | Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML |
| NCT06783790 | — | P2 | recruiting | Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT |
| NCT06993883 | AML | N/A | completed | Use of Venetoclax , AML , Sohag , Egypt |
MDS (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06765928 | — | P2 | not yet recruiting | Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT |
| NCT05226455 | — | P1/P2 | active not recruiting | Venetoclax in Patients With MDS or AML in Relapse After AHSCT |
| NCT07318662 | — | N/A | active not recruiting | Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML |
Diffuse Large B Cell Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06516978 | — | P2 | not yet recruiting | A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL |
| NCT04572763 | — | P1/P2 | active not recruiting | Copanlisib Plus Venetoclax in R/R DLBCL |
| NCT05863845 | — | N/A | unknown | Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL |
Acute Myeloid Leukemia Refractory (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06372717 | — | P1 | recruiting | A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS |
| NCT05211570 | — | P1/P2 | recruiting | AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
| NCT06150040 | AML-NET | P1/P2 | terminated | Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] |
Mantle Cell Lymphoma (MCL) (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05951959 | TrAVeRse | P2 | active not recruiting | A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma |
| NCT06496308 | — | P3 | recruiting | Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment |
| NCT04477486 | — | P2 | completed | Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma |
B Acute Lymphoblastic Leukemia (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04872790 | — | P1 | active not recruiting | Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia |
| NCT05157971 | — | P1 | active not recruiting | Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia |
| NCT06078306 | B-ALL | P2 | unknown | CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). |
Adult Acute Myeloid Leukemia (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06045819 | PREDICLAX | N/A | recruiting | Relation Between Venetoclax Plasma Concentration and Remission in Adults with Acute Myeloid Leukemia (PREDICLAX) |
| NCT05262465 | — | N/A | unknown | Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML |
| NCT03226418 | — | P2 | completed | Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06387121 | — | P2 | recruiting | Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL |
| NCT05660473 | — | P2 | recruiting | Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia |
| NCT06237192 | — | N/A | recruiting | MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients |
AL Amyloidosis (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05486481 | ALTITUDE | P1/P2 | withdrawn | Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) |
| NCT05451771 | — | P1/P2 | recruiting | Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis |
| NCT03000660 | ABT-199 | P1 | terminated | Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis |
Recurrent Mantle Cell Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05910801 | V-MIND | P2 | recruiting | Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma |
| NCT04939272 | — | P1/P2 | active not recruiting | Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma |
| NCT04990778 | — | P2 | withdrawn | Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma |
Lymphoma, Non-Hodgkin (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05618366 | — | P1 | terminated | Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma |
| NCT03357627 | — | P1 | completed | A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma |
| NCT02055820 | NHL | P1/P2 | completed | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL |
Recurrent Chronic Lymphocytic Leukemia (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04941716 | — | P2 | recruiting | Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial |
| NCT04169737 | — | P2 | recruiting | Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| NCT03045328 | — | P2 | completed | Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL |
Acute Myelogenous Leukemia (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04278768 | AML | P1/P2 | suspended | Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) |
| NCT04172844 | PAVE | P1 | terminated | Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia |
| NCT02287233 | — | P1/P2 | completed | A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia |
AML (Acute Myeloid Leukemia) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07425808 | FIT-AML | P2/P3 | not yet recruiting | FLT3-ITD Targeted Therapy in Fit AML Patients |
| NCT07514832 | — | P2 | recruiting | VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial |
Leukemia, Myeloid (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07439211 | GAVEL | P1 | not yet recruiting | Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia |
| NCT04748848 | — | P1 | terminated | A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy |
Recurrent B Acute Lymphoblastic Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07133997 | — | P1 | recruiting | Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia |
| NCT03808610 | — | P1/P2 | terminated | Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia |
Acute Lymphoblastic Leukemia, in Relapse (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05745714 | HEM-iSMART C | P1/P2 | recruiting | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies |
| NCT05740449 | HEM-iSMART A | P1/P2 | withdrawn | HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies |
AML - Acute Myeloid Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06696183 | SEQUENCE | P2 | recruiting | Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment |
| NCT07014462 | DLIT-AML | P1 | enrolling by invitation | A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML |
Acute Leukemia of Ambiguous Lineage (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06317662 | — | P2 | recruiting | Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia |
| NCT05901974 | — | P2 | recruiting | Venetoclax Combined With Azactidine in the Treatment of ALAL |
Lymphoma, Mantle-Cell (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06558604 | GLOASIS | P2 | recruiting | Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma |
| NCT03567876 | — | P2 | completed | Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL |
Refractory Acute Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06466395 | — | P1 | recruiting | A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias |
| NCT06397027 | — | P1 | recruiting | A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias |
Acute Monocytic Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06504459 | — | P2 | recruiting | Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML |
| NCT05566054 | VAC | P2 | recruiting | Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia |
Relapsed or Refractory Acute Myeloid Leukemia (AML) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06660368 | — | P2 | recruiting | BCL2i CLAG-M in R/R Acute Myeloid Leukemia |
| NCT03218683 | — | P1 | terminated | Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies. |
Light Chain (AL) Amyloidosis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06629818 | — | P2 | recruiting | Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14) |
| NCT05996406 | — | P2 | active not recruiting | Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14) |
Acute Myeloid Leukemia in Remission (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04062266 | — | P2 | active not recruiting | AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission |
| NCT07163793 | — | P2 | recruiting | Pilot Study of Reduced Venetoclax Exposure |
Relapsed Adult AML (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06007911 | — | P1 | withdrawn | Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
| NCT04330820 | RELAX | P1/P2 | unknown | Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) |
T Acute Lymphoblastic Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00501826 | — | P2 | recruiting | Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma |
| NCT06210750 | T-ALL | P2 | withdrawn | Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) |
Ann Arbor Stage II Follicular Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06471738 | — | P2 | recruiting | Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma |
| NCT04450173 | — | P2 | active not recruiting | Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma |
Relapsed/Refractory Acute Myeloid Leukaemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06621212 | — | P2 | recruiting | Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML |
| NCT06434662 | — | P2 | recruiting | Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML |
Secondary Acute Myeloid Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05513131 | — | P2 | unknown | Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML |
| NCT05780879 | G-CSF | P2 | terminated | A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia |
CLL/SLL (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04523428 | REVEAL | P2 | recruiting | REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) |
| NCT05791409 | AETHER | P1/P2 | recruiting | Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL |
Healthy Volunteers (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06070948 | — | P1 | withdrawn | A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants |
| NCT05909553 | — | P1 | completed | Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers |
Blastoid Variant Mantle Cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03946878 | — | P2 | active not recruiting | Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma |
| NCT05861050 | — | P1/P2 | recruiting | Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma |
Acute Myeloid Leukemia, in Relapse (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05317403 | — | P1 | recruiting | Venetoclax to Augment Epigenetic Modification and Chemotherapy |
| NCT05506332 | — | P1 | recruiting | Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia |
Myelodysplastic Syndrome (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04227847 | — | P1 | recruiting | A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies |
| NCT05564650 | — | P1 | completed | Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome |
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05057494 | MAJIC | P3 | active not recruiting | A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| NCT04981912 | — | P1 | active not recruiting | Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients |
Relapsed or Refractory Acute Myeloid Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05522192 | — | P1/P2 | unknown | Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia |
| NCT04666649 | — | P1 | completed | Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) |
Relapsed Non Hodgkin Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05053659 | — | P1 | active not recruiting | Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma |
| NCT03505944 | VALERIA | P1/P2 | unknown | Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma |
Acute Biphenotypic Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02115295 | — | P2 | recruiting | Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia |
| NCT04797767 | — | P1/P2 | recruiting | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms |
Hematopoietic and Lymphoid Cell Neoplasm (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04874194 | — | P1/P2 | terminated | Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 |
| NCT04752163 | — | P1/P2 | terminated | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia |
Hematologic Malignancy (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04809181 | — | P2 | unknown | Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients |
| NCT05084027 | — | P2 | unknown | Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT |
Lymphoma, Large B-Cell, Diffuse (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04790903 | R | P1 | terminated | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) |
| NCT02987400 | — | P2 | completed | Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL |
Myelodysplastic Syndrome (MDS) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04401748 | Verona | P3 | active not recruiting | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome |
| NCT04812548 | STIMULUS-MDS3 | P2 | terminated | A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants |
Hematologic Malignancies (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04588922 | — | P1/P2 | recruiting | Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML |
| NCT03557619 | — | P1 | recruiting | A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies |
Recurrent B-Cell Non-Hodgkin Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04447716 | — | P1 | active not recruiting | An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment |
| NCT04659044 | — | P2 | terminated | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma |
Relapsed/Refractory Chronic Lymphocytic Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04623541 | EPCORE™ CLL-1 | P1/P2 | active not recruiting | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome |
| NCT03708003 | — | P2 | terminated | Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL |
Breast Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04298918 | — | P1/P2 | terminated | A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer |
| NCT04274933 | — | P1 | terminated | A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy |
Blastic Plasmacytoid Dendritic Cell Neoplasm (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04216524 | — | P2 | recruiting | Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm |
| NCT03485547 | BPDCN | P1 | completed | Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04188405 | — | P2 | completed | Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia |
| NCT03878524 | SMMART | P1 | terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial |
Acute Bilineal Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04128501 | — | P2 | active not recruiting | Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting |
| NCT02397720 | — | P2 | completed | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia |
Diffuse Large B-Cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03984448 | — | P2/P3 | active not recruiting | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas |
| NCT03036904 | V+DA-EPOCH-R | P1 | completed | Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas |
Diffuse Large B-cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03955783 | — | P1 | completed | Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies |
| NCT03255096 | — | P1 | completed | A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 |
Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03768063 | IMbrella B | P3 | active not recruiting | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study |
| NCT02391480 | — | P1 | completed | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer |
Acute Myeloid Leukaemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03672695 | — | P1 | completed | Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia. |
| NCT03217838 | — | P1 | terminated | Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. |
Advanced Solid Tumors (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03000257 | ABBV-181 | P1 | completed | A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors |
| NCT03082209 | — | P1 | completed | A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies |
Myelodysplastic Syndromes (MDS) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02942290 | MDS | P1 | active not recruiting | A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS) |
| NCT02966782 | MDS | P1 | completed | A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS) |
Relapsed/Refractory Multiple Myeloma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02755597 | Bellini | P3 | completed | A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy |
| NCT01794520 | — | P1/P2 | completed | Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma |
Lymphocytic Leukemia, Chronic (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02242942 | — | P3 | completed | Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia |
| NCT01685892 | — | P1 | completed | A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia |
Core Binding Factor Acute Myeloid Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06917911 | GO | P2 | recruiting | Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) |
Myeloid Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07604233 | — | P1/P2 | not yet recruiting | Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML |
LAL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07522801 | ALL-TARGET | P2 | not yet recruiting | A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL |
Leukemia Acute Myeloid (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07605949 | RAVEN | P2 | not yet recruiting | Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML |
Kidney Failure Chronic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07358195 | — | Early P1 | not yet recruiting | Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation |
Adult ALL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06991920 | — | N/A | not yet recruiting | Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage |
T-cell Prolymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07311746 | — | P1/P2 | not yet recruiting | Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia |
B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07520006 | — | P1/P2 | not yet recruiting | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies |
Ph-Like (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07454226 | — | N/A | recruiting | ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL |
HIV-1 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07481175 | INITIATE | P1 | recruiting | Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study) |
Ph+ ALL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07493161 | — | N/A | recruiting | Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL |
Acute Lymphoblastic Leukemia, Adult (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07495631 | — | N/A | recruiting | Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia |
Venentoclax (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07396480 | — | P3 | recruiting | Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial |
Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06958705 | — | P2 | recruiting | Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy |
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07007052 | TAGVEN | P2 | not yet recruiting | Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients |
High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06649812 | — | P2 | recruiting | Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma |
Leukemia, B-Cell, Chronic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07082452 | SEVENAZA | P3 | not yet recruiting | A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction |
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07154264 | TAI-SHAN10 | P2 | recruiting | A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) |
Targeted Therapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07032727 | — | P2 | recruiting | Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations |
Adult T-cell Leukemia/Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07159620 | — | P2 | recruiting | Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients |
Older Patients (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07052422 | — | P2/P3 | not yet recruiting | VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT |
Myelodysplastic Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07047183 | — | P2 | recruiting | Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes |
Acute Promyelocytic Leukemia (APL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07187505 | — | N/A | active not recruiting | Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia |
B-Cell Acute Lymphoblastic Leukemia, Adult (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07199855 | — | P2 | active not recruiting | Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia |
Myelodysplastic Syndrome/Acute Myeloid Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06454409 | — | P1 | suspended | Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia |
T-cell-prolymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06810778 | PTCL | P1/P2 | recruiting | Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) |
Early T Acute Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07012447 | — | P2 | recruiting | Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations |
Myelodysplastic Syndrome(MDS) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06548230 | MDS | P1/P2 | recruiting | A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) |
Relapsed/Refractory AML (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06763666 | — | P4 | not yet recruiting | CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML |
Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06563804 | — | P1/P2 | terminated | A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML |
T Lymphoblastic Leukemia/Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06712121 | — | P2 | recruiting | Venetoclax and Decitabine in R/R T-ALL |
CML,Blast Phase (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06757855 | — | P1/P2 | recruiting | Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML |
Acute Lymphoblastic Leukemia ALL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06764238 | CCCG-I/HR-ALL | P2/P3 | recruiting | Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol |
Acute Lymphobkastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07039877 | — | P2 | recruiting | Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients |
Acute T Lymphpblastic Leukemia/Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06742463 | — | P2 | recruiting | VHAG in Treating R/R T-ALL/LBL |
Precursor B-Cell Acute Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06754267 | — | P2 | recruiting | Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL |
Healthy Volunteer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06742086 | — | P1 | completed | A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants |
Recurrent Hairy Cell Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06311227 | — | P2 | recruiting | Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia |
Newly Diagnosed Acute Myeloid Leukemia (AML) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07514936 | — | P2 | recruiting | Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia |
FLT3 Gene Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06561880 | FLT3AML-2024 | P1/P2 | recruiting | The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation |
Higher-risk Myelodysplastic Syndromes (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06471946 | — | P1/P2 | recruiting | VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS |
Mutant IDH1 Inhibitor Olutasidenib (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06445959 | — | P1/P2 | recruiting | Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib |
Precursor B-Cell Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06554626 | — | P2 | recruiting | Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL |
Relapsed Myelodysplastic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06399640 | — | P1 | recruiting | Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia |
Multiple Myeloma in Relapse (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06115135 | — | P2 | recruiting | A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma |
Philadelphia Chromosome Negative ALL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06481241 | — | N/A | recruiting | Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL |
Philadelphia Positive Acute Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06481228 | — | N/A | recruiting | Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL |
AML/MDS (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05986240 | — | P1 | recruiting | Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML |
ACUTE MYELOID LEUKEMIA; AML (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06387420 | — | P1/P2 | not yet recruiting | A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia |
Refractory Acute Myeloid Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06177067 | — | P1 | recruiting | Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia |
ETP-ALL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06361329 | — | P3 | recruiting | Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL |
HIV-1-infection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05668026 | AMBER | P1/P2 | recruiting | Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART |
Recurrent Transformed Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06247540 | — | P2 | withdrawn | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
Intermediate Risk Acute Myeloid Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06394011 | — | P2 | recruiting | Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients |
Ph-Positive Acute Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06578546 | — | P2 | unknown | Chemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALL |
Amyloidosis; Systemic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06192979 | — | N/A | recruiting | Optimize First-line Treatment for AL Amyloidosis With t (11; 14) |
AML, Childhood (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06221683 | GMCAII | P2 | recruiting | Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML |
Waldenstrom's Macroglobulinaemia Refractory (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06200220 | — | N/A | unknown | Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia |
Untreated Myelodysplastic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05782127 | — | P1/P2 | active not recruiting | Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes |
Myeloproliferative Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05074355 | — | P2 | recruiting | Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms |
Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06082934 | — | P1/P2 | recruiting | Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia |
Acute Myelocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06105658 | — | P2 | unknown | Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML |
Idiopathic Pulmonary Fibrosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05976217 | — | Early P1 | completed | Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis |
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05665530 | — | P1 | completed | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies |
Mantle Cell Lymphoma Refractory (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05864742 | — | P2 | active not recruiting | Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma |
Acute Promyelocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06544109 | Ven APL | P2/P3 | enrolling by invitation | Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients |
Relapsed/Refractory Acute Myeloid Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06084819 | — | P2 | recruiting | Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia |
APL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05881265 | — | P2 | recruiting | Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia |
Leukemia, Lymphoblastic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05464836 | — | P2 | terminated | Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL |
Myelodysplastic Syndromes, de Novo (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05292664 | — | P1 | recruiting | Venetoclax Basket Trial for High Risk Hematologic Malignancies |
Relapsed and Refractory Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05530421 | SELVEDge | P2 | recruiting | Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma |
Refractory/Relapse Acute Myeloid Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05807347 | — | P2 | unknown | Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia |
Hypomethylating Agent (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05841771 | — | P2 | recruiting | Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies. |
AML, Adult Recurrent (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05829226 | AML | P1 | completed | A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) |
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05594784 | — | P2 | completed | Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL |
Metastatic Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05725200 | EVIDENT | P2 | recruiting | Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer |
Refractory Acute Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05192889 | — | P1/P2 | active not recruiting | Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax |
Recurrent AL Amyloidosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04847453 | — | P1 | active not recruiting | Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis |
Hemophagocytic Lymphohistiocytosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05546060 | — | P1 | unknown | Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH |
Acute Myeloid Leukemia (AML) in Remission (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05404906 | — | P2/P3 | recruiting | AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission |
Secondary Myelodysplastic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05379166 | — | P2 | active not recruiting | Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome |
Relapsed or Refractory Hematologic Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04926285 | VEN-OM | P1 | completed | Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML) |
Philadelphia Chromosome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05433532 | — | P2 | completed | Study of Azacitidine,Venetoclax,and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients |
Myelodysplastic/Myeloproliferative Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05282719 | — | P2 | unknown | Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults |
Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05211336 | VIPOR | P1 | active not recruiting | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System |
Lymphoplasmacytic Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04840602 | — | P2 | recruiting | Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma |
ALL, Recurrent, Adult (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05182385 | BCP-ALL | P1/P2 | active not recruiting | Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) |
Acute Leukemia of Ambiguous Lineage in Relapse (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04898894 | — | P1 | active not recruiting | Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia |
Acute T-Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05149378 | — | P2 | completed | Venetoclax Based Regimen for R/R T-ALL |
Recurrent Acute Biphenotypic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04975919 | — | P2 | active not recruiting | Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia |
Richter's Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04939363 | — | P2 | completed | A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome; |
Renal Impairment (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04810598 | — | P1 | completed | Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function |
Relapsed Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04543916 | — | P1/P2 | withdrawn | Venetoclax and Irinotecan in Relapsed/Refractory SCLC |
Myeloid Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04778410 | — | P2 | terminated | Study of Magrolimab Combinations in Participants With Myeloid Malignancies |
Marginal Zone Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04416451 | — | P2 | active not recruiting | A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma |
Non Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04419389 | R/R | P1/P2 | terminated | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) |
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04607772 | RR | P1/P2 | withdrawn | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) |
Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04553692 | IGM-8444 | P1 | terminated | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers |
Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04422210 | ES-SCLC | P1 | terminated | A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC). |
AML With Monocytic Differentiation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04372433 | — | P1 | completed | IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML |
Recurrent Chronic Myelomonocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04550442 | — | P1/P2 | terminated | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia |
Lymphoma, B-Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04161248 | — | Early P1 | active not recruiting | Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma |
Non Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04274907 | NSCLC | P1 | terminated | A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression |
Primary CNS Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04073147 | VENOBI-CNS | P1 | terminated | Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma |
High Grade B-Cell Lymphoma, Not Otherwise Specified (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04285268 | — | P2 | withdrawn | Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
CTCL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04171791 | CTCL | P1 | completed | A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL) |
Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03886649 | — | P1 | terminated | Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. |
CLL Transformation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04082897 | MOLTO | P2 | active not recruiting | ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation |
Intermediate Risk Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04010968 | ERADIC | P2 | completed | Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia |
Breast Neoplasm Female (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03900884 | PALVEN | P1 | active not recruiting | Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer |
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03874052 | — | P1 | recruiting | Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
Haematological Malignancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04068597 | — | P1/P2 | recruiting | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies |
Castration Levels of Testosterone (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03751436 | — | P1 | completed | Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer |
Refractory Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03884972 | — | P1 | withdrawn | Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor |
CCND1 Positive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03872180 | — | P2 | active not recruiting | Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma |
Relapsed Refractory Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03732703 | MyDRUG | P1/P2 | completed | Myeloma-Developing Regimens Using Genomics (MyDRUG) |
Non-hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03713580 | — | P1 | active not recruiting | Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma |
Relapsed or Refractory Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03739554 | — | P1 | completed | CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL |
Acute Myeloid Leukemia With FLT3/ITD Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03735875 | — | P1/P2 | terminated | Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia |
B-Cell Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03755947 | — | P2 | completed | Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia |
T-Cell Lymphoma Relapsed (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03552692 | — | P2 | terminated | Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma |
Hematopoietic Cell Transplantation Recipient (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03583424 | — | P1/P2 | completed | Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma |
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03584009 | Veronica | P2 | terminated | A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy |
Anaplastic Large Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03534180 | — | P2 | completed | Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma |
Recurrent Adult Lymphoblastic Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03504644 | — | P1/P2 | active not recruiting | Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia |
Cancer - Acute Myeloid Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03484520 | MK7965 | P1 | terminated | A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03576547 | — | P1/P2 | terminated | Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia |
Follicular Lymphoma (FL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03547115 | — | P1 | terminated | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML |
Acute Lymphoblastic Leukemia (ALL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03181126 | — | P1 | completed | A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma |
Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03236857 | — | P1 | completed | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies |
High Risk Myelodysplastic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03214562 | — | P1/P2 | recruiting | Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia |
Acute Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03176277 | — | P1/P2 | terminated | A Study of ONO-7475 in Patients With Acute Leukemias |
Diffuse Large B-cell-lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03064867 | — | P1/P2 | active not recruiting | Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
Chronic Lymphocytic Leukemia in Relapse (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03226301 | RR-CLL | P2 | active not recruiting | A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations |
Mantle-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03112174 | SYMPATICO | P3 | completed | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) |
Richter Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03054896 | — | P2 | active not recruiting | A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome |
Refractory Follicular Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02956382 | — | P1/P2 | completed | Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma |
B-Cell Lymphoma, Unspecified (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02992522 | — | P1 | active not recruiting | Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03013998 | — | P1/P2 | recruiting | Study of Biomarker-Based Treatment of Acute Myeloid Leukemia |
Leukemia, Lymphocytic, Chronic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02758665 | CLL2-GiVe | P2 | completed | Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL |
Non-Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02611323 | FL | P1/P2 | completed | A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) |
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02689440 | — | P2 | active not recruiting | Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia |
Recurrent Acute Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02392572 | — | P1/P2 | recruiting | ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome |
Non-Hodgkin Lymphoma (NHL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02265731 | — | P1/P2 | completed | Study Evaluating Venetoclax in Subjects With Hematological Malignancies |
Relapsed Childhood ALL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05215405 | — | N/A | no longer available | Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL |
Myelofibrosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03592576 | — | N/A | no longer available | Expanded Access to Navitoclax |
Venetoclax pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SC | NCT07044687 | P4 | recruiting | Acute Myeloid Leukemia | 100 | — |
| LymBIO | NCT04790045 | P4 | not yet recruiting | Chronic Lymphocytic Leukemia | 30 | — |
| SC | NCT05144243 | P4 | active not recruiting | Acute Myeloid Leukemia (AML) | 44 | — |
| VR | NCT05947851 | P3 | recruiting | Leukemia, Lymphocytic, Chronic, B-Cell | 735 | — |
| BGB-11417 | NCT06073821 | P3 | active not recruiting | CLL | 652 | — |
| CELESTIAL-RRCLL | NCT06943872 | P3 | recruiting | Chronic Lymphocytic Leukemia | 630 | — |
| BGB-11417 | NCT07277231 | P3 | recruiting | Chronic Lymphocytic Leukemia | 500 | — |
| AML | NCT05183035 | P3 | recruiting | Acute Myeloid Leukemia | 130 | PMID 39368878 |
| SEVENAZA | NCT07082452 | P3 | not yet recruiting | Leukemia, B-Cell, Chronic | 262 | — |
| VAG-3+7-G | NCT07407140 | P3 | not yet recruiting | AML, Adult | 300 | — |
| VENP-A-QUI | NCT07478991 | P3 | not yet recruiting | Acute Myeloid Leukemia, Adult | 376 | — |
| CaDAnCe-302 | NCT06846671 | P3 | recruiting | CLL | 250 | — |
| cAMeLot-2 | NCT06852222 | P3 | recruiting | Leukemia, Myeloid, Acute | 600 | — |
| MAJIC | NCT05057494 | P3 | active not recruiting | Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 607 | PMID 36102212 |
| GLOW | NCT03462719 | P3 | active not recruiting | Leukemia, Lymphocytic, Chronic, B-Cell | 211 | PMID 37944541 |
| EVOLVE 1 | NCT07075016 | P3 | recruiting | Acute Myeloid Leukemia | 227 | — |
| CLL | NCT04269902 | P3 | recruiting | Chronic Lymphocytic Leukemia | 247 | — |
| IMbrella B | NCT03768063 | P3 | active not recruiting | Cancer | 1,000 | — |
| TLS | NCT06428019 | P3 | recruiting | Chronic Lymphocytic Leukemia | 170 | — |
| BRUIN CLL-322 | NCT04965493 | P3 | active not recruiting | Chronic Lymphocytic Leukemia | 600 | — |
| SEQUOIA | NCT03336333 | P3 | active not recruiting | Chronic Lymphocytic Leukemia | 590 | PMID 33054121 |
| CLL17 | NCT04608318 | P3 | active not recruiting | Chronic Lymphoid Leukemia | 897 | PMID 41358601 |
| Verona | NCT04401748 | P3 | active not recruiting | Myelodysplastic Syndrome (MDS) | 531 | PMID 38065202 |
| AMPLIFY | NCT03836261 | P3 | active not recruiting | Chronic Lymphocytic Leukemia | 984 | PMID 33796237 |
| REGAL | NCT04229979 | P3 | active not recruiting | Acute Myeloid Leukemia | 127 | PMID 39606837 |
| Viale-a | NCT02993523 | P3 | active not recruiting | Acute Myeloid Leukemia (AML) | 443 | PMID 40913104 |
| VIALE-M | NCT04102020 | P3 | completed | Acute Myeloid Leukemia (AML) | 112 | PMID 35852098 |
| VIALE-T | NCT04161885 | P3 | terminated | Acute Myeloid Leukemia (AML) | 465 | — |
| CRISTALLO | NCT04285567 | P3 | completed | Chronic Lymphocytic Leukemia (CLL) | 166 | — |
| SYMPATICO | NCT03112174 | P3 | completed | Mantle-Cell Lymphoma | 366 | PMID 34717692 |
| ENHANCE-3 | NCT05079230 | P3 | terminated | Acute Myeloid Leukemia | 378 | PMID 37703506 |
| ENHANCE-2 | NCT04778397 | P3 | terminated | Acute Myeloid Leukemia | 258 | PMID 40009500 |
| GAIA | NCT02950051 | P3 | completed | Chronic Lymphocytic Leukemia | 926 | PMID 38821083 |
| CLL | NCT03406156 | P3 | completed | Chronic Lymphocytic Leukemia (CLL) | 120 | — |
| Bellini | NCT02755597 | P3 | completed | Relapsed/Refractory Multiple Myeloma | 291 | PMID 33129376 |
| MURANO | NCT02005471 | P3 | completed | Chronic Lymphocytic Leukemia | 389 | PMID 35605176 |
| AML | NCT03941964 | P3 | completed | Acute Myeloid Leukemia (AML) | 60 | PMID 38711253 |
| VENICE I | NCT02756611 | P3 | completed | Chronic Lymphocytic Leukemia | 258 | PMID 38467131 |
| VENICE II | NCT02980731 | P3 | completed | Chronic Lymphocytic Leukemia (CLL) | 210 | PMID 34632935 |
| LDAC | NCT04509622 | P3 | completed | Acute Myeloid Leukemia (AML) | 14 | — |
| EVIDENT | NCT05725200 | P2 | recruiting | Metastatic Colorectal Cancer | 40 | — |
| ALL | NCT06390319 | P2 | recruiting | T-cell Acute Lymphoblastic Leukemia | 100 | — |
| PVO | NCT06967610 | P2 | recruiting | Chronic Lymphocytic Leukemia | 40 | — |
| VIWA-1 | NCT05099471 | P2 | recruiting | Waldenstrom Macroglobulinemia | 80 | PMID 37348018 |
| REVEAL | NCT04523428 | P2 | recruiting | CLL/SLL | 60 | — |
| ESR-23-22182 | NCT07014917 | P2 | recruiting | Chronic Lymphocytic Leukemia | 62 | — |
| GLOASIS | NCT06558604 | P2 | recruiting | Lymphoma, Mantle-Cell | 100 | — |
| T-ALL | NCT06561074 | P2 | recruiting | T-cell Acute Lymphoblastic Leukemia | 22 | — |
| TAGVEN | NCT07007052 | P2 | not yet recruiting | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | 33 | — |
| LD-VenEx | NCT05431257 | P2 | recruiting | Acute Myeloid Leukemia | 117 | — |
| TAGALONG | NCT05442216 | P2 | recruiting | Acute Myeloid Leukemia | 53 | — |
| Benefit VA | NCT06520098 | P2 | recruiting | Chronic Lymphocytic Leukemia | 100 | — |
| HMA | NCT05766514 | P2 | withdrawn | Acute Myeloid Leukemia | 0 | — |
| V-MIND | NCT05910801 | P2 | recruiting | Recurrent Mantle Cell Lymphoma | 100 | — |
| SEQUENCE | NCT06696183 | P2 | recruiting | AML - Acute Myeloid Leukemia | 60 | — |
| SELVEDge | NCT05530421 | P2 | recruiting | Relapsed and Refractory Multiple Myeloma | 33 | — |
| ALL-TARGET | NCT07522801 | P2 | not yet recruiting | LAL | 93 | — |
| TRILLIUM | NCT06456463 | P2 | recruiting | Acute Myeloid Leukemia | 83 | — |
| TAI-SHAN10 | NCT07154264 | P2 | recruiting | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 66 | — |
| BRAVE | NCT06524375 | P2 | active not recruiting | Chronic Lymphocytic Leukemia | 118 | — |
| GMCAII | NCT06221683 | P2 | recruiting | AML, Childhood | 500 | — |
| MAVRiC | NCT07024706 | P2 | not yet recruiting | Chronic Lymphocytic Leukemia (CLL) | 80 | — |
| AML | NCT06317649 | P2 | recruiting | Acute Myeloid Leukemia | 147 | — |
| MYELOMATCH | NCT05564390 | P2 | recruiting | Acute Myeloid Leukemia | 2,000 | PMID 36902217 |
| OLUVENAZA | NCT06782542 | P2 | recruiting | Acute Myeloid Leukemia | 16 | — |
| VHAG | NCT07507825 | P2 | not yet recruiting | Acute Myeloid Leukemia (AML) | 61 | PMID 39531539 |
| TAILOR | NCT05963074 | P2 | recruiting | Leukemia, Lymphocytic, Chronic, B-Cell | 320 | — |
| GATE1 | NCT06522386 | P2 | active not recruiting | Mantle Cell Lymphoma | 50 | — |
| LAMSA2020 | NCT04968015 | P2 | active not recruiting | Acute Myeloid Leukemia | 134 | — |
| ReVenG | NCT04895436 | P2 | recruiting | Chronic Lymphocytic Leukemia (CLL) | 75 | — |
| STOP VEN | NCT06557421 | P2 | recruiting | Acute Myeloid Leukemia | 50 | — |
| TrAVeRse | NCT05951959 | P2 | active not recruiting | Mantle Cell Lymphoma (MCL) | 108 | — |
| AVENHIR | NCT05768711 | P2 | active not recruiting | Chronic Myeloid Leukemia | 44 | — |
| ZANU-VEN | NCT05168930 | P2 | recruiting | Chronic Lymphocytic Leukemia (CLL) | 45 | — |
| DAV-AML-2024 | NCT06635681 | P2 | recruiting | AML (Acute Myelogenous Leukemia) | 380 | — |
| VINCENT | NCT05904106 | P2 | recruiting | Acute Myeloid Leukemia | 146 | — |
| RAVEN | NCT07605949 | P2 | not yet recruiting | Leukemia Acute Myeloid | 88 | — |
| WM | NCT07387471 | P2 | recruiting | Waldenstrom Macroglobulinemia | 14 | — |
| VERDI | NCT06668558 | P2 | recruiting | Acute Myeloid Leukemia | 29 | — |
| VenCM | NCT06537843 | P2 | recruiting | Acute Myeloid Leukemia | 100 | — |
| CLL | NCT05536349 | P2 | recruiting | Leukemia | 60 | — |
| WM | NCT07231952 | P2 | recruiting | Waldenstrom Macroglobulinemia | 40 | — |
| HO171 | NCT06014489 | P2 | recruiting | AML, Adult | 142 | PMID 42007248 |
| MBG453 | NCT05201066 | P2 | active not recruiting | Myelodysplastic Syndromes | 33 | — |
| CLL | NCT05650723 | P2 | active not recruiting | Leukemia, Lymphocytic, Chronic, B-Cell | 50 | — |
| AVO | NCT03580928 | P2 | active not recruiting | Chronic Lymphocytic Leukemia (CLL) | 72 | PMID 39645236 |
| VALUABLE | NCT04758975 | P2 | recruiting | Chronic Lymphocytic Leukemia (CLL) | 55 | — |
| GO | NCT06917911 | P2 | recruiting | Core Binding Factor Acute Myeloid Leukemia | 162 | — |
| VCA | NCT05305859 | P2 | recruiting | Leukemia, Myeloid, Acute | 30 | — |
| MM | NCT02899052 | P2 | active not recruiting | Multiple Myeloma | 120 | PMID 34470049 |
| SAV | NCT05736965 | P2 | recruiting | AML, Adult | 58 | — |
| VenSwitch | NCT06156579 | P2 | recruiting | AML | 27 | — |
| AVS | NCT05736978 | P2 | recruiting | AML | 58 | — |
| ERASE | NCT05628623 | P2 | not yet recruiting | Leukemia, Myeloid, Acute | 184 | PMID 24062400 |
| CLL | NCT03824483 | P2 | recruiting | Chronic Lymphocytic Leukemia (CLL) | 230 | PMID 34826411 |
| AML | NCT06773208 | P2 | recruiting | Acute Myeloid Leukemia (AML) | 30 | — |
| BLAST MRD AML-2 | NCT04284787 | P2 | active not recruiting | Acute Myeloid Leukemia | 60 | — |
| LOXO-305 | NCT06466122 | P2 | recruiting | Chronic Lymphocytic Leukemia | 30 | — |
| AML | NCT05603884 | P2 | recruiting | Leukemia, Myeloid, Acute | 66 | — |
| CLL2-BZAG | NCT04515238 | P2 | active not recruiting | Chronic Lymphoid Leukemia | 42 | PMID 39883943 |
| MOLTO | NCT04082897 | P2 | active not recruiting | CLL Transformation | 28 | PMID 39270702 |
| RIVER-81 | NCT06191263 | P2 | recruiting | Acute Myeloid Leukemia | 98 | — |
| VAC | NCT05566054 | P2 | recruiting | Acute Monocytic Leukemia | 92 | — |
| T-ALL | NCT06210750 | P2 | withdrawn | T Acute Lymphoblastic Leukemia | 0 | — |
| CLL | NCT04447768 | P2 | active not recruiting | Chronic Lymphocytic Leukemia (CLL) | 100 | — |
| Venetoclax | NCT04501939 | P2 | active not recruiting | Chronic Lymphocytic Leukemia | 5 | PMID 34398557 |
| CLL | NCT03986034 | P2 | recruiting | Chronic Lymphocytic Leukemia | 75 | PMID 27178240 |
| RR-CLL | NCT03226301 | P2 | active not recruiting | Chronic Lymphocytic Leukemia in Relapse | 230 | PMID 40249856 |
| ENABLE | NCT04763928 | P2 | active not recruiting | Acute Myeloid Leukemia | 101 | — |
| VARIANT | NCT05701215 | P2 | active not recruiting | Chronic Myeloid Leukemia | 10 | — |
| IV | NCT05105841 | P2 | completed | Chronic Lymphocytic Leukemia (CLL) | 20 | — |
| PEVENAZA | NCT04266795 | P2 | completed | Acute Myeloid Leukemia (AML) | 164 | PMID 39606906 |
| B-ALL | NCT06078306 | P2 | unknown | B Acute Lymphoblastic Leukemia | 20 | — |
| IMPROVE | NCT04754035 | P2 | unknown | Chronic Lymphocytic Leukemia | 31 | PMID 35921541 |
| G-CSF | NCT05780879 | P2 | terminated | Secondary Acute Myeloid Leukemia | 10 | — |
| V-FIRST | NCT03455504 | P2 | unknown | Acute Myeloid Leukemia | 124 | PMID 40048742 |
| ERADIC | NCT04010968 | P2 | completed | Intermediate Risk Chronic Lymphocytic Leukemia | 120 | — |
| STIMULUS-AML1 | NCT04150029 | P2 | terminated | Acute Myeloid Leukemia | 90 | — |
| AML | NCT04905407 | P2 | terminated | Acute Myeloid Leukemia | 66 | — |
| PrE0405 | NCT03834688 | P2 | completed | Mantle Cell Lymphoma | 33 | — |
| Captivate | NCT02910583 | P2 | completed | Leukemia | 323 | PMID 34618601 |
| VenEx | NCT04267081 | P2 | completed | Acute Myeloid Leukemia | 104 | PMID 39357056 |
| CLL2-BAAG | NCT03787264 | P2 | completed | Chronic Lymphoid Leukemia | 46 | PMID 35594173 |
| VeRitAs | NCT03455517 | P2 | completed | Chronic Myeloid Leukemia | 77 | PMID 36632738 |
| STIMULUS-MDS3 | NCT04812548 | P2 | terminated | Myelodysplastic Syndrome (MDS) | 20 | — |
| CORAL | NCT05209308 | P2 | withdrawn | CLL | 0 | — |
| PrE0403 | NCT03113422 | P2 | completed | Follicular Lymphoma | 56 | PMID 40355425 |
| CLL | NCT04016805 | P2 | terminated | Chronic Lymphocytic Leukemia | 41 | — |
| CLL2-GiVe | NCT02758665 | P2 | completed | Leukemia, Lymphocytic, Chronic | 41 | — |
| COSMOS | NCT02639910 | P2 | completed | Leukemia, Lymphocytic, Chronic, B-Cell | 24 | PMID 34414843 |
| GDC-0199 | NCT02141282 | P2 | completed | Chronic Lymphocytic Leukemia | 127 | PMID 31023700 |
| Veronica | NCT03584009 | P2 | terminated | Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer | 103 | — |
| GDC-0199 | NCT02187861 | P2 | completed | Follicular Lymphoma | 163 | PMID 32785666 |
Terminated and withdrawn Venetoclax trials (106)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05955261suspendedA Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
- NCT06247540withdrawnVenetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- NCT05766514withdrawnTrial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
- NCT06454409suspendedRegorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT05740449withdrawnHEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- NCT05263284suspended8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
- NCT06802523suspendedTesting the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia
- NCT05486481withdrawnVenetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
- NCT04543916withdrawnVenetoclax and Irinotecan in Relapsed/Refractory SCLC
- NCT06158100suspendedVenetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
- NCT06337331withdrawnAdding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant
- NCT06770257withdrawnDaunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy
- NCT06007911withdrawnVenetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- NCT06210750withdrawnAdding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT06514261suspendedTesting the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
- NCT04550442terminatedVenetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT03808610terminatedLow-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
- NCT05268003terminatedA Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
- NCT04278768suspendedDose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- NCT03404193terminatedVenetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
- NCT05618366terminatedTazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
- NCT04160052terminatedVenetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
- NCT03926624terminatedTrial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
- NCT04607772withdrawnStudy of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT03708003terminatedIbrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
- NCT04937166terminatedA Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
- NCT06563804terminatedA Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
- NCT04964505terminatedUproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia
- NCT05317936terminatedPirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
- NCT04161885terminatedA Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
- NCT05780879terminatedA Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia
- NCT06508489terminatedA Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
- NCT06070948withdrawnA Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants
- NCT05025423terminatedPhase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma
- NCT06449482terminatedSelinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
- NCT04435691terminatedMagrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
- NCT06150040terminatedAcute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]
- NCT05275439terminatedPhase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
- NCT04553692terminatedPhase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
- NCT04150029terminatedA Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
- NCT03932318withdrawnVenetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
- NCT04285268withdrawnRituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- NCT05799079terminatedDecitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant
- NCT04874194terminatedOmacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
- NCT03940352terminatedHDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
- NCT05464836terminatedPhase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL
- NCT04905407terminatedTamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- NCT05168202terminatedA Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- NCT03547115terminatedA Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
- NCT03530683terminatedA Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- NCT03576547terminatedVenetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
- NCT04790903terminatedA Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT04029688terminatedA Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
- NCT05079230terminatedStudy of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
- NCT04336982terminatedA Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
- NCT04659044terminatedPolatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- NCT04778397terminatedStudy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- NCT04778410terminatedStudy of Magrolimab Combinations in Participants With Myeloid Malignancies
- NCT05361057terminatedEfficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients
- NCT05107856terminatedPRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
- NCT04655391withdrawnGlasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
- NCT03492125terminatedA Study Of The Selective PKC-β Inhibitor MS- 553
- NCT04752163terminatedDS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- NCT04092179terminatedStudy of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
- NCT06085638withdrawnPhase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia
- NCT04755244terminatedA Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)
- NCT03735875terminatedVenetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
- NCT04912063terminatedStudy to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
- NCT04812548terminatedA Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants
- NCT04722601terminatedA Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
- NCT04990778withdrawnVenetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma
- NCT05209308withdrawnRituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
- NCT03552692terminatedUse of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma
- NCT03176277terminatedA Study of ONO-7475 in Patients With Acute Leukemias
- NCT03801525terminatedStudy to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
- NCT03484520terminatedA Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- NCT03379051terminatedPhase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
- NCT04016805terminatedStudy to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
- NCT03634228terminatedMilademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia
- NCT04748848terminatedA Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy
- NCT03886649terminatedCopanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
- NCT04172844terminatedPevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia
- NCT03856112withdrawnIxazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma
- NCT04073147terminatedVenetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma
- NCT03218683terminatedStudy of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.
- NCT04419389terminatedAPR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)
- NCT03943342withdrawnIbrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance
- NCT03584009terminatedA Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
- NCT02951117withdrawnA Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment
- NCT04230564withdrawnAcute Myeloid Leukemia Real World Treatment Patterns
- NCT03217838terminatedSafety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.
- NCT02640833withdrawnA Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
- NCT04298918terminatedA Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- NCT04274907terminatedA Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
- NCT03878524terminatedSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- NCT03343678withdrawnThis Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax
- NCT04422210terminatedA Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
- NCT04493099withdrawnAlvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML
- NCT04274933terminatedA Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy
- NCT03567616terminatedA Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
- NCT03701321withdrawnDaratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
- NCT03135262terminatedA Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT03884972withdrawnTrabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor
- NCT03797261terminatedA Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
- NCT03000660terminatedTrial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
- NCT03785184withdrawnA Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
All Venetoclax trials (686)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05725200 | EVIDENT | Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer | P2 | recruiting | 40 | Oslo University Hospital | Sep 2022 |
| NCT02689440 | Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia | P2 | active not recruiting | 155 | M.D. Anderson Cancer Center | Feb 2016 | |
| NCT05947851 | VR | A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). | P3 | recruiting | 735 | Merck Sharp & Dohme LLC | Aug 2023 |
| NCT07320235 | IMAGINE | Imetelstat Combinations in Relapsed AML | P1 | recruiting | 36 | Douglas Tremblay | Jan 2026 |
| NCT05955261 | A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia | P2 | suspended | 70 | St. Jude Children's Research Hospital | Jul 2023 | |
| NCT06390319 | ALL | Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) | P2 | recruiting | 100 | St. Jude Children's Research Hospital | Dec 2024 |
| NCT07604233 | Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML | P1/P2 | not yet recruiting | 30 | M.D. Anderson Cancer Center | Nov 2026 | |
| NCT06967610 | PVO | Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). | P2 | recruiting | 40 | M.D. Anderson Cancer Center | Jul 2025 |
| NCT07520006 | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies | P1/P2 | not yet recruiting | 150 | Nurix Therapeutics, Inc. | May 2026 | |
| NCT05099471 | VIWA-1 | Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia | P2 | recruiting | 80 | Christian Buske | Mar 2025 |
| NCT05734495 | Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia | P2 | active not recruiting | 46 | Dana-Farber Cancer Institute | May 2023 | |
| NCT06073821 | BGB-11417 | Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) | P3 | active not recruiting | 652 | BeOne Medicines | Nov 2023 |
| NCT04523428 | REVEAL | REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) | P2 | recruiting | 60 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Dec 2020 |
| NCT05791409 | AETHER | Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL | P1/P2 | recruiting | 112 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Apr 2024 |
| NCT07175415 | HEM-iSMART E | HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | P1/P2 | not yet recruiting | 42 | Princess Maxima Center for Pediatric Oncology | Oct 2026 |
| NCT06644183 | IOA-244 | Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) | P1/P2 | recruiting | 64 | Jennifer R. Brown, MD, PhD | Mar 2025 |
| NCT07581002 | REVIVAL | A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) | P2/P3 | not yet recruiting | 660 | AbbVie | Jul 2026 |
| NCT07014917 | ESR-23-22182 | Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL | P2 | recruiting | 62 | Zulfa Omer | Dec 2025 |
| NCT06991920 | Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage | N/A | not yet recruiting | 50 | Institute of Hematology & Blood Diseases Hospital, China | Jun 2026 | |
| NCT07294677 | CAVALRY | CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL | P1/P2 | recruiting | 104 | University of Chicago | Mar 2026 |
| NCT06558604 | GLOASIS | Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma | P2 | recruiting | 100 | The Lymphoma Academic Research Organisation | Feb 2025 |
| NCT04628026 | Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 | P3 | recruiting | 650 | University of Ulm | Sep 2022 | |
| NCT05091424 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | P1 | recruiting | 137 | Hoffmann-La Roche | Mar 2022 | |
| NCT05745714 | HEM-iSMART C | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | P1/P2 | recruiting | 26 | Princess Maxima Center for Pediatric Oncology | Oct 2025 |
| NCT07425808 | FIT-AML | FLT3-ITD Targeted Therapy in Fit AML Patients | P2/P3 | not yet recruiting | 230 | European Organisation for Research and Treatment of Cancer - EORTC | Dec 2026 |
| NCT05751044 | HEM-iSMART B | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | P1/P2 | recruiting | 26 | Princess Maxima Center for Pediatric Oncology | Oct 2025 |
| NCT02416388 | BIG-1 | Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR | P2/P3 | recruiting | 3,100 | University Hospital, Angers | Jan 2015 |
| NCT07513129 | Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma | P1 | not yet recruiting | 18 | M.D. Anderson Cancer Center | Sep 2026 | |
| NCT06561074 | T-ALL | A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) | P2 | recruiting | 22 | M.D. Anderson Cancer Center | Sep 2025 |
| NCT06943872 | CELESTIAL-RRCLL | A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) | P3 | recruiting | 630 | BeOne Medicines | Jun 2025 |
| NCT06466395 | A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias | P1 | recruiting | 22 | M.D. Anderson Cancer Center | Feb 2025 | |
| NCT06247540 | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | P2 | withdrawn | 0 | Northwestern University | Mar 2024 | |
| NCT07277231 | BGB-11417 | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia | P3 | recruiting | 500 | BeOne Medicines | Jan 2026 |
| NCT07007312 | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | P3 | recruiting | 1,300 | Kura Oncology, Inc. | Sep 2025 | |
| NCT06510309 | Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma | P2 | recruiting | 33 | Gottfried von Keudell, MD PhD | Feb 2026 | |
| NCT07007052 | TAGVEN | Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients | P2 | not yet recruiting | 33 | French Innovative Leukemia Organisation | Dec 2025 |
| NCT04802590 | Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma | P2 | active not recruiting | 210 | The Lymphoma Academic Research Organisation | Jan 2022 | |
| NCT05431257 | LD-VenEx | Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling | P2 | recruiting | 117 | Rigshospitalet, Denmark | May 2022 |
| NCT07059975 | UPDATE AML | UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML | Early P1 | recruiting | 36 | Joanna Yi | Oct 2025 |
| NCT04941716 | Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial | P2 | recruiting | 20 | Fred Hutchinson Cancer Center | May 2023 | |
| NCT05442216 | TAGALONG | Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents | P2 | recruiting | 53 | Joshua Zeidner | May 2024 |
| NCT07238686 | Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS | P2 | recruiting | 40 | Beijing 302 Hospital | Jun 2025 | |
| NCT07078591 | Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML | P2 | recruiting | 50 | Beijing 302 Hospital | Jun 2025 | |
| NCT06855810 | CCCG-TALL-2025 | Newly-diagnosed Pediatric T-cell ALL Protocol | P2/P3 | recruiting | 610 | Institute of Hematology & Blood Diseases Hospital, China | Mar 2025 |
| NCT06764238 | CCCG-I/HR-ALL | Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol | P2/P3 | recruiting | 1,800 | Institute of Hematology & Blood Diseases Hospital, China | Jan 2025 |
| NCT04739813 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | P1 | active not recruiting | 34 | National Cancer Institute (NCI) | Jul 2021 | |
| NCT06810778 | PTCL | Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | P1/P2 | recruiting | 12 | Jonsson Comprehensive Cancer Center | May 2025 |
| NCT03314181 | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | P2 | active not recruiting | 156 | AbbVie | Apr 2018 | |
| NCT05183035 | AML | Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | P3 | recruiting | 130 | PedAL BCU, LLC | Oct 2022 |
| NCT07539818 | Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML | P3 | not yet recruiting | 788 | Institute of Hematology & Blood Diseases Hospital, China | Apr 2026 | |
| NCT07082452 | SEVENAZA | A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction | P3 | not yet recruiting | 262 | Gustave Roussy, Cancer Campus, Grand Paris | Sep 2025 |
| NCT07311746 | Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia | P1/P2 | not yet recruiting | 36 | M.D. Anderson Cancer Center | Jun 2026 | |
| NCT07407140 | VAG-3+7-G | VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML | P3 | not yet recruiting | 300 | Institute of Hematology & Blood Diseases Hospital, China | Apr 2026 |
| NCT07148180 | A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax | P1/P2 | recruiting | 31 | Jacqueline Garcia, MD | Feb 2026 | |
| NCT06520098 | Benefit VA | A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | P2 | recruiting | 100 | VA Office of Research and Development | Oct 2025 |
| NCT05766514 | HMA | Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction | P2 | withdrawn | 0 | University of Florida | Apr 2025 |
| NCT06448013 | A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia | P1 | recruiting | 22 | M.D. Anderson Cancer Center | Mar 2025 | |
| NCT06397027 | A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias | P1 | recruiting | 22 | M.D. Anderson Cancer Center | Dec 2024 | |
| NCT05910801 | V-MIND | Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | P2 | recruiting | 100 | Academic and Community Cancer Research United | Jan 2024 |
| NCT06841952 | Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia | N/A | not yet recruiting | 158 | The First Affiliated Hospital of Soochow University | Feb 2025 | |
| NCT04062266 | AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission | P2 | active not recruiting | 50 | M.D. Anderson Cancer Center | Sep 2019 | |
| NCT07374029 | Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML | P1 | recruiting | 30 | David Avigan | Feb 2026 | |
| NCT06598384 | VA as Maintenance Therapy Post Allo-HSCT in MDS and AML | P2 | not yet recruiting | 40 | Navy General Hospital, Beijing | Sep 2024 | |
| NCT06419634 | ORM-6151 | Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | P1 | recruiting | 105 | Bristol-Myers Squibb | May 2024 |
| NCT06454409 | Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia | P1 | suspended | 20 | City of Hope Medical Center | May 2025 | |
| NCT05677919 | Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia | P2 | active not recruiting | 72 | Mayo Clinic | Jan 2023 | |
| NCT07159620 | Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients | P2 | recruiting | 27 | The First Affiliated Hospital of Soochow University | Sep 2025 | |
| NCT06471946 | VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS | P1/P2 | recruiting | 54 | Navy General Hospital, Beijing | Oct 2024 | |
| NCT07511062 | Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML | P1 | not yet recruiting | 32 | Northside Hospital, Inc. | Aug 2026 | |
| NCT03868722 | Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment | P2/P3 | recruiting | 212 | Rigshospitalet, Denmark | Oct 2019 | |
| NCT05292664 | Venetoclax Basket Trial for High Risk Hematologic Malignancies | P1 | recruiting | 30 | Andrew E. Place, MD | Mar 2023 | |
| NCT07396480 | Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial | P3 | recruiting | 186 | First Affiliated Hospital of Zhejiang University | Mar 2026 | |
| NCT05404906 | AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission | P2/P3 | recruiting | 124 | The First Affiliated Hospital of Soochow University | Jun 2022 | |
| NCT04843904 | SAVE | Safe Accelerated Venetoclax Escalation in CLL | P1 | active not recruiting | 40 | Dana-Farber Cancer Institute | Apr 2021 |
| NCT02115295 | Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia | P2 | recruiting | 508 | M.D. Anderson Cancer Center | May 2014 | |
| NCT07478991 | VENP-A-QUI | Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) | P3 | not yet recruiting | 376 | PETHEMA Foundation | Mar 2026 |
| NCT06696183 | SEQUENCE | Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment | P2 | recruiting | 60 | Technische Universität Dresden | Apr 2025 |
| NCT05735184 | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | P1 | recruiting | 420 | Kura Oncology, Inc. | Jul 2023 | |
| NCT07153497 | Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) | P2 | not yet recruiting | 132 | National Cancer Institute (NCI) | May 2026 | |
| NCT03766763 | Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A | P2 | active not recruiting | 82 | French Innovative Leukemia Organisation | May 2019 | |
| NCT06972641 | Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation | P2/P3 | recruiting | 126 | Ruijin Hospital | Jun 2025 | |
| NCT05986240 | Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML | P1 | recruiting | 38 | Montefiore Medical Center | May 2024 | |
| NCT07493161 | Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL | N/A | recruiting | 110 | Institute of Hematology & Blood Diseases Hospital, China | Apr 2026 | |
| NCT05530421 | SELVEDge | Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma | P2 | recruiting | 33 | University of Miami | Mar 2023 |
| NCT03613532 | Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN | P1 | active not recruiting | 102 | Jacqueline Garcia, MD | Oct 2018 | |
| NCT07522801 | ALL-TARGET | A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL | P2 | not yet recruiting | 93 | Philippe ROUSSELOT | Sep 2026 |
| NCT07454226 | ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL | N/A | recruiting | 92 | Institute of Hematology & Blood Diseases Hospital, China | May 2026 | |
| NCT07495631 | Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia | N/A | recruiting | 43 | Institute of Hematology & Blood Diseases Hospital, China | Apr 2026 | |
| NCT07283094 | FHD-286 | FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia | P1 | recruiting | 33 | Montefiore Medical Center | Feb 2026 |
| NCT06846671 | CaDAnCe-302 | A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors | P3 | recruiting | 250 | BeOne Medicines | Apr 2025 |
| NCT06456463 | TRILLIUM | A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy | P2 | recruiting | 83 | Stemline Therapeutics, Inc. | Jan 2025 |
| NCT07407660 | Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax | P3 | not yet recruiting | 250 | Peking University People's Hospital | Feb 2026 | |
| NCT07481175 | INITIATE | Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study) | P1 | recruiting | 38 | Thomas Aagaard Rasmussen | Apr 2026 |
| NCT07154264 | TAI-SHAN10 | A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) | P2 | recruiting | 66 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Sep 2025 |
| NCT06524375 | BRAVE | A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period | P2 | active not recruiting | 118 | Genentech, Inc. | Aug 2024 |
| NCT06084819 | Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | P2 | recruiting | 200 | Chinese PLA General Hospital | Aug 2023 | |
| NCT07358195 | Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation | Early P1 | not yet recruiting | 3 | Massachusetts General Hospital | Jul 2026 | |
| NCT07060001 | Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker | P2 | not yet recruiting | 112 | The Methodist Hospital Research Institute | Apr 2026 | |
| NCT07177079 | HDA | High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML) | P1 | recruiting | 30 | Kittika Poonsombudlert | Mar 2026 |
| NCT07052422 | VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT | P2/P3 | not yet recruiting | 160 | Nanfang Hospital, Southern Medical University | Jul 2025 | |
| NCT06221683 | GMCAII | Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML | P2 | recruiting | 500 | Children's Hospital of Soochow University | Jan 2024 |
| NCT06548230 | MDS | A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | P1/P2 | recruiting | 40 | M.D. Anderson Cancer Center | Mar 2025 |
| NCT05740449 | HEM-iSMART A | HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | P1/P2 | withdrawn | 0 | Princess Maxima Center for Pediatric Oncology | Oct 2023 |
| NCT07228273 | Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia | P2 | recruiting | 102 | OHSU Knight Cancer Institute | Dec 2025 | |
| NCT06852222 | cAMeLot-2 | A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | P3 | recruiting | 600 | Janssen Research & Development, LLC | Jun 2025 |
| NCT07199855 | Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia | P2 | active not recruiting | 24 | Zhejiang University | Jun 2025 | |
| NCT07014462 | DLIT-AML | A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML | P1 | enrolling by invitation | 20 | University of Vermont | Sep 2025 |
| NCT07047183 | Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes | P2 | recruiting | 46 | Yehui Tan | Jul 2025 | |
| NCT06445959 | Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib | P1/P2 | recruiting | 78 | M.D. Anderson Cancer Center | Aug 2024 | |
| NCT05401097 | IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) | P2 | recruiting | 125 | Alice Mims | Sep 2022 | |
| NCT07218510 | Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial | P2 | recruiting | 33 | City of Hope Medical Center | Jan 2026 | |
| NCT07032727 | Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations | P2 | recruiting | 68 | M.D. Anderson Cancer Center | Sep 2025 | |
| NCT05864742 | Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma | P2 | active not recruiting | 40 | Peter MacCallum Cancer Centre, Australia | Sep 2023 | |
| NCT05211336 | VIPOR | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System | P1 | active not recruiting | 14 | National Cancer Institute (NCI) | Apr 2022 |
| NCT07437950 | Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | P2 | not yet recruiting | 126 | National Cancer Institute (NCI) | Oct 2026 | |
| NCT07023588 | Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease | P2 | recruiting | 70 | Yehui Tan | Jun 2025 | |
| NCT02966756 | A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | P2 | recruiting | 110 | AbbVie | Oct 2017 | |
| NCT07024706 | MAVRiC | Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab | P2 | not yet recruiting | 80 | AstraZeneca | Jan 2026 |
| NCT06317649 | AML | Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | P2 | recruiting | 147 | National Cancer Institute (NCI) | Sep 2024 |
| NCT05564390 | MYELOMATCH | MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | P2 | recruiting | 2,000 | National Cancer Institute (NCI) | Jun 2024 |
| NCT07582159 | Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | P2 | not yet recruiting | 35 | City of Hope Medical Center | Dec 2026 | |
| NCT05057494 | MAJIC | A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P3 | active not recruiting | 607 | AstraZeneca | Sep 2022 |
| NCT03462719 | GLOW | A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | P3 | active not recruiting | 211 | Janssen Research & Development, LLC | Apr 2018 |
| NCT06516978 | A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL | P2 | not yet recruiting | 528 | The First Affiliated Hospital with Nanjing Medical University | Oct 2024 | |
| NCT07469046 | VAH vs VA in Newly Diagnosed Elderly AML | P3 | not yet recruiting | 308 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Apr 2026 | |
| NCT06782542 | OLUVENAZA | Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy | P2 | recruiting | 16 | Justin Watts, MD | Mar 2026 |
| NCT07507825 | VHAG | Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) | P2 | not yet recruiting | 61 | First People's Hospital of Hangzhou | Mar 2026 |
| NCT07075016 | EVOLVE 1 | Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy | P3 | recruiting | 227 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Aug 2025 |
| NCT05287568 | CC-486 and Venetoclax for Acute Myeloid Leukemia | P1 | recruiting | 35 | University of Colorado, Denver | Dec 2022 | |
| NCT05963074 | TAILOR | A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia | P2 | recruiting | 320 | Janssen Research & Development, LLC | May 2024 |
| NCT07490288 | Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML | N/A | recruiting | 27 | Institute of Hematology & Blood Diseases Hospital, China | May 2026 | |
| NCT04560322 | Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL | P2 | recruiting | 40 | Massachusetts General Hospital | Oct 2020 | |
| NCT06522386 | GATE1 | GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma | P2 | active not recruiting | 50 | M.D. Anderson Cancer Center | Jan 2025 |
| NCT07439211 | GAVEL | Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia | P1 | not yet recruiting | 48 | Jacqueline Garcia, MD | Jul 2026 |
| NCT04968015 | LAMSA2020 | Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission | P2 | active not recruiting | 134 | French Innovative Leukemia Organisation | May 2022 |
| NCT04895436 | ReVenG | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | P2 | recruiting | 75 | AbbVie | Mar 2022 |
| NCT05263284 | 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia | P1 | suspended | 30 | City of Hope Medical Center | Dec 2022 | |
| NCT06863259 | Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL | P1 | recruiting | 28 | Children's Hospital Medical Center, Cincinnati | May 2025 | |
| NCT06802523 | Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia | P1 | suspended | 53 | National Cancer Institute (NCI) | Apr 2026 | |
| NCT07514832 | VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial | P2 | recruiting | 48 | Beijing 302 Hospital | Apr 2026 | |
| NCT06317662 | Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | P2 | recruiting | 153 | National Cancer Institute (NCI) | Jun 2025 | |
| NCT06470841 | CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML | P2 | not yet recruiting | 85 | Navy General Hospital, Beijing | Sep 2024 | |
| NCT06387121 | Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL | P2 | recruiting | 53 | Institute of Hematology & Blood Diseases Hospital, China | Apr 2024 | |
| NCT06191978 | ASTX727 | A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) | P1 | recruiting | 40 | M.D. Anderson Cancer Center | Mar 2024 |
| NCT05486481 | ALTITUDE | Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) | P1/P2 | withdrawn | 0 | Alfred Chung, MD | Jan 2024 |
| NCT05853965 | BELI(E)VE | Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma | P1/P2 | recruiting | 45 | Universitätsklinikum Hamburg-Eppendorf | Jun 2023 |
| NCT05342584 | Venetoclax AML | Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS | P1 | recruiting | 99 | Montefiore Medical Center | May 2022 |
| NCT04797767 | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms | P1/P2 | recruiting | 62 | University of Washington | Feb 2022 | |
| NCT03504644 | Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia | P1/P2 | active not recruiting | 40 | ECOG-ACRIN Cancer Research Group | Aug 2018 | |
| NCT03013998 | Study of Biomarker-Based Treatment of Acute Myeloid Leukemia | P1/P2 | recruiting | 3,000 | Beat AML, LLC | Nov 2016 | |
| NCT07264010 | Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study | P2/P3 | not yet recruiting | 87 | Nanfang Hospital, Southern Medical University | Dec 2025 | |
| NCT06284486 | A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib | P1/P2 | recruiting | 8 | M.D. Anderson Cancer Center | Sep 2024 | |
| NCT06757855 | Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML | P1/P2 | recruiting | 29 | Institute of Hematology & Blood Diseases Hospital, China | Jan 2025 | |
| NCT06042725 | MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma | P1 | recruiting | 100 | Mayo Clinic | Mar 2024 | |
| NCT04639362 | CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD. | P2 | active not recruiting | 85 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Dec 2020 | |
| NCT05782127 | Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes | P1/P2 | active not recruiting | 36 | Groupe Francophone des Myelodysplasies | Dec 2023 | |
| NCT06651229 | A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms | P1 | recruiting | 155 | Janssen Research & Development, LLC | Mar 2025 | |
| NCT06557421 | STOP VEN | De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients | P2 | recruiting | 50 | Institut Paoli-Calmettes | Feb 2026 |
| NCT04256317 | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | P2/P3 | recruiting | 316 | Taiho Oncology, Inc. | May 2020 | |
| NCT07486726 | Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia | P1/P2 | not yet recruiting | 112 | Shanghai Jiao Tong University School of Medicine | Mar 2026 | |
| NCT07163793 | Pilot Study of Reduced Venetoclax Exposure | P2 | recruiting | 41 | Northwell Health | Oct 2024 | |
| NCT05951959 | TrAVeRse | A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma | P2 | active not recruiting | 108 | AstraZeneca | Dec 2023 |
| NCT05768711 | AVENHIR | Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) | P2 | active not recruiting | 44 | Groupe Francophone des Myelodysplasies | Oct 2023 |
| NCT06686108 | Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention | P2 | recruiting | 59 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Oct 2024 | |
| NCT05168930 | ZANU-VEN | Zanubrutinib and Venetoclax in CLL (ZANU-VEN) | P2 | recruiting | 45 | Dana-Farber Cancer Institute | Feb 2022 |
| NCT06611839 | IDH1-AML-2024 | Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML | P1/P2 | recruiting | 23 | Institute of Hematology & Blood Diseases Hospital, China | Oct 2025 |
| NCT06635681 | DAV-AML-2024 | Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML | P2 | recruiting | 380 | Institute of Hematology & Blood Diseases Hospital, China | Sep 2024 |
| NCT04269902 | CLL | Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | P3 | recruiting | 247 | National Cancer Institute (NCI) | Mar 2021 |
| NCT05904106 | VINCENT | Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML | P2 | recruiting | 146 | Technische Universität Dresden | Apr 2024 |
| NCT04140487 | Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm | P1/P2 | recruiting | 97 | M.D. Anderson Cancer Center | Dec 2019 | |
| NCT06712121 | Venetoclax and Decitabine in R/R T-ALL | P2 | recruiting | 28 | Seoul National University Hospital | Jan 2025 | |
| NCT06511882 | Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD | P2 | recruiting | 37 | H. Lee Moffitt Cancer Center and Research Institute | Nov 2024 | |
| NCT03422393 | Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib | P1 | active not recruiting | 24 | Michael Choi | May 2018 | |
| NCT07132684 | Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients | P3 | recruiting | 240 | Institute of Hematology & Blood Diseases Hospital, China | Aug 2025 | |
| NCT07183878 | Ven-BUCY | Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study) | N/A | recruiting | 138 | First Affiliated Hospital of Zhejiang University | Aug 2025 |
| NCT06544109 | Ven APL | Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients | P2/P3 | enrolling by invitation | 98 | The First Affiliated Hospital of Soochow University | Aug 2023 |
| NCT07605949 | RAVEN | Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML | P2 | not yet recruiting | 88 | UNC Lineberger Comprehensive Cancer Center | Jul 2026 |
| NCT07387471 | WM | Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) | P2 | recruiting | 14 | AbbVie | Mar 2026 |
| NCT06668558 | VERDI | Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia | P2 | recruiting | 29 | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | Dec 2024 |
| NCT05520567 | A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | P1/P2 | active not recruiting | 70 | Astellas Pharma Global Development, Inc. | Jan 2023 | |
| NCT06536010 | Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML | N/A | recruiting | 50 | Yang Xiaotian | Nov 2021 | |
| NCT03768063 | IMbrella B | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | P3 | active not recruiting | 1,000 | Hoffmann-La Roche | Feb 2019 |
| NCT04227847 | A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies | P1 | recruiting | 178 | Seagen, a wholly owned subsidiary of Pfizer | Aug 2020 | |
| NCT06445907 | Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia | P1 | active not recruiting | 17 | M.D. Anderson Cancer Center | Feb 2025 | |
| NCT06483906 | Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML. | P2 | recruiting | 56 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Jul 2024 | |
| NCT06537843 | VenCM | Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia | P2 | recruiting | 100 | Hospital Municipal São José | Dec 2023 |
| NCT06742463 | VHAG in Treating R/R T-ALL/LBL | P2 | recruiting | 50 | First Affiliated Hospital of Zhejiang University | Dec 2024 | |
| NCT06481241 | Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL | N/A | recruiting | 77 | Institute of Hematology & Blood Diseases Hospital, China | Jun 2024 | |
| NCT05834244 | ADVENT-AML | A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) | P1 | recruiting | 32 | M.D. Anderson Cancer Center | Oct 2023 |
| NCT04847453 | Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis | P1 | active not recruiting | 24 | National Cancer Institute (NCI) | Aug 2022 | |
| NCT04543916 | Venetoclax and Irinotecan in Relapsed/Refractory SCLC | P1/P2 | withdrawn | 0 | Virginia Commonwealth University | Jun 2021 | |
| NCT07133997 | Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia | P1 | recruiting | 26 | City of Hope Medical Center | Jun 2026 | |
| NCT06744556 | HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML | P2 | active not recruiting | 41 | Institute of Hematology & Blood Diseases Hospital, China | Jan 2025 | |
| NCT06481228 | Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL | N/A | recruiting | 82 | Institute of Hematology & Blood Diseases Hospital, China | Jun 2024 | |
| NCT05197192 | A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL | P3 | recruiting | 202 | German CLL Study Group | Apr 2022 | |
| NCT03319901 | Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL | P1/P2 | active not recruiting | 82 | Dana-Farber Cancer Institute | Oct 2017 | |
| NCT06954987 | Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | P2 | not yet recruiting | 244 | National Cancer Institute (NCI) | Jul 2026 | |
| NCT03701282 | Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia | P3 | active not recruiting | 720 | National Cancer Institute (NCI) | Feb 2019 | |
| NCT07012447 | Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations | P2 | recruiting | 32 | yuejun Liu | Apr 2025 | |
| NCT06504459 | Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML | P2 | recruiting | 40 | OHSU Knight Cancer Institute | Jan 2025 | |
| NCT07131059 | MRD-positive AML Clinical Study | N/A | recruiting | 120 | Institute of Hematology & Blood Diseases Hospital, China | May 2024 | |
| NCT05536349 | CLL | Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) | P2 | recruiting | 60 | M.D. Anderson Cancer Center | Dec 2022 |
| NCT07231952 | WM | A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) | P2 | recruiting | 40 | Memorial Sloan Kettering Cancer Center | Nov 2025 |
| NCT03984448 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | P2/P3 | active not recruiting | 363 | National Cancer Institute (NCI) | Oct 2019 | |
| NCT06634394 | APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | P1 | recruiting | 39 | Aptevo Therapeutics | Oct 2024 | |
| NCT06428019 | TLS | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | P3 | recruiting | 170 | AbbVie | Aug 2024 |
| NCT06014489 | HO171 | A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML | P2 | recruiting | 142 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Jan 2024 |
| NCT04840602 | Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma | P2 | recruiting | 92 | National Cancer Institute (NCI) | Jan 2022 | |
| NCT05805098 | VHA | Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML | P2/P3 | recruiting | 60 | The First Affiliated Hospital of Soochow University | Mar 2023 |
| NCT04623541 | EPCORE™ CLL-1 | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome | P1/P2 | active not recruiting | 194 | Genmab | Nov 2020 |
| NCT06571825 | RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR | P4 | recruiting | 118 | He Huang | Jul 2024 | |
| NCT05201066 | MBG453 | Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. | P2 | active not recruiting | 33 | Novartis Pharmaceuticals | Feb 2023 |
| NCT05391750 | Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma | P1 | active not recruiting | 7 | Emory University | Oct 2022 | |
| NCT03946878 | Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | P2 | active not recruiting | 32 | M.D. Anderson Cancer Center | Aug 2019 | |
| NCT06958705 | Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy | P2 | recruiting | 79 | The First Affiliated Hospital with Nanjing Medical University | Dec 2025 | |
| NCT04273139 | Ibrutinib + Venetoclax in Untreated WM | P2 | active not recruiting | 45 | Dana-Farber Cancer Institute | Jul 2020 | |
| NCT07392242 | A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia | P2 | recruiting | 45 | Memorial Sloan Kettering Cancer Center | Jan 2026 | |
| NCT03826992 | CPX-351 | Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia | P1 | recruiting | 21 | Children's Hospital Medical Center, Cincinnati | Dec 2018 |
| NCT05807932 | FLAMSA | Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML | P1/P2 | recruiting | 38 | Heinrich-Heine University, Duesseldorf | Jun 2023 |
| NCT05010122 | ASTX727 | ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | P1/P2 | recruiting | 42 | M.D. Anderson Cancer Center | Jul 2021 |
| NCT06765928 | Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT | P2 | not yet recruiting | 73 | Ruijin Hospital | Jan 2025 | |
| NCT04801797 | Venetoclax + Azacitidine vs. Induction Chemotherapy in AML | P2 | active not recruiting | 172 | Massachusetts General Hospital | May 2021 | |
| NCT03661307 | Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | P1/P2 | recruiting | 73 | M.D. Anderson Cancer Center | Oct 2018 | |
| NCT07557056 | Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P2 | not yet recruiting | 25 | Jennifer Woyach | May 2026 | |
| NCT07255872 | A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia | P2/P3 | not yet recruiting | 216 | Sichuan Baili Pharmaceutical Co., Ltd. | Mar 2026 | |
| NCT07486479 | Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | P3 | not yet recruiting | 204 | The First Affiliated Hospital of Soochow University | Mar 2026 | |
| NCT07451912 | Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML | P1/P2 | recruiting | 29 | The First Affiliated Hospital of Soochow University | Sep 2025 | |
| NCT06783790 | Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT | P2 | recruiting | 20 | Institute of Hematology & Blood Diseases Hospital, China | Jan 2025 | |
| NCT06158100 | DLI | Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) | P1 | suspended | 25 | Antonio M Jimenez Jimenez | Dec 2024 |
| NCT07514936 | Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | P2 | recruiting | 120 | Chinese PLA General Hospital | Nov 2024 | |
| NCT05554393 | Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | P2 | recruiting | 153 | National Cancer Institute (NCI) | Sep 2024 | |
| NCT06621199 | Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML | P2 | recruiting | 42 | First Affiliated Hospital of Zhejiang University | Jul 2024 | |
| NCT06621212 | Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML | P2 | recruiting | 72 | First Affiliated Hospital of Zhejiang University | Jul 2024 | |
| NCT06115135 | A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma | P2 | recruiting | 39 | Oncotherapeutics | Jun 2024 | |
| NCT06429098 | Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML | P2 | recruiting | 40 | The First Affiliated Hospital of Soochow University | Jan 2024 | |
| NCT05650723 | CLL | Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab | P2 | active not recruiting | 50 | Weill Medical College of Cornell University | May 2023 |
| NCT05365035 | A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts | P2 | recruiting | 60 | M.D. Anderson Cancer Center | Sep 2022 | |
| NCT04988555 | DSP-5336 | A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | P1/P2 | recruiting | 606 | Sumitomo Pharma America, Inc. | Feb 2022 |
| NCT04708054 | Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS | P2/P3 | recruiting | 324 | M.D. Anderson Cancer Center | Oct 2021 | |
| NCT04855695 | Avo In R/R And Previously Untreated MCL | P1/P2 | recruiting | 72 | Austin I Kim | Jul 2021 | |
| NCT04588922 | Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | P1/P2 | recruiting | 160 | Sellas Life Sciences Group | May 2021 | |
| NCT03874052 | Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | P1 | recruiting | 51 | Jennifer Saultz | Aug 2019 | |
| NCT03580928 | AVO | Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL | P2 | active not recruiting | 72 | Dana-Farber Cancer Institute | Aug 2018 |
| NCT06754267 | Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL | P2 | recruiting | 36 | First Affiliated Hospital of Zhejiang University | Dec 2024 | |
| NCT06386302 | Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia | N/A | recruiting | 184 | Institute of Hematology & Blood Diseases Hospital, China | Aug 2024 | |
| NCT06232694 | Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML | N/A | recruiting | 54 | The First Affiliated Hospital with Nanjing Medical University | Jan 2024 | |
| NCT04758975 | VALUABLE | Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) | P2 | recruiting | 55 | Paolo Ghia | Sep 2022 |
| NCT05660473 | Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia | P2 | recruiting | 100 | Institute of Hematology & Blood Diseases Hospital, China | Aug 2022 | |
| NCT06328179 | Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. | N/A | recruiting | 34 | Huai'an First People's Hospital | May 2022 | |
| NCT03844815 | Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia | P1 | active not recruiting | 26 | University of Chicago | Nov 2019 | |
| NCT04872790 | Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia | P1 | active not recruiting | 20 | OHSU Knight Cancer Institute | Sep 2022 | |
| NCT06390306 | The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP | — | recruiting | 30 | Peking University People's Hospital | Jul 2024 | |
| NCT03223610 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | P1/P2 | recruiting | 155 | National Cancer Institute (NCI) | Feb 2018 | |
| NCT03054896 | A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome | P2 | active not recruiting | 69 | Dana-Farber Cancer Institute | Mar 2017 | |
| NCT07044687 | SC | Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India | P4 | recruiting | 100 | AbbVie | Jul 2025 |
| NCT06660368 | BCL2i CLAG-M in R/R Acute Myeloid Leukemia | P2 | recruiting | 52 | H. Lee Moffitt Cancer Center and Research Institute | Nov 2024 | |
| NCT06429449 | Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia | P1 | recruiting | 30 | University of Colorado, Denver | Jul 2024 | |
| NCT06152809 | CIML NK Cells With Venetoclax for AML | P1 | recruiting | 10 | Dana-Farber Cancer Institute | Feb 2024 | |
| NCT03539744 | A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. | P3 | active not recruiting | 265 | AbbVie | Oct 2018 | |
| NCT04774393 | Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | P1/P2 | recruiting | 84 | M.D. Anderson Cancer Center | May 2021 | |
| NCT03331198 | CLL | Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | P1/P2 | recruiting | 320 | Juno Therapeutics, a Subsidiary of Celgene | Nov 2017 |
| NCT06917911 | GO | Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) | P2 | recruiting | 162 | National Cancer Institute (NCI) | Feb 2027 |
| NCT06643962 | Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy | N/A | recruiting | 83 | Affiliated Hospital of Nantong University | Oct 2024 | |
| NCT06232655 | Cladribine Venetoclax in Monocytic AML | P2 | recruiting | 20 | University of Colorado, Denver | Feb 2024 | |
| NCT04965493 | BRUIN CLL-322 | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | P3 | active not recruiting | 600 | Loxo Oncology, Inc. | Sep 2021 |
| NCT03336333 | SEQUOIA | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL | P3 | active not recruiting | 590 | BeiGene | Oct 2017 |
| NCT02250937 | Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | P2 | active not recruiting | 116 | M.D. Anderson Cancer Center | Oct 2014 | |
| NCT05356169 | Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia | P2/P3 | active not recruiting | 312 | Institute of Hematology & Blood Diseases Hospital, China | May 2022 | |
| NCT06399640 | Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia | P1 | recruiting | 60 | Vanderbilt-Ingram Cancer Center | Aug 2024 | |
| NCT05939180 | VA vs DA for Newly Diagnosed Hig-risk AML | P2/P3 | recruiting | 116 | The First Affiliated Hospital of Soochow University | Apr 2024 | |
| NCT04898894 | Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | P1 | active not recruiting | 37 | St. Jude Children's Research Hospital | Nov 2021 | |
| NCT04608318 | CLL17 | Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) | P3 | active not recruiting | 897 | German CLL Study Group | Mar 2021 |
| NCT03471260 | Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies | P1/P2 | recruiting | 96 | M.D. Anderson Cancer Center | Mar 2018 | |
| NCT03214562 | Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia | P1/P2 | recruiting | 116 | M.D. Anderson Cancer Center | Sep 2017 | |
| NCT06649812 | Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma | P2 | recruiting | 120 | National Cancer Institute (NCI) | Oct 2025 | |
| NCT07244367 | Maintenance Venetoclax in AML Fit Patients | N/A | recruiting | 80 | Sohag University | Sep 2025 | |
| NCT06237192 | MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients | N/A | recruiting | 200 | National Research Center for Hematology, Russia | Apr 2023 | |
| NCT05226455 | Venetoclax in Patients With MDS or AML in Relapse After AHSCT | P1/P2 | active not recruiting | 55 | Groupe Francophone des Myelodysplasies | Nov 2022 | |
| NCT06561880 | FLT3AML-2024 | The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation | P1/P2 | recruiting | 66 | Institute of Hematology & Blood Diseases Hospital, China | Oct 2024 |
| NCT06337331 | Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant | P2 | withdrawn | 0 | Northside Hospital, Inc. | Aug 2024 | |
| NCT03844048 | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | P3 | active not recruiting | 165 | AbbVie | Sep 2019 | |
| NCT06554626 | Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL | P2 | recruiting | 20 | First Affiliated Hospital of Zhejiang University | Aug 2024 | |
| NCT06129734 | Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant | P1/P2 | recruiting | 20 | Benjamin Tomlinson | Jul 2025 | |
| NCT06536959 | VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS | P2 | recruiting | 67 | Beijing 302 Hospital | Jul 2024 | |
| NCT04401748 | Verona | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | P3 | active not recruiting | 531 | AbbVie | Sep 2020 |
| NCT06496308 | Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment | P3 | recruiting | 78 | Ruijin Hospital | Jul 2024 | |
| NCT03969446 | Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory | P1 | recruiting | 54 | City of Hope Medical Center | May 2020 | |
| NCT07187505 | Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia | N/A | active not recruiting | 28 | Anhui Medical University | Jul 2025 | |
| NCT02756897 | Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia | P2 | active not recruiting | 234 | M.D. Anderson Cancer Center | Jul 2016 | |
| NCT06903702 | A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia | P2 | recruiting | 100 | Memorial Sloan Kettering Cancer Center | Jun 2025 | |
| NCT06746519 | BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia | P1/P2 | recruiting | 135 | Chen Suning | Dec 2024 | |
| NCT06652685 | Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia | P2 | not yet recruiting | 218 | Ruijin Hospital | Oct 2024 | |
| NCT06451861 | Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML | P2 | recruiting | 240 | Guangdong Provincial People's Hospital | Aug 2024 | |
| NCT06384261 | A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy | P2 | active not recruiting | 140 | OncoVerity, Inc. | Jul 2024 | |
| NCT06501196 | A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome | P1 | recruiting | 170 | BlossomHill Therapeutics | Jun 2024 | |
| NCT05305859 | VCA | Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML | P2 | recruiting | 30 | The First Affiliated Hospital of Xiamen University | Jan 2022 |
| NCT03041688 | AMG-232 | Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia | P1 | active not recruiting | 58 | National Cancer Institute (NCI) | Feb 2018 |
| NCT02899052 | MM | Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) | P2 | active not recruiting | 120 | AbbVie | Jan 2017 |
| NCT03523975 | Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma | P1/P2 | recruiting | 28 | City of Hope Medical Center | Dec 2018 | |
| NCT06770257 | Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy | P2 | withdrawn | 0 | Institute of Hematology & Blood Diseases Hospital, China | Dec 2025 | |
| NCT06471738 | Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma | P2 | recruiting | 30 | Chinese PLA General Hospital | Jul 2024 | |
| NCT05673057 | Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome | P1/P2 | active not recruiting | 249 | Molecular Partners AG | Dec 2022 | |
| NCT04975919 | Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | P2 | active not recruiting | 20 | M.D. Anderson Cancer Center | Sep 2021 | |
| NCT04419519 | Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax | P2 | active not recruiting | 81 | Memorial Sloan Kettering Cancer Center | May 2020 | |
| NCT03113643 | AML | SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | P1 | recruiting | 72 | Dana-Farber Cancer Institute | Jun 2017 |
| NCT03128879 | Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL | P2 | recruiting | 90 | M.D. Anderson Cancer Center | Jun 2017 | |
| NCT06311227 | Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia | P2 | recruiting | 20 | National Cancer Institute (NCI) | Dec 2024 | |
| NCT04150887 | ELEVATE | Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia | P1 | active not recruiting | 61 | OncoVerity, Inc. | Dec 2019 |
| NCT06372717 | A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS | P1 | recruiting | 100 | Apollo Therapeutics Ltd | Jun 2024 | |
| NCT06007911 | Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | P1 | withdrawn | 0 | Medical College of Wisconsin | Aug 2024 | |
| NCT06387420 | A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia | P1/P2 | not yet recruiting | 180 | Akeso | Apr 2024 | |
| NCT06177067 | Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | P1 | recruiting | 24 | St. Jude Children's Research Hospital | Apr 2024 | |
| NCT05736965 | SAV | A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia | P2 | recruiting | 58 | Shanghai Tong Ren Hospital | Feb 2023 |
| NCT04450173 | Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma | P2 | active not recruiting | 40 | University of California, Davis | Feb 2021 | |
| NCT04447716 | An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment | P1 | active not recruiting | 4 | Thomas Jefferson University | Oct 2020 | |
| NCT03850574 | TUSCANY | Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia | P1/P2 | recruiting | 240 | Aptose Biosciences Inc. | Mar 2019 |
| NCT03586609 | Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia | P2 | recruiting | 145 | M.D. Anderson Cancer Center | Oct 2018 | |
| NCT05529069 | Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients | P2 | recruiting | 30 | M.D. Anderson Cancer Center | Jan 2023 | |
| NCT06393985 | Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL | P2 | recruiting | 30 | The First Affiliated Hospital of Soochow University | Apr 2024 | |
| NCT05157971 | Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia | P1 | active not recruiting | 24 | City of Hope Medical Center | Mar 2022 | |
| NCT06672146 | Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) | P2 | recruiting | 93 | National Cancer Institute (NCI) | May 2025 | |
| NCT05554406 | Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | P2 | recruiting | 335 | National Cancer Institute (NCI) | Sep 2024 | |
| NCT06361329 | Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL | P3 | recruiting | 81 | First Affiliated Hospital of Zhejiang University | Apr 2024 | |
| NCT06192979 | Optimize First-line Treatment for AL Amyloidosis With t (11; 14) | N/A | recruiting | 41 | Jin Lu, MD | Jan 2024 | |
| NCT06156579 | VenSwitch | Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML | P2 | recruiting | 27 | University Hospital Tuebingen | Nov 2023 |
| NCT05428969 | BEXMAB | A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies | P1/P2 | active not recruiting | 181 | Faron Pharmaceuticals Ltd | Jun 2022 |
| NCT05184842 | Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML | P2 | recruiting | 91 | Montefiore Medical Center | Mar 2022 | |
| NCT04068597 | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | P1/P2 | recruiting | 250 | CellCentric Ltd. | Aug 2019 | |
| NCT07318662 | Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML | — | active not recruiting | 224 | Guangdong Provincial People's Hospital | Jan 2020 | |
| NCT03710772 | Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | P2 | active not recruiting | 51 | M.D. Anderson Cancer Center | May 2019 | |
| NCT05736978 | AVS | Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results | P2 | recruiting | 58 | Shanghai Tong Ren Hospital | Mar 2023 |
| NCT05453903 | AML | A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies | P1 | active not recruiting | 196 | Janssen Research & Development, LLC | Oct 2022 |
| NCT05222984 | Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax | P1 | active not recruiting | 17 | City of Hope Medical Center | Jul 2022 | |
| NCT05628623 | ERASE | Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment | P2 | not yet recruiting | 184 | Eastern Cooperative Oncology Group | Oct 2024 |
| NCT05192889 | Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax | P1/P2 | active not recruiting | 35 | St. Jude Children's Research Hospital | Aug 2022 | |
| NCT04086264 | IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | P1/P2 | active not recruiting | 218 | AbbVie | Nov 2019 | |
| NCT03824483 | CLL | Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) | P2 | recruiting | 230 | Memorial Sloan Kettering Cancer Center | Feb 2019 |
| NCT02846623 | Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome | P2 | active not recruiting | 50 | M.D. Anderson Cancer Center | Jan 2017 | |
| NCT05388006 | Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P2 | recruiting | 27 | Mayo Clinic | Jan 2023 | |
| NCT04939272 | Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | P1/P2 | active not recruiting | 8 | City of Hope Medical Center | Jun 2022 | |
| NCT05861050 | Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | P1/P2 | recruiting | 50 | City of Hope Medical Center | Aug 2023 | |
| NCT07044544 | Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies | P1 | recruiting | 20 | University of Alabama at Birmingham | Jul 2025 | |
| NCT06773208 | AML | A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML) | P2 | recruiting | 30 | Memorial Sloan Kettering Cancer Center | Jan 2025 |
| NCT05317403 | Venetoclax to Augment Epigenetic Modification and Chemotherapy | P1 | recruiting | 40 | Medical College of Wisconsin | Mar 2023 | |
| NCT03862157 | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | P1/P2 | active not recruiting | 40 | M.D. Anderson Cancer Center | Feb 2019 | |
| NCT03836261 | AMPLIFY | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | P3 | active not recruiting | 984 | Acerta Pharma BV | Feb 2019 |
| NCT02942290 | MDS | A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS) | P1 | active not recruiting | 129 | AbbVie | Jan 2017 |
| NCT04284787 | BLAST MRD AML-2 | BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia | P2 | active not recruiting | 60 | National Cancer Institute (NCI) | Feb 2021 |
| NCT06763341 | A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | P1 | recruiting | 12 | City of Hope Medical Center | Jul 2025 | |
| NCT06990321 | Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia | P3 | recruiting | 68 | Yehui Tan | Jun 2025 | |
| NCT07007949 | a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia | P2 | recruiting | 42 | The First Affiliated Hospital of Soochow University | Jun 2025 | |
| NCT06466122 | LOXO-305 | Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi | P2 | recruiting | 30 | Kerry Rogers | Nov 2024 |
| NCT05074355 | Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms | P2 | recruiting | 40 | University Health Network, Toronto | Nov 2023 | |
| NCT04790045 | LymBIO | Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens | P4 | not yet recruiting | 30 | Paolo Ghia | Nov 2023 |
| NCT05603884 | AML | VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | P2 | recruiting | 66 | The First Affiliated Hospital of Xiamen University | Dec 2022 |
| NCT05455294 | Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | P1 | active not recruiting | 16 | Jacqueline Garcia, MD | Jul 2022 | |
| NCT05506332 | Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia | P1 | recruiting | 10 | University Hospital, Antwerp | Jul 2022 | |
| NCT05211570 | AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | P1/P2 | recruiting | 78 | AB Science | Jun 2022 | |
| NCT05010772 | Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | P1 | recruiting | 125 | M.D. Anderson Cancer Center | Oct 2021 | |
| NCT04657081 | AML | Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) | P1/P2 | active not recruiting | 101 | Taiho Oncology, Inc. | Feb 2021 |
| NCT04229979 | REGAL | Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 | P3 | active not recruiting | 127 | Sellas Life Sciences Group | Feb 2021 |
| NCT04581512 | Study to Evaluate the Safety and Tolerability of EP0042 | P1/P2 | recruiting | 70 | Ellipses Pharma | Nov 2020 | |
| NCT04515238 | CLL2-BZAG | Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL | P2 | active not recruiting | 42 | German CLL Study Group | Oct 2020 |
| NCT04161248 | Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma | Early P1 | active not recruiting | 40 | Canadian Cancer Trials Group | Sep 2020 | |
| NCT04216524 | Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm | P2 | recruiting | 40 | M.D. Anderson Cancer Center | May 2020 | |
| NCT04128501 | Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | P2 | active not recruiting | 100 | M.D. Anderson Cancer Center | May 2020 | |
| NCT04082897 | MOLTO | ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation | P2 | active not recruiting | 28 | Niguarda Hospital | Oct 2019 |
| NCT03513562 | Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | P2 | active not recruiting | 28 | Ohio State University Comprehensive Cancer Center | Mar 2019 | |
| NCT03629171 | Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia | P2 | recruiting | 52 | M.D. Anderson Cancer Center | Oct 2018 | |
| NCT03467867 | A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | P2 | active not recruiting | 25 | Georgetown University | Apr 2018 | |
| NCT06394011 | Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients | P2 | recruiting | 60 | The First Affiliated Hospital of Soochow University | Feb 2024 | |
| NCT03737981 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia | P3 | active not recruiting | 465 | National Cancer Institute (NCI) | Jan 2019 | |
| NCT05016947 | Venetoclax Plus Inotuzumab for B-ALL | P1 | active not recruiting | 23 | Dana-Farber Cancer Institute | Sep 2021 | |
| NCT05379166 | Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome | P2 | active not recruiting | 33 | Uma Borate | Jun 2022 | |
| NCT06324994 | Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma. | P2 | not yet recruiting | 10 | Dalian Medical University | May 2024 | |
| NCT05668026 | AMBER | Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART | P1/P2 | recruiting | 18 | University of Aarhus | Apr 2024 |
| NCT06220162 | VAC Regimen for AML Patients Who Failed to Response to VA Regimen | P2 | recruiting | 32 | The First Affiliated Hospital of Soochow University | Feb 2024 | |
| NCT05360160 | ASTX727 | A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) | P1/P2 | recruiting | 43 | M.D. Anderson Cancer Center | Oct 2022 |
| NCT05376111 | Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients | P2 | recruiting | 28 | The First Affiliated Hospital of Soochow University | Apr 2022 | |
| NCT05053659 | Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma | P1 | active not recruiting | 23 | Paolo Caimi, MD | Jun 2022 | |
| NCT03980171 | LEVERAGE | Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma | P1/P2 | active not recruiting | 50 | Peter MacCallum Cancer Centre, Australia | Aug 2019 |
| NCT02392572 | ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome | P1/P2 | recruiting | 120 | M.D. Anderson Cancer Center | Nov 2015 | |
| NCT05597306 | VenBom | Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia | P1 | recruiting | 18 | Terrence J Bradley, MD | Nov 2022 |
| NCT04817241 | ASTX727 | Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients | P1/P2 | active not recruiting | 5 | National Cancer Institute (NCI) | Feb 2022 |
| NCT06082934 | Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia | P1/P2 | recruiting | 30 | Xijing Hospital | Nov 2023 | |
| NCT05657652 | CAV Regimen for R/R Ph- B-ALL | N/A | recruiting | 36 | The First Affiliated Hospital of Soochow University | Oct 2022 | |
| NCT05336812 | Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia | P2 | recruiting | 52 | Ohio State University Comprehensive Cancer Center | Sep 2022 | |
| NCT04746235 | Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia | P2 | active not recruiting | 85 | M.D. Anderson Cancer Center | Feb 2021 | |
| NCT04282811 | Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy | — | active not recruiting | 321 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Jul 2020 | |
| NCT00501826 | Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | P2 | recruiting | 160 | M.D. Anderson Cancer Center | Jul 2007 | |
| NCT06629818 | Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14) | P2 | recruiting | 36 | Peking Union Medical College Hospital | Oct 2024 | |
| NCT06191263 | RIVER-81 | Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML | P2 | recruiting | 98 | Ryvu Therapeutics SA | Jan 2024 |
| NCT05451771 | Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis | P1/P2 | recruiting | 53 | Rajshekhar Chakraborty, MD | Oct 2022 | |
| NCT05566054 | VAC | Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia | P2 | recruiting | 92 | The First Affiliated Hospital of Soochow University | Mar 2022 |
| NCT06210750 | T-ALL | Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) | P2 | withdrawn | 0 | National Cancer Institute (NCI) | Aug 2024 |
| NCT06514261 | Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML | P1 | suspended | 45 | National Cancer Institute (NCI) | Dec 2024 | |
| NCT06928376 | A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients | P2 | recruiting | 160 | Chinese PLA General Hospital | Apr 2024 | |
| NCT05554419 | Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) | P2 | not yet recruiting | 184 | National Cancer Institute (NCI) | Jul 2026 | |
| NCT05600894 | Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm | P2 | active not recruiting | 132 | National Cancer Institute (NCI) | Jun 2023 | |
| NCT02992522 | Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | P1 | active not recruiting | 22 | Beth Christian | Feb 2017 | |
| NCT06697327 | Daunorubicin + Cytarabine + Venetoclax in de Novo AML | N/A | enrolling by invitation | 94 | Anhui Medical University | Feb 2025 | |
| NCT05054465 | ITALLI001 | A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL | P1/P2 | not yet recruiting | 48 | Israeli Medical Association | Oct 2021 |
| NCT04447768 | CLL | The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) | P2 | active not recruiting | 100 | Memorial Sloan Kettering Cancer Center | Dec 2020 |
| NCT04572763 | Copanlisib Plus Venetoclax in R/R DLBCL | P1/P2 | active not recruiting | 48 | Dana-Farber Cancer Institute | Sep 2021 | |
| NCT04981912 | Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients | P1 | active not recruiting | 4 | University of California, San Diego | Sep 2021 | |
| NCT04501939 | Venetoclax | Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax | P2 | active not recruiting | 5 | University of California, San Diego | Aug 2020 |
| NCT04655755 | Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | P1/P2 | active not recruiting | 52 | M.D. Anderson Cancer Center | Jan 2021 | |
| NCT04169737 | Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P2 | recruiting | 168 | M.D. Anderson Cancer Center | Jul 2020 | |
| NCT03986034 | CLL | Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | P2 | recruiting | 75 | National Heart, Lung, and Blood Institute (NHLBI) | Jun 2019 |
| NCT03534323 | Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS | P1/P2 | active not recruiting | 55 | Dana-Farber Cancer Institute | Jul 2018 | |
| NCT06382168 | DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia | P1/P2 | recruiting | 39 | Delta-Fly Pharma, Inc. | Jun 2024 | |
| NCT06434662 | Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML | P2 | recruiting | 34 | First Affiliated Hospital of Zhejiang University | Feb 2024 | |
| NCT06265545 | Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia | N/A | recruiting | 120 | Institute of Hematology & Blood Diseases Hospital, China | Feb 2024 | |
| NCT04416451 | A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma | P2 | active not recruiting | 6 | Memorial Sloan Kettering Cancer Center | May 2021 | |
| NCT03226301 | RR-CLL | A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations | P2 | active not recruiting | 230 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Jun 2017 |
| NCT02993523 | Viale-a | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy | P3 | active not recruiting | 443 | AbbVie | Feb 2017 |
| NCT04188405 | Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia | P2 | completed | 20 | M.D. Anderson Cancer Center | May 2020 | |
| NCT03709758 | Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML | P1 | active not recruiting | 50 | Dana-Farber Cancer Institute | Oct 2018 | |
| NCT05522192 | Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia | P1/P2 | unknown | 70 | Hui Zeng | Jul 2022 | |
| NCT05386576 | ALL | A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | Early P1 | active not recruiting | 12 | Memorial Sloan Kettering Cancer Center | Jun 2022 |
| NCT04603001 | Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations | P1 | active not recruiting | 260 | Eli Lilly and Company | Nov 2020 | |
| NCT06357182 | Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia | P1 | recruiting | 24 | OHSU Knight Cancer Institute | Aug 2024 | |
| NCT04550442 | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | P1/P2 | terminated | 34 | M.D. Anderson Cancer Center | Sep 2020 | |
| NCT05564650 | Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome | P1 | completed | 6 | Thomas Jefferson University | Jan 2023 | |
| NCT03808610 | Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia | P1/P2 | terminated | 53 | M.D. Anderson Cancer Center | Apr 2019 | |
| NCT07039877 | Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients | P2 | recruiting | 12 | Hospital Universitario Dr. Jose E. Gonzalez | Jan 2025 | |
| NCT05182385 | BCP-ALL | Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) | P1/P2 | active not recruiting | 30 | Goethe University | Dec 2021 |
| NCT04763928 | ENABLE | Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax | P2 | active not recruiting | 101 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Dec 2021 |
| NCT03872180 | Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma | P2 | active not recruiting | 23 | Emory University | Apr 2019 | |
| NCT05268003 | A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia | P2 | terminated | 4 | M.D. Anderson Cancer Center | Jun 2022 | |
| NCT04278768 | AML | Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | P1/P2 | suspended | 366 | Curis, Inc. | Jul 2020 |
| NCT05005299 | VICTORY | Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation | P1 | unknown | 18 | Melbourne Health | Jun 2022 |
| NCT05144243 | SC | Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China | P4 | active not recruiting | 44 | AbbVie | Jan 2022 |
| NCT03557619 | A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies | P1 | recruiting | 12 | AbbVie | Jul 2019 | |
| NCT04809181 | Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients | P2 | unknown | 95 | First Affiliated Hospital of Zhejiang University | Mar 2021 | |
| NCT03404193 | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome | P2 | terminated | 235 | M.D. Anderson Cancer Center | Jan 2018 | |
| NCT05901974 | Venetoclax Combined With Azactidine in the Treatment of ALAL | P2 | recruiting | 23 | Sheng-Li Xue, MD | Jul 2023 | |
| NCT05618366 | Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma | P1 | terminated | 3 | Weill Medical College of Cornell University | Jun 2023 | |
| NCT04102020 | VIALE-M | A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy | P3 | completed | 112 | AbbVie | Mar 2020 |
| NCT03573024 | Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia | P2 | completed | 36 | University of Colorado, Denver | Nov 2018 | |
| NCT04160052 | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome | P1/P2 | terminated | 51 | M.D. Anderson Cancer Center | Oct 2019 | |
| NCT06578546 | Chemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALL | P2 | unknown | 30 | The First Affiliated Hospital of Soochow University | Feb 2024 | |
| NCT06105658 | Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML | P2 | unknown | 20 | Anhui Provincial Hospital | Oct 2023 | |
| NCT06109064 | Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDS | P2 | unknown | 14 | Anhui Provincial Hospital | Oct 2023 | |
| NCT05807347 | Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia | P2 | unknown | 42 | Hematology department of the 920th hospital | Feb 2023 | |
| NCT06045819 | PREDICLAX | Relation Between Venetoclax Plasma Concentration and Remission in Adults with Acute Myeloid Leukemia (PREDICLAX) | — | recruiting | 100 | University Hospital, Caen | Apr 2024 |
| NCT05701215 | VARIANT | Venetoclax After TKI to Target Persisting Stem Cells in CML | P2 | active not recruiting | 10 | Thomas Ernst, PD Dr. med. | Aug 2023 |
| NCT03609593 | Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia | P2 | completed | 42 | Nicole Lamanna | Nov 2018 | |
| NCT05665530 | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies | P1 | completed | 86 | Prelude Therapeutics | Sep 2023 | |
| NCT03926624 | Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage | P3 | terminated | 167 | Delta-Fly Pharma, Inc. | Nov 2019 | |
| NCT05881265 | Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia | P2 | recruiting | 30 | Shanghai Jiao Tong University School of Medicine | May 2023 | |
| NCT06763666 | CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML | P4 | not yet recruiting | 172 | Nanfang Hospital, Southern Medical University | Feb 2025 | |
| NCT05841771 | Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies. | P2 | recruiting | 78 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Jan 2023 | |
| NCT05829226 | AML | A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) | P1 | completed | 101 | PureTech | Dec 2022 |
| NCT04607772 | RR | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | P1/P2 | withdrawn | 0 | Karyopharm Therapeutics Inc | Nov 2020 |
| NCT04613622 | Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia | — | unknown | 500 | National Taiwan University Hospital | Aug 2020 | |
| NCT04616274 | Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia | — | unknown | 500 | National Taiwan University Hospital | Jul 2020 | |
| NCT03900884 | PALVEN | Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer | P1 | active not recruiting | 17 | Peter MacCallum Cancer Centre, Australia | Sep 2019 |
| NCT03713580 | Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma | P1 | active not recruiting | 25 | Case Comprehensive Cancer Center | Mar 2019 | |
| NCT06087419 | A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients | P1/P2 | unknown | 42 | Institute of Hematology & Blood Diseases Hospital, China | Oct 2023 | |
| NCT03740529 | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | P1/P2 | completed | 803 | Loxo Oncology, Inc. | Mar 2019 | |
| NCT05371054 | VVIP | Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies | P1/P2 | completed | 8 | National Cancer Institute (NCI) | Apr 2023 |
| NCT03466294 | Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML | P2 | completed | 42 | University of Colorado, Denver | May 2018 | |
| NCT06200220 | Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia | — | unknown | 45 | Poitiers University Hospital | Dec 2023 | |
| NCT05503355 | A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML | P1/P2 | unknown | 80 | BioSight Ltd. | Aug 2022 | |
| NCT04905810 | Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure | P2 | recruiting | 20 | Brian Jonas | Feb 2022 | |
| NCT05863845 | Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL | N/A | unknown | 52 | Ruijin Hospital | Jun 2023 | |
| NCT03708003 | Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL | P2 | terminated | 30 | Swiss Cancer Institute | Mar 2019 | |
| NCT03662724 | VENreg | Venetoclax Registry | — | unknown | 100 | Hannover Medical School | Nov 2017 |
| NCT04937166 | DSP107 | A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies | P1 | terminated | 25 | Kahr Medical | Jan 2022 |
| NCT02296918 | Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL | P1 | completed | 69 | Acerta Pharma BV | Dec 2014 | |
| NCT03567876 | Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL | P2 | completed | 141 | Fondazione Italiana Linfomi - ETS | Sep 2018 | |
| NCT06563804 | A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML | P1/P2 | terminated | 13 | Servier Bio-Innovation LLC | Feb 2025 | |
| NCT05105841 | IV | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | P2 | completed | 20 | AbbVie | Nov 2021 |
| NCT06742086 | A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants | P1 | completed | 72 | AbbVie | Dec 2024 | |
| NCT04964505 | Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia | P1 | terminated | 16 | Brian Jonas | Jul 2021 | |
| NCT05317936 | LOXO-305 | Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax | P1/P2 | terminated | 3 | M.D. Anderson Cancer Center | Nov 2022 |
| NCT04266795 | PEVENAZA | A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy | P2 | completed | 164 | Takeda | Oct 2020 |
| NCT05546060 | Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH | P1 | unknown | 20 | Beijing Friendship Hospital | Jul 2022 | |
| NCT05996406 | Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14) | P2 | active not recruiting | 36 | Peking Union Medical College Hospital | Sep 2023 | |
| NCT05513131 | Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML | P2 | unknown | 30 | The First Affiliated Hospital with Nanjing Medical University | Sep 2021 | |
| NCT04161885 | VIALE-T | A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) | P3 | terminated | 465 | AbbVie | Feb 2020 |
| NCT06078306 | B-ALL | CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). | P2 | unknown | 20 | The First Affiliated Hospital of Soochow University | Apr 2024 |
| NCT04754035 | IMPROVE | Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia | P2 | unknown | 31 | Paolo Ghia | Nov 2017 |
| NCT06068621 | Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia | P2 | completed | 200 | Chinese PLA General Hospital | Mar 2023 | |
| NCT04330820 | RELAX | Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) | P1/P2 | unknown | 55 | Technische Universität Dresden | Apr 2020 |
| NCT02242942 | Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia | P3 | completed | 445 | Hoffmann-La Roche | Dec 2014 | |
| NCT03069352 | A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy | P3 | completed | 211 | AbbVie | May 2017 | |
| NCT05780879 | G-CSF | A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia | P2 | terminated | 10 | University of Michigan Rogel Cancer Center | Jun 2024 |
| NCT06508489 | SAR443579 | A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies | P1/P2 | terminated | 7 | Sanofi | Aug 2024 |
| NCT06070948 | A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants | P1 | withdrawn | 0 | AbbVie | Oct 2023 | |
| NCT05262465 | Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML | N/A | unknown | 300 | guomei | Jul 2020 | |
| NCT04476199 | Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT | P2 | active not recruiting | 100 | Gruppo Italiano Trapianto di Midollo Osseo | Dec 2019 | |
| NCT04687761 | Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old | P1/P2 | completed | 113 | PETHEMA Foundation | Nov 2020 | |
| NCT04477486 | Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma | P2 | completed | 13 | AbbVie | Sep 2020 | |
| NCT04666649 | Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) | P1 | completed | 27 | University of Maryland, Baltimore | Mar 2021 | |
| NCT05025423 | Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma | P2 | terminated | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jun 2022 | |
| NCT06993883 | AML | Use of Venetoclax , AML , Sohag , Egypt | — | completed | 43 | Sohag University | Mar 2023 |
| NCT05662956 | A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients | P2 | completed | 114 | Hematology department of the 920th hospital | Dec 2022 | |
| NCT03485547 | BPDCN | Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | P1 | completed | 5 | Dana-Farber Cancer Institute | Aug 2018 |
| NCT05654194 | Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML | P3 | unknown | 30 | The First Affiliated Hospital of Soochow University | Oct 2022 | |
| NCT06449482 | Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy | P1/P2 | terminated | 6 | Institute of Hematology & Blood Diseases Hospital, China | May 2023 | |
| NCT05594784 | Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL | P2 | completed | 79 | Institute of Hematology & Blood Diseases Hospital, China | Oct 2022 | |
| NCT04435691 | Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia | P1/P2 | terminated | 110 | M.D. Anderson Cancer Center | Jul 2020 | |
| NCT04285567 | CRISTALLO | A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation | P3 | completed | 166 | Hoffmann-La Roche | May 2020 |
| NCT06030089 | VENETACIBLE | Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven | N/A | completed | 20 | Centre Hospitalier Universitaire de Nice | Feb 2024 |
| NCT05264883 | Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML | P3 | unknown | 170 | The First Affiliated Hospital with Nanjing Medical University | Mar 2021 | |
| NCT06150040 | AML-NET | Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] | P1/P2 | terminated | 1 | Centre Leon Berard | Sep 2024 |
| NCT04926285 | VEN-OM | Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML) | P1 | completed | 6 | University of Illinois at Chicago | Jun 2022 |
| NCT05275439 | SL | Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML | P1 | terminated | 106 | Shattuck Labs, Inc. | Mar 2022 |
| NCT04512105 | Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia | P1 | completed | 6 | University of California, Irvine | Dec 2020 | |
| NCT04867928 | Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia | P2 | unknown | 35 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Mar 2022 | |
| NCT04372433 | IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML | P1 | completed | 67 | Immune-Onc Therapeutics | Sep 2020 | |
| NCT03455504 | V-FIRST | Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia | P2 | unknown | 124 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Oct 2018 |
| NCT04010968 | ERADIC | Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia | P2 | completed | 120 | French Innovative Leukemia Organisation | Sep 2019 |
| NCT04553692 | IGM-8444 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers | P1 | terminated | 272 | IGM Biosciences, Inc. | Sep 2020 |
| NCT05941585 | Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia | N/A | completed | 60 | Institute of Hematology & Blood Diseases Hospital, China | Aug 2023 | |
| NCT05177731 | Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML | P3 | active not recruiting | 188 | Chen Suning | Mar 2022 | |
| NCT05149378 | Venetoclax Based Regimen for R/R T-ALL | P2 | completed | 25 | The First Affiliated Hospital of Soochow University | Nov 2021 | |
| NCT03732703 | MyDRUG | Myeloma-Developing Regimens Using Genomics (MyDRUG) | P1/P2 | completed | 103 | Multiple Myeloma Research Consortium | Apr 2019 |
| NCT04939363 | A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome; | P2 | completed | 12 | Bnai Zion Medical Center | Aug 2021 | |
| NCT05583175 | Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies | P2 | unknown | 50 | Xianmin Song, MD | Nov 2022 | |
| NCT04150029 | STIMULUS-AML1 | A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy | P2 | terminated | 90 | Novartis Pharmaceuticals | Sep 2020 |
| NCT03226418 | Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia | P2 | completed | 75 | University of Nebraska | Jul 2017 | |
| NCT03932318 | Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients | P1/P2 | withdrawn | 0 | Actinium Pharmaceuticals | Mar 2023 | |
| NCT05084027 | Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT | P2 | unknown | 50 | First Affiliated Hospital of Zhejiang University | Oct 2021 | |
| NCT04285268 | Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | P2 | withdrawn | 0 | Rutgers, The State University of New Jersey | May 2020 | |
| NCT05799079 | Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant | P2 | terminated | 1 | Sanjay Mohan | Apr 2023 | |
| NCT04874194 | Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 | P1/P2 | terminated | 24 | M.D. Anderson Cancer Center | Dec 2021 | |
| NCT04589728 | Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96 | — | completed | 202 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Feb 2021 | |
| NCT03955783 | Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies | P1 | completed | 78 | Sanjay Mohan | Jun 2019 | |
| NCT03940352 | AML | HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) | P1 | terminated | 52 | Novartis Pharmaceuticals | Jun 2019 |
| NCT05659992 | Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia | P2 | completed | 30 | Chinese PLA General Hospital | Dec 2022 | |
| NCT05464836 | Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL | P2 | terminated | 2 | M.D. Anderson Cancer Center | Apr 2023 | |
| NCT04905407 | AML | Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | P2 | terminated | 66 | Syros Pharmaceuticals | Aug 2021 |
| NCT05168202 | A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes | P1 | terminated | 56 | Bristol-Myers Squibb | Jan 2022 | |
| NCT03834688 | PrE0405 | Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age | P2 | completed | 33 | PrECOG, LLC. | Jan 2020 |
| NCT03547115 | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML | P1 | terminated | 84 | MEI Pharma, Inc. | May 2018 | |
| NCT03530683 | PF-07901801 | A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma | P1 | terminated | 189 | Pfizer | May 2018 |
| NCT03867682 | Venetoclax and Lintuzumab-Ac225 in AML Patients | P1/P2 | unknown | 38 | Actinium Pharmaceuticals | Jan 2020 | |
| NCT03112174 | SYMPATICO | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) | P3 | completed | 366 | Pharmacyclics LLC. | Jun 2017 |
| NCT04599634 | VENOM | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | P1 | completed | 11 | National Cancer Institute (NCI) | Dec 2021 |
| NCT03576547 | Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia | P1/P2 | terminated | 9 | M.D. Anderson Cancer Center | Jun 2018 | |
| NCT04790903 | R | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) | P1 | terminated | 50 | Hoffmann-La Roche | Jul 2021 |
| NCT04029688 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors | P1/P2 | terminated | 38 | Hoffmann-La Roche | Jan 2020 | |
| NCT05362942 | Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia | P2 | unknown | 52 | Beijing 302 Hospital | May 2022 | |
| NCT05155709 | AML | A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. | P1 | completed | 14 | Novartis Pharmaceuticals | May 2022 |
| NCT05433532 | Study of Azacitidine,Venetoclax,and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients | P2 | completed | 20 | The First Affiliated Hospital of Soochow University | May 2022 | |
| NCT05079230 | ENHANCE-3 | Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia | P3 | terminated | 378 | Gilead Sciences | Jul 2022 |
| NCT04336982 | A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia | P1 | terminated | 22 | Celgene | Aug 2020 | |
| NCT05893472 | A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML. | P1/P2 | unknown | 45 | ZePing Zhou | Apr 2023 | |
| NCT04824924 | A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy | P2 | unknown | 100 | Shanghai Jiao Tong University School of Medicine | Mar 2021 | |
| NCT04659044 | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | P2 | terminated | 3 | Academic and Community Cancer Research United | Apr 2021 | |
| NCT02910583 | Captivate | Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) | P2 | completed | 323 | Pharmacyclics LLC. | Sep 2016 |
| NCT04778397 | ENHANCE-2 | Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated | P3 | terminated | 258 | Gilead Sciences | Jul 2021 |
| NCT05976217 | Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis | Early P1 | completed | 3 | University of Alabama at Birmingham | Oct 2023 | |
| NCT02956382 | Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma | P1/P2 | completed | 24 | Georgetown University | Mar 2017 | |
| NCT04778410 | Study of Magrolimab Combinations in Participants With Myeloid Malignancies | P2 | terminated | 54 | Gilead Sciences | Jun 2021 | |
| NCT03063944 | STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy | P1 | completed | 37 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Mar 2017 | |
| NCT02950051 | GAIA | Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation | P3 | completed | 926 | German CLL Study Group | Dec 2016 |
| NCT04267081 | VenEx | Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening | P2 | completed | 104 | Helsinki University Central Hospital | Feb 2020 |
| NCT03399539 | Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma | P1 | completed | 8 | Mayo Clinic | May 2018 | |
| NCT04070768 | GO | Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 | P1 | completed | 18 | John Quigley | Sep 2019 |
| NCT04487106 | Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | P2 | completed | 21 | M.D. Anderson Cancer Center | Jul 2020 | |
| NCT05361057 | Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients | P2 | terminated | 20 | Institute of Hematology & Blood Diseases Hospital, China | Jun 2022 | |
| NCT03295240 | The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma | Early P1 | completed | 10 | Memorial Sloan Kettering Cancer Center | Sep 2017 | |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | P1 | terminated | 21 | Prelude Therapeutics | Mar 2022 | |
| NCT04887857 | OMNIVERSE | A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML) | P1 | completed | 6 | Celgene | Dec 2021 |
| NCT04655391 | Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation | P1 | withdrawn | 0 | City of Hope Medical Center | Jun 2022 | |
| NCT03492125 | A Study Of The Selective PKC-β Inhibitor MS- 553 | P1/P2 | terminated | 60 | MingSight Pharmaceuticals, Inc | May 2018 | |
| NCT04752163 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | P1/P2 | terminated | 17 | M.D. Anderson Cancer Center | Mar 2021 | |
| NCT04092179 | Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers | P1/P2 | terminated | 27 | University Health Network, Toronto | Nov 2020 | |
| NCT06085638 | Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia | P1/P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Sep 2023 | |
| NCT02397720 | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia | P2 | completed | 150 | M.D. Anderson Cancer Center | Apr 2015 | |
| NCT05312112 | Real World Outcomes Using Novel Agents for AML in the UK | — | unknown | 1,000 | Guy's and St Thomas' NHS Foundation Trust | May 2022 | |
| NCT03787264 | CLL2-BAAG | Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL | P2 | completed | 46 | German CLL Study Group | Jan 2019 |
| NCT05909553 | Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers | P1 | completed | 15 | AbbVie | Jun 2023 | |
| NCT04075747 | V-FAST | A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia | P1 | completed | 57 | Jazz Pharmaceuticals | Dec 2019 |
| NCT04755244 | ALX148 | A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) | P1 | terminated | 14 | ALX Oncology Inc. | May 2021 |
| NCT03064867 | Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P1/P2 | active not recruiting | 65 | Molly Gallogly | Jun 2017 | |
| NCT03751436 | Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer | P1 | completed | 10 | Roswell Park Cancer Institute | Aug 2019 | |
| NCT03735875 | Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia | P1/P2 | terminated | 8 | M.D. Anderson Cancer Center | Jan 2019 | |
| NCT03534180 | Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma | P2 | completed | 12 | City of Hope Medical Center | Aug 2018 | |
| NCT03406156 | CLL | A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy | P3 | completed | 120 | AbbVie | Aug 2018 |
| NCT03672695 | Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia. | P1 | completed | 37 | Institut de Recherches Internationales Servier | Nov 2018 | |
| NCT03455517 | VeRitAs | Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia | P2 | completed | 77 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Oct 2018 |
| NCT04912063 | IV | Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome | P1 | terminated | 40 | AbbVie | Jun 2021 |
| NCT04812548 | STIMULUS-MDS3 | A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants | P2 | terminated | 20 | Novartis Pharmaceuticals | May 2021 |
| NCT03739554 | CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL | P1 | completed | 5 | Cyclacel Pharmaceuticals, Inc. | Jan 2019 | |
| NCT03236857 | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies | P1 | completed | 143 | AbbVie | Nov 2017 | |
| NCT04017546 | CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS | P1 | completed | 14 | Cyclacel Pharmaceuticals, Inc. | Aug 2019 | |
| NCT02966782 | MDS | A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS) | P1 | completed | 70 | AbbVie | Mar 2017 |
| NCT05471700 | Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients | N/A | completed | 40 | Zhujiang Hospital | Sep 2022 | |
| NCT04722601 | A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma | P1/P2 | terminated | 2 | University of Chicago | Sep 2021 | |
| NCT04990778 | Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma | P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Nov 2021 | |
| NCT05053425 | Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML | N/A | unknown | 30 | LanZhou University | Oct 2021 | |
| NCT05209308 | CORAL | Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL | P2 | withdrawn | 0 | MEI Pharma, Inc. | Nov 2022 |
| NCT05282719 | Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults | P2 | unknown | 33 | The First Affiliated Hospital of Soochow University | Apr 2022 | |
| NCT03552692 | Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma | P2 | terminated | 22 | Fondazione Italiana Linfomi - ETS | Sep 2018 | |
| NCT05048615 | Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML | P2 | completed | 15 | Hospital Universitario Dr. Jose E. Gonzalez | Jul 2021 | |
| NCT03176277 | A Study of ONO-7475 in Patients With Acute Leukemias | P1/P2 | terminated | 42 | Ono Pharmaceutical Co., Ltd. | Jun 2017 | |
| NCT03113422 | PrE0403 | Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy | P2 | completed | 56 | PrECOG, LLC. | Dec 2017 |
| NCT04752527 | Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features | P2 | unknown | 42 | The First Affiliated Hospital of Soochow University | Feb 2021 | |
| NCT03801525 | ULTRA-V | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) | P2/P3 | terminated | 277 | TG Therapeutics, Inc. | May 2019 |
| NCT03484520 | MK7965 | A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia | P1 | terminated | 48 | AbbVie | Jul 2018 |
| NCT03505944 | VALERIA | Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma | P1/P2 | unknown | 59 | Nordic Lymphoma Group | Jul 2018 |
| NCT04146038 | Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | P2 | completed | 5 | Rutgers, The State University of New Jersey | Oct 2020 | |
| NCT04038437 | LIT | A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML | P1 | completed | 35 | Jazz Pharmaceuticals | Oct 2019 |
| NCT03873857 | FORTE | A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation | — | completed | 71 | AbbVie | Feb 2019 |
| NCT04277442 | Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia | P1 | completed | 1 | National Cancer Institute (NCI) | Mar 2020 | |
| NCT03276468 | Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas | P2 | completed | 136 | The Lymphoma Academic Research Organisation | Feb 2018 | |
| NCT04810598 | Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function | P1 | completed | 12 | AbbVie | Jul 2021 | |
| NCT02755597 | Bellini | A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy | P3 | completed | 291 | AbbVie | Jul 2016 |
| NCT02611323 | FL | A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | P1/P2 | completed | 133 | Hoffmann-La Roche | Mar 2016 |
| NCT02005471 | MURANO | A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | P3 | completed | 389 | Hoffmann-La Roche | Mar 2014 |
| NCT03194932 | Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage | P1 | completed | 62 | St. Jude Children's Research Hospital | Jul 2017 | |
| NCT03379051 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL | P1/P2 | terminated | 78 | TG Therapeutics, Inc. | Mar 2018 | |
| NCT04016805 | CLL | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax | P2 | terminated | 41 | TG Therapeutics, Inc. | Aug 2019 |
| NCT02877550 | Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients | P1 | completed | 25 | Swiss Cancer Institute | Feb 2017 | |
| NCT03634228 | Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia | P1/P2 | terminated | 16 | M.D. Anderson Cancer Center | Dec 2018 | |
| NCT02758665 | CLL2-GiVe | Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL | P2 | completed | 41 | University of Ulm | Sep 2016 |
| NCT03000257 | ABBV-181 | A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors | P1 | completed | 182 | AbbVie | Dec 2016 |
| NCT03941964 | AML | A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy | P3 | completed | 60 | AbbVie | Aug 2019 |
| NCT02756611 | VENICE I | A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) | P3 | completed | 258 | AbbVie | Jun 2016 |
| NCT04748848 | A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy | P1 | terminated | 1 | Celgene | Oct 2021 | |
| NCT03886649 | Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. | P1 | terminated | 7 | Swiss Cancer Institute | Nov 2019 | |
| NCT04172844 | PAVE | Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia | P1 | terminated | 16 | Medical College of Wisconsin | Jan 2020 |
| NCT03390296 | OX40 | OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia | P1/P2 | completed | 50 | M.D. Anderson Cancer Center | Dec 2017 |
| NCT05215405 | Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL | — | no longer available | 0 | Kathleen Ludwig | — | |
| NCT03082209 | A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies | P1 | completed | 153 | AbbVie | Mar 2017 | |
| NCT04214860 | APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies | P1 | completed | 51 | Aprea Therapeutics | Dec 2019 | |
| NCT03856112 | Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma | P1/P2 | withdrawn | 0 | National Cancer Institute (NCI) | Jun 2019 | |
| NCT02639910 | COSMOS | Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi | P2 | completed | 24 | MorphoSys AG | Nov 2016 |
| NCT02980731 | VENICE II | A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). | P3 | completed | 210 | AbbVie | Dec 2016 |
| NCT02141282 | GDC-0199 | A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy | P2 | completed | 127 | AbbVie | Sep 2014 |
| NCT01794520 | Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma | P1/P2 | completed | 117 | AbbVie | Oct 2012 | |
| NCT04073147 | VENOBI-CNS | Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma | P1 | terminated | 4 | Klinikum Stuttgart | May 2020 |
| NCT03036904 | V+DA-EPOCH-R | Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas | P1 | completed | 31 | Weill Medical College of Cornell University | Feb 2017 |
| NCT03873493 | A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia | P2 | completed | 14 | AbbVie | Jan 2020 | |
| NCT02987400 | Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL | P2 | completed | 22 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Jan 2017 | |
| NCT03218683 | Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies. | P1 | terminated | 70 | AstraZeneca | Aug 2017 | |
| NCT03583424 | Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma | P1/P2 | completed | 19 | Ohio State University Comprehensive Cancer Center | Sep 2018 | |
| NCT03625505 | A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia | P1 | completed | 61 | AbbVie | Oct 2018 | |
| NCT04419389 | R/R | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) | P1/P2 | terminated | 1 | Aprea Therapeutics | Mar 2021 |
| NCT02287233 | A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia | P1/P2 | completed | 94 | AbbVie | Dec 2014 | |
| NCT03045328 | Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL | P2 | completed | 22 | Steven E. Coutre | Sep 2017 | |
| NCT03357627 | A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma | P1 | completed | 43 | Calithera Biosciences, Inc | Feb 2018 | |
| NCT03943342 | Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance | P2 | withdrawn | 0 | Kerry Rogers | Mar 2020 | |
| NCT04171791 | CTCL | A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL) | P1 | completed | 4 | Yale University | Jan 2020 |
| NCT03312530 | A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma | P1/P2 | completed | 49 | Hoffmann-La Roche | Nov 2017 | |
| NCT03584009 | Veronica | A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy | P2 | terminated | 103 | Hoffmann-La Roche | Sep 2018 |
| NCT02951117 | A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment | P1 | withdrawn | 0 | AbbVie | Aug 2017 | |
| NCT04509622 | LDAC | A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML) | P3 | completed | 14 | AbbVie | Oct 2020 |
| NCT04230564 | Acute Myeloid Leukemia Real World Treatment Patterns | — | withdrawn | 0 | Pfizer | Oct 2020 | |
| NCT03217838 | Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. | P1 | terminated | 50 | AstraZeneca | Jul 2017 | |
| NCT02265731 | Study Evaluating Venetoclax in Subjects With Hematological Malignancies | P1/P2 | completed | 38 | AbbVie | Sep 2014 | |
| NCT02640833 | A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor | P1 | withdrawn | 0 | AbbVie | Jul 2016 | |
| NCT04298918 | A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer | P1/P2 | terminated | 1 | Hoffmann-La Roche | Sep 2020 | |
| NCT04274907 | NSCLC | A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression | P1 | terminated | 2 | AbbVie | Jun 2020 |
| NCT03755947 | Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia | P2 | completed | 3 | Grupo Cooperativo de Hemopatías Malignas | Dec 2018 | |
| NCT03441555 | A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia | P1 | completed | 36 | AbbVie | May 2018 | |
| NCT01211457 | AML | Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) | P1/P2 | unknown | 65 | Cyclacel Pharmaceuticals, Inc. | Jun 2010 |
| NCT03878524 | SMMART | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | P1 | terminated | 2 | OHSU Knight Cancer Institute | Apr 2020 |
| NCT02670044 | A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy | P1 | completed | 88 | Hoffmann-La Roche | Mar 2016 | |
| NCT03343678 | This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax | P1 | withdrawn | 0 | Boehringer Ingelheim | Jan 2018 | |
| NCT03181126 | A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma | P1 | completed | 69 | AbbVie | Nov 2017 | |
| NCT04422210 | ES-SCLC | A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC). | P1 | terminated | 2 | Hoffmann-La Roche | Sep 2020 |
| NCT04493099 | Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML | P1/P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Oct 2020 | |
| NCT01742988 | CUDC-907 | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma | P1 | completed | 106 | Curis, Inc. | Dec 2012 |
| NCT04274933 | A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy | P1 | terminated | 4 | AbbVie | May 2020 | |
| NCT04454580 | Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy | — | unknown | 15 | Ospedale Maggiore Di Trieste | Aug 2020 | |
| NCT01671904 | CLL | A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL) | P1 | completed | 84 | Genentech, Inc. | Jan 2014 |
| NCT03567616 | A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | P2 | terminated | 8 | AbbVie | Oct 2018 | |
| NCT03701321 | Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma | P1/P2 | withdrawn | 0 | National Cancer Institute (NCI) | Jan 2019 | |
| NCT03135262 | FL | A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) | P1/P2 | terminated | 29 | Hoffmann-La Roche | Jun 2017 |
| NCT03884972 | Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor | P1 | withdrawn | 0 | M.D. Anderson Cancer Center | Jun 2019 | |
| NCT03797261 | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies | P1 | terminated | 9 | AbbVie | Mar 2019 | |
| NCT03000660 | ABT-199 | Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis | P1 | terminated | 3 | Tufts Medical Center | Jan 2017 |
| NCT01685892 | A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia | P1 | completed | 82 | Genentech, Inc. | Nov 2012 | |
| NCT03785184 | A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy | P2 | withdrawn | 0 | AbbVie | Apr 2019 | |
| NCT02391480 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | P1 | completed | 128 | AbbVie | Apr 2015 | |
| NCT03255096 | A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 | P1 | completed | 39 | Hoffmann-La Roche | Aug 2017 | |
| NCT02055820 | NHL | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL | P1/P2 | completed | 267 | Hoffmann-La Roche | Nov 2013 |
| NCT03592576 | Expanded Access to Navitoclax | — | no longer available | 0 | AbbVie | — | |
| NCT02187861 | GDC-0199 | A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL) | P2 | completed | 163 | Hoffmann-La Roche | Dec 2014 |
| NCT03123029 | Expanded Access to Venetoclax | — | available | 0 | AbbVie | — |
Venetoclax clinical trials: frequently asked questions
- How many Venetoclax clinical trials are there?
- 686 Venetoclax clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 257 are actively recruiting participants. 116 are marked completed.
- Are Venetoclax clinical trials recruiting in 2026?
- Yes — 257 Venetoclax trials are actively recruiting in 2026, with 2387 U.S. sites across 50 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Venetoclax being studied for?
- Venetoclax is being studied for Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Refractory Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML) and 574 more. The trials are grouped by indication on this page.
- What phase is Venetoclax in?
- Venetoclax clinical trials span 5 Phase 4, 59 Phase 3, 269 Phase 2, 158 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Venetoclax clinical trials?
- The lead sponsor across the most Venetoclax trials is M.D. Anderson Cancer Center, with 253 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Venetoclaxas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: